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Abstract 
Since discovery of COL6A1, A2 and A3 as disease-causing genes in collagen VI-related 
myopathies, several investigations have been done to identify novel genes which are 
responsible for collagen VI-related myopathy phenotypes with no mutations in COL6A1-A3 
genes. By exome sequencing of five affected individuals from pedigrees lying in the 
phenotypic spectrum of Bethlem-like myopathy but no mutations in COL6A1-A3 genes, we 
identified two missense and one splice variant mutation acting as dominant negative in the 
gene COL12A1 in three pedigrees with overall six affected individuals. In silico analysis 
predicted pathogenecity of these mutations. Immunohistochemical studies revealed in two 
missense mutations misfolded collagen XII could secrete to extracellular matrix but could 
not assemble to its structure, while for the splice variant mutation the misfolded protein 
could not secrete out of the cells. Phenotypic spectrum of collagen XII affected individuals 
from our cohort included mild to moderate progressive muscle weakness, joint hyperlaxity, 
skin involvements such as keloid formation and scoliosis. 
Studying suprastructure of extracellular matrix via electron microscopy in the affected 
individuals by in vitro collagen fibrillogenesis of concentrated collagen extracted from cell 
culture and collagen fibrils surrounded cultured fibroblast, we could not reveal any 
differences in fibril diameter. Adult fibroblast/ C2C12 coculture demonstrated extracellular 
matrix of affected individuals did not have properties which are required for increasing 
myoblast differentiation as it was seen in intact extracellular matrix.  
Our investigation on Bethlem-like myopathy heterogeneity introduced COL12A1 as the 
new disease-causing gene in Bethlem-like phenotype with no mutations in COL6A1-A3 
genes. However, more research in this field is required to decipher pathogenic mechanism 
of collagen XII mutation. 
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Chapter 1 Introduction 
1.1 Neuromuscular disorders classification and description: 
 Neuromuscular disorders (NMD) are described as progressive muscle weakness which 
could lead to pronounced physical disabilities (de Visser and Oliver, 2017).These 
disorders encompass a spectrum of diseases where peripheral nervous system from the 
anterior horn cell which is part of spinal cord that enervate axial body muscles, nerve 
fibres, the neuromuscular junction to the muscle can be involved (Turakhia et al., 2013). 
All types of neuromuscular disorders share the unifying aspect of abnormal muscle 
function. This pathologic function could result in abnormalities and disease symptoms 
(Birnkrant and Noritz, 2008). Because of the progressive nature of neuromuscular 
disorders, the symptoms also include chronic symptoms such as impaired to loss of 
ambulation, joint contractures or joint hyperlaxities, skeletal abnormalities (particularly 
scoliosis), cardiac abnormalities and respiratory failure. Signs of dynamic impairments 
such as fatigable weakness, myalgia, rhabdomyolysis and exercise intolerance are also 
present in neuromuscular disorders (Turakhia et al., 2013). 
 Paediatric neuromuscular disorders represent a sub-group of neuromuscular disorders 
with onset in childhood (Al-Ghamdi et al., 2017). Most paediatric neuromuscular disorders 
have genetic etiology. Like other genetic disorders, these diseases lead to lifelong 
morbidities and often childhood mortality. In addition, possible and potential treatments for 
these disorders are rare and yet premature (Dowling et al., 2017). 
 Paediatric neuromuscular disorders with genetic basis can be presented as de novo –
Genetic variant that arise in children but are not present in either parents – or inherited 
disorders. For those with known and underpinning genetic etiology, the pattern of 
inheritance can be autosomal dominant or autosomal recessive or X-linked. While among 
all pediatric NMDs the untreatable ones are prevailing the others, identifying the genetic 
underlying cause for these disorders become an important issue. Recognizing etiologic 
basis of these disorders helps to find right palliative care and genetic consultation. 
Neuromuscular disorders are caused by wide variety of genes. So far over three hundred 
different genes were identified which associated with different neuromuscular disorders 
(Dohrn et al., 2017). In this section, we describe the different and most common pediatric 
neuromuscular disorders with genetic basis.  
 
 
 
 
2 
 
1.1.1 Muscular Dystrophies (MD): 
 Muscular Dystrophies are a clinically and genetically variable group of disorders unified by 
presence of muscle weakness and its following disabilities and a dystrophic pattern 
observed in muscle in biopsies. Generally, muscular dystrophies can be categorized as: 
dystrophinopathies (DMD and Becker MD), myotonic dystrophies, limb girdle muscular 
dystrophies, Emery-Dreifus muscular dystrophies and congenital muscular dystrophies. 
There are common themes in diagnostic and treatment approaches related to all these 
muscular dystrophies (Dowling et al., 2017). 
 Duchenne muscular dystrophy (DMD) is one of the most common pediatric 
neuromuscular conditions. It presents during infancy by progressive muscle weakness. 
However, other organs such as heart, brain and smooth muscles will involve. Dilated 
cardiomyopathy and respiratory failure are two common symptoms. This X-linked 
recessive primary muscle disorder has a prevalence of 1 in 5000 boys. It is mostly caused 
by out of frame deletion in the gene DMD, which encodes Dystrophin, a membrane 
stabilizer protein. In 1956 Dubowitz described a combination of splints, physiotherapy and 
antibiotics as treatment for this disorder (Dowling et al., 2017). Since then, with help of 
multi-disciplinary treatments DMD is not a childhood life-limiting disorder. Furthermore, 
continuous efforts are undergoing to develop mutation-specific treatment approaches for 
this disorder (Aartsma-Rus et al., 2017b). Becker muscular dystrophy is another 
dystrophinopathy with milder symptoms compared to DMD. Typically BMD starts after first 
decade of life, loss of ambulation occurred in the third decade of life and cardiomyopathy 
is variable. Typically, BMD patients have longer life expectancy compared to DMD. Becker 
muscular dystrophy is result of a small, partially functional protein due to a deletion in 
genetic code which does not lead to frame shift variation (Dohrn et al., 2017). 
 Myotonic Dystrophy (MD) is a systemic disorder caused by CTG repeats expansion that 
results in accumulation of toxic mRNA in the nucleus. MD can be categorized in two main 
types: Type 1 which presents in childhood or early adulthood with weakness of facial 
muscles and distal extremities. In MD1 the triplet expansions (50 to>3500) occur in 3` UTR 
of the Dystrophia Myotonica protein kinase (DMPK) gene locus. MD type 2 is due to CCTG 
expansion (75 to approximately 1100) in the first intron of the gene Zinc finger protein 9 
(ZFN9). At birth, hypotonia, respiratory problems and feeding difficulties are cardinal 
features. During infancy these patients develop cardiac problems, delayed motor 
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milestones and learning disabilities including features of autism spectrum. Some non-
muscle related symptoms such as cardiac arrhythmia, childhood cataract, dysphagia, 
mental retardation and infertility with insulin-resistance are present in Myotonic 
Dystrophies. At the moment, most non-genetic based therapies aim to alleviate non-
neuromuscular symptoms. Genetic approaches to reduce the amount of toxic RNA are 
under investigation (Dowling et al., 2017). 
 Limb Girdle Muscular Dystrophies (LGMDs) are a group of genetically diverse and 
clinically heterogeneous muscular dystrophies. LGMDs symptoms usually start after the 
first year of life with limb girdle progressive muscular weakness, dystrophic muscle 
biopsies and high Creatine kinase (CK) level. LGMDs are subclassified into two major 
groups: Autosomal dominant LGMD or LGMD1 and autosomal recessive LGMD or 
LGMD2.  So far, more than eight genes are associated with LGMD1 (LGMD1A-LGMD1H) 
and at least twenty three genes lead to LGMD2 (LGMD2A-LGMD2W). In total, over 50 
genetic loci were identified in LGMDs. The diverse heterogeneity highlights the problem of 
clinical diagnosis difficulties and various differential diagnosis (Monies et al., 2016). 
Autosomal dominant form of LGMD is less common and responsible for 10-15% of the 
disease frequency. Overall frequency of LGMDs is between14000 to 45000. Among 
different types of LGMDs, type 2A, also known as primary calpainopathy due to mutations 
in CAPN3 at 25-30% is the most common form of LGMD. LGMD2I accounts for 20% of 
LGMD cases and caused by mutations in FKRP gene .Mutations in other genes are rare in 
LGMDs and usually cause adult-onset LGMDs like dysferlinopathy and ANO5 related 
LGMD. Several pharmaceutical and genetical approaches are undergoing to treat LGMDs, 
while few investigations lead to clinical trials like AVV based gene therapy for LGMD2I and 
calpainopathy (Bushby et al., 2007; Patel et al., 2008). 
 Emery-Dreifuss Muscular Dystrophy (EDMD) is a muscular dystrophy caused by 
mutations in various genes. However, most EDMD cases are associated with Lamin A 
(LMNA) or EMERIN mutations. The hall mark of EDMDs clinical presentation is muscle 
weakness of the scapula-peroneal region with a range of severity. EDMD can be life-
limiting in many cases like LMNA associated EDMD which demonstrated with rapid 
progression of muscle weakness, severe contractures and early death. There is a 
significant clinical and genetical overlap between EDMD and other neuromuscular or non-
muscular diseases (such as lipodystrophy and progeria). Palliative treatments for some 
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symptoms of the disease, such as fatal cardiac arrhythmia is one of the key elements of 
therapeutic plan in these patients. Genetic-based treatments such as exon-skipping for 
exon 3 or 5 of LMNA gene, adenovirus therapies for EMERIN or allele specific-silencing 
are of consideration (Dowling et al., 2017). 
 Congenital Muscular Dystrophies (CMDs) are a group of muscular dystrophies with 
common age of onset. Usually these diseases start twelve to eighteen months after birth. 
Symptoms include progressive muscle weakness, skeletal deformity, joint and skin 
involvement. CMDs according to genetic cause can be categorized in three different 
subgroups: LAMA2-related CMDs (merosin deficient CMDs or MDC1A), collagen VI-
related (Ullrich CMD and Bethlem myopathy) and dystroglycaopathies. Like other 
muscular dystrophies, CMDs represent a spectrum of heterogenic and clinically diverse 
group of disorders. Other rare subtypes of CMDs include Marinesco-Sjogern syndrome, 
LMNA-related muscular dystrophies and rigid spine muscular dystrophies (Mercuri and 
Muntoni, 2012).  
 At present, palliative treatments for CMD symptoms are applied in patients. However, 
many genetic approaches included AAV deliveries and CRISPR/CAS 9 for MDCA1, allele 
specific antisense oligonucleotide for collagen VI-related muscular dystrophy and 
molecular approached to improve muscle-matrix adhesion in different CMDs has been 
tested (Bolduc et al., 2014; Dowling et al., 2017). Collagen VI-related muscular 
dystrophies, as the main focus of this research will be described in details later. 
1.1.2 Spinal Muscular atrophy (SMA): 
 SMA is another common pediatric disorder caused by different genes. However, the most 
common genetic cause is mutations in SMN1 gene. This is an autosomal recessive 
disorder with incidence of 1 in 6000 to 1 in 10000 live birth per year. Atrophy of myofibres 
under the microscope is the hallmark of the disease. However, a dramatic genetic and 
phenotypic variation was observed in SMAs with four types of childhood onset (type 
0,I,II,III) and one type of adult onset (type IV).Type I SMA or Werdnig-Hoffman disease is 
the most common one with a deteriorating course and high death incidence. Clinical 
manifestations of SMA include hypotonia with poor head control, proximal muscle 
weakness, feeding and respiratory problems, weak cough and weak cry which start before 
six month of age. Severe forms can never sit. A centromeric gene to SMN1 called SMN2 
act as the main modifier for SMA phenotypic variation. SMN2 encodes a protein with 20% 
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activity of SMN1 protein. The increased copy number variant of the SMN2 gene lead to a 
milder SMA phenotype (Aartsma-Rus et al., 2017a). Gene therapies based on modification 
of SMN2 protein for therapeutic approaches are under investigation (Ramirez et al., 2018). 
Moreover, Nusinersen, an antisense oligonucleotide which target SMN2 exon 7 to include 
it in final transcript shows promising result in clinical trials (Scoto et al., 2017). However, 
treatment approaches for this disorder are still under development  and SMA is still one of 
the common cause of death during childhood (Dowling et al., 2017). 
1.1.3 Charcot-Marie-Tooth disease (CMT): 
 CMT is one of the most common paediatric neuropathies with a prevalence of 1 in 2500 
births. A marked phenotypic and genetic variation is associated with Charcot-Marie-Tooth 
(CMT) disorder. To date, mutations in over 80 genes have been identified as disease-
causing. However, the majority of cases are caused by mutations in four genes: PMP22, 
MPZ, GJB32 and MFN2. Duplication in PMP22so far are the most common cause of CMT. 
Peripheral nerve fibres are the primary pathologic region in CMT disease. Also the 
disorder could involve axon or the myelination of Schwan cells. CMT is subcategorized 
depending on the mode of inheritance (dominant vs recessive) and location of pathology. 
CMT1, CM2 and CM3 caused by neuron demyelination, while CM4 is due to axonal 
demyelination.  Progressive distal muscle weakness, hand and food deformities and loss 
of sensory perception are the common clinical symptoms and signs of CMT patients. 
Genetic based therapies focus on decreasing PMP22 level as this is the mutation of 
excessive protein dosage. Like other paediatric neuropathies the success of different 
treatment strategies in CMT is limited and under investigation (Dohrn et al., 2017). 
1.1.4 Congenital myasthenic syndromes (CMS): 
 CMSs are disorders caused by mutations that affect or dysregulate the neuromuscular 
junction. So far near 30genes have been identified as disease causing.  Mutations in the 
acetylcholine receptor subunit epsilon (CHRNE) are the most frequent cause of CMS. 
Phenotypically, Congenital Myasthenic Syndrome is characterized by facial, mainly ocular 
and bulbar, and muscle weakness which has a fluctuating pattern. Ptosis is one common 
signs in CMS patients. Autoimmune myasthenia gravis has got common symptoms with 
CMS and is a differential diagnosis. Congenital myasthenic syndrome has got a defect-
based classification, disease-onset, with postsynaptic mutation as the most common form 
(~70%) and presynaptic, synptic and synptopathic as other forms. Severity and response 
to treatment is markedly variable among CMS patients. Cholinesterase inhibitor, 
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Pyridostigmine, is the primary treatment in most patients. However, the response to drug is 
variable with some patients showing no effect or even worsening of symptoms. The 
treatment for slow channel CMS-a particular postsynaptic form of CMS with severe 
progression and loss of ambulation in adult stage-(due to gain of function mutation) could 
worsen the symptoms. Whether due to the rarity of the disease or relative effectiveness of 
present drugs, other therapeutic approaches for CMS patients` are not well developed. 
Given the fact that CMS patients response to drugs is variable depending on the genetic 
base of the disease, identifying genetic subtypes in these patients is very important 
(Chaouch et al., 2012; Nicole et al., 2014). 
1.1.5Congenital Myopathies (CMs): 
 CMs are a group of largely variable neuromuscular disorders in terms of genetic cause. 
Clinical presentations of CMs include a spectrum of severe to non-progressive muscle 
weakness, hypotonia and respiratory involvement. Like congenital muscular dystrophies 
(CMDs), CMs start at infancy but could be distinguished from CMDs by non-dystrophic 
muscle appearance and normal serum CK levels.  Core myopathies, Centronuclear 
myopathies, Nemaline rod myopathies and fibre type disproportion are the most common 
examples of congenital myopathies. So far, mutations in over 20 genes are associated 
with CMs and ryanodine receptor (RYR1) mutations are the most common cause. While 
no approved drugs exist for CM patients, several clinical trials for drugs such as Dantrolen 
for RYR1 mutations and L-tyrosin for nemalin myopathy are undergoing research. AAV 
based therapies are also in consideration (Dowling et al., 2017). 
 As mentioned above paediatric neuromuscular disorders are a group of large and 
heterogeneous disease. Clinical presentations of these disorders are markedly variable for 
one disease but overlapping between different groups of neuromuscular disorders. 
Considering this fact, treatment of these diseases is complicated. One major advance 
which could benefit prognosis, consultation and treatment of neuromuscular disorders is 
the identification of the underlying genetic cause (Dohrn et al., 2017). 
1.2 Collagen VI-related myopathies: 
 Collagen VI- related myopathies comprise a spectrum of diseases with Ullrich congenital 
muscular dystrophy (UCMD) in the severe end and Bethlem myopathy(BM) in the milder 
end of the spectrum (Bonnemann, 2011). Collagen VI-related myopathies like other 
neuromuscular disorders, are a group of heterogeneous and clinically diverse disorders.  
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COL6A1, A2, A3 genes which encode heterotrimeric microfibrillar collagen VI protein were 
the first genes to be recognized in collagen VI-related myopathies as pathogenic (Lampe 
et al., 1993). Collagen VI-related myopathies, are a subgroup of congenital muscular 
dystrophies (CMDs), this group of disorders are unified by progressive muscle weakness 
and dystrophic signs in muscle biopsy (Bushby et al., 2014).  
 UCMD was initially reported by Otto Ullrich (1930) as “Atonic-Sclerotic muscular 
dystrophy”. He characterized muscle weakness and joint hypermobility together with 
evolving and significant joint contractures in UCMD patients (Bonnemann, 2011). Ullrich 
congenital muscular dystrophy remained as a severe muscular entity mostly reported in 
European and Japanese patients. However, case reports of UCMD from different parts of 
the world have expanded its geographical prevalence (Furukawa and Toyokura, 1977; 
Allamand et al., 2010; Bozorgmehr et al., 2013). 
 Bethlem myopathy was initially reported by Bethlem and Van Vijngaarden (1976) in the 
Netherland. They recognized the disease as an autosomal-dominant disorder with 
progressive muscle weakness and joint hypermobility. Since then, several reports of 
Bethlem patients have been published.  In 1988 the author of a report of Bethlem 
myopathy in a pedigree of French-Canadian individuals with four affected members 
suggested the name Bethlem myopathy for this distinct clinico-genetic entity (Mohire et al., 
1988). 
 Mutations in COL6A genes were first recognized in Bethlem myopathy as disease-
causing  in the pedigrees of large families from Netherland in 1996 (Jobsis et al., 1996) 
and USA in 1998 (Pan et al., 1998). It was after this discovery that scientists in Italy 
(Bertini and Peppe) noticed common clinical symptoms between Bethlem and Ullrich 
myopathies. This leadto the identification of collagen VI as disease-causing gene in Ullrich 
in 2001(Camacho Vanegas et al., 2001). The term collagen VI-related myopathy was 
coined afterwards. 
1.2.1 Clinical presentation: 
 As mentioned above Ullrich congenital muscular dystrophy and Bethlem myopathy are 
two distinct clinical entities which form the two ends of collagen VI related myopathy 
spectrum. However, intermediate phenotypes with overlapping features of UCMD and BM 
can be found in between. 
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1.2.1.1 Ullrich congenital muscular dystrophy: 
 Congenital muscular dystrophy type Ullrich (UCMD, MIM: 254090) presents at birth or the 
first year of life. However, like other neuromuscular disorders the diagnosis of UCMD 
cannot be made immediately after birth. UCMD patients present with hypotonia, muscle 
weakness and joint hyperlaxity. Distal joints can be extremely hyperlax allowing fingers to 
bend back to the dorsal surface of wrist or drop down to the wrist. This feature may mimic 
other neuromuscular disorders such as Ehlers Danlos syndrome. Joint hyperlaxity leads to 
congenital hip dislocation in about 50% of patients (Bonnemann, 2011). While distal joint 
hyperlaxity is a prominent feature in UCMD patients, some patients also present with 
proximal joint contractures at birth. Contractures are normally seen in hips, knees and 
elbows (Lampe et al., 2008). Other signs of UCMD at birth includes torticollis (Spasm in 
neck muscle which leads to lateral bending of neck from central body axis), skeletal 
deformities such as kyphosis (internal bending of spine), kyphoscoliosis (internal and 
latheral bending of spine) and pes adductus (internal bending of foot from central body 
axis) Prominent calcaneus is another common sign. Overall 50% of UCMD patients shows 
skeletal system deformities (Bonnemann, 2011).   
 Presence of one of the above-mentioned signs in conjunction with delayed motor 
milestones suggests UCMD diagnosis. Connective tissue symptoms are a key factor in 
UCMD diagnosis and could differentiate between UCMD and other neuromuscular 
disorders. 
 Delayed motor milestones are progressive in UCMD. While most severe UCMD patients 
never achieve independent walking, some manage to crawl. Walking ability in others is 
diminished during childhood as a result of progressive muscle weakness or development 
of contractures in lower limb joints. At the median age of ten years old, most UCMD 
patients are wheelchair dependent. Muscle weakness affects both upper and lower limbs 
with preserved antigravity force in even severe patients (Bonnemann et al., 2011).  
 Skin involvement is another symptom in UCMD. Excessive keloid formation after surgery 
is one example of skin signs. Hyperkeratosis pilaris (pathches of extra skin formation 
sometimes in different colour from normal skin) in extensor surfaces of upper limb is seen 
in these patients. The skin signs are not specific to UCMD patients. However, should be 
considered in most severe cases (Bonnemann et al., 2011). Figure 1.1 and 1.2 shows 
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some signs and symptoms of collagen VI-related myopathies and particularly UCMD 
patients. 
 
 
  
Figure 1.1.Different symptoms of collagen VI-related muscle 
patients. Contractures in elbow (A), ankle and knee (B), 
fingers(C,D), skin involvement such as hyperthrophy (E), kloid 
formation (F), joint contractures in foot fingers and hand fingers 
(G,H), joint hyperlaxities (I, J, K) (Bushby et al., 2014). 
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 Some other features of UCMD are respiratory involvement and feeding difficulties. Both 
symptoms occur in the context of muscle weakness. Restrictive pattern of pulmonary 
disease due to chest wall and diaphragmatic muscle weakness needs to be monitored in 
Figure 1.2.Clinical presentations of UCMD 
patients.(A) Patient able to walk with mild knee and 
elbow contracture. (B) Typical contractures of UCMD in 
elbow, pectoralis major, hips, knees. (C) Prominent 
calcaneus and striking hiperlaxity in toes finger. (D) 
Phalangeal hyperlaxity (Bonnemann, 2011). 
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these patients. Supportive care should be considered in most severe cases who develop 
esophagogastreal reflux or need to be fed through the stomach. Cardiac involvement is 
not reported for UCMD patients and intact cardiac system could help in differential 
diagnosis in these patients (Bushby et al., 2014). 
1.2.1.2 Bethlem myopathy: 
 Bethlem myopathy is another collagen VI-related myopathy disorder which form the milder 
end of collagen VI-related myopathy spectrum. Bethlem myopathy (BM, MIM:158810) 
could present at birth with symptoms such as torticoli- twisted neck or abnormal flexion of 
head or neck muscles-congenital deformity in which the heel is flexed inward and the foot 
is plantar flexed- and skeletal deformities such as equinovarus deformity (Skletal deformity 
with outward heel flexion) and foot dorsiflexor contractures (50%). Muscle weakness is 
either not present at birth or very mild. Contractures which present at birth will resolve 
during the first year of life. However, usually new contractures set in during the first decade 
of life. Contractures involve distal joints like Achilles tendon, elbows, pectoralis muscles, 
long finger flexors and particularly interphalangeal muscle of 2 to 5 digits. Adult affected 
individuals often cannot put the plantar surface of their hands together (Bonnemann, 
2011). Figure 1.3 shows some signs of Bethlem myopathy. 
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 These contractures often progress during the course of the disease. Limited hand function 
due to contractures has been reported in BM patients. Distal joints hyperlaxity is another 
connective tissue sign in Bethlem patients. However, it might not be severe as Ullrich 
affected individuals. 
 Delayed motor milestones such as delay in ambulatory state or difficulties to run have 
been reported in BM patients. However, the weakness is less and has a stable pattern 
before the third decade of life. At this time, muscle weakness which is mostly present in 
proximal muscle starts to progress.  By the age of fifty, around two thirds of BM patients 
lose their ambulation. However, many BM patients present a  mild muscle weakness which 
they do not notice it themselves and it is only identified during neural examinations 
(Bonnemann et al., 2011). Respiratory involvement is another feature of BM (Quijano-Roy 
et al., 2014). Like UCMD patients, respiratory involvement results from rib cage muscle 
stiffness and weak diaphragmatic muscles. Respiratory symptoms are often seen in most 
Figure 1.3.Clinical presentations of Bethlem 
myopathy. (A) Patients are able to stand and walk with 
elbow and knee contractures. (B) Typical finger 
contractures in Bethlem myopathy. (C) keloid formation 
in Bethlem myopathy (Bonnemann, 2011). 
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severe BM cases and monitoring is needed (Foley et al., 2013). Skin involvement in BM 
patients is mostly present as keloid formation without velvety skin (Bushby et al., 2014). 
Cardiac problems have been reported just in one case of BM with asymmetrical septal 
hypertrophy. This finding may represent an incidental sign (Bonnemann, 2011).  
 Signs and symptoms mentioned above are representing more classical features of 
Bethlem myopathy. However, a wide number of signs and symptoms are attributed to BM. 
Those with prominent proximal weakness and less joint involvements mimic limb girdle 
muscular dystrophy (LGMD), whereas those with less muscle weakness signs and more 
contractures could overlap with myosclerosis. These issues will be described later in 
differential diagnosis section (Demir et al., 2004; Allamand et al., 2010). 
1.2.1.3 Intermediate phenotype: 
 Discovery of collagen VI as disease-causing gene in both UCMD and Bethlem conditions 
in conjunction with improvements in diagnostic tools leads to better understanding of 
collagen VI-related myopathy phenotypic spectrum (Mercuri et al., 2002). The term 
intermediate phenotype is attributed to all patients with collagen VI mutations but a 
transitional severity in their phenotypes. Patients in this group show a phenotype more 
severe than Bethlem but milder than UCMD. Intermediate phenotype patients present at 
birth with muscle weakness which could be severe. Also other features at birth may 
overlap Bethlem and UCMD. They could have severe distal hyperlaxities of UCMD at birth, 
whereas interphalangeal contractures of BM also exists.  Muscle weakness could be 
stable with achieved ambulation. However, walking aids may be needed. Ambulation could 
be lost at later age than in typical UCMD patients or last even longer time than BM 
patients. Respiratory involvement is seen in intermediate phenotypes as well. Respiratory 
problems like other collagen VI-related patients need to be monitored (Bushby et al., 
2014). 
1.2.2 Prevalence of collagen VI-related myopathies: 
 A prevalence of 0.13 in 100000 for UCMD and 0.77 for BM has been reported so far. With 
different reports of collagen VI-related myopathies from all around the world, a worldwide 
distribution was proposed for these disorders (Allamand et al., 2010). However, new 
reports of collagen VI-related myopathies with different features are emerging (Clement et 
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al., 2012; Mercuri and Muntoni, 2012). An increasing number of reports of heterogeneity 
associated with collagen VI-related myopathy phenotypes can be found in the literature.  
1.2.2.1 Prevalence of heterogenic collagen-VI related myopathies: 
 An emerging number of patients with collagen VI-related myopathy phenotypes have 
been reported that does not have any mutations in their COL6A1-A3 genes (Bonnemann, 
2011). A retrospective study of congenital muscular dystrophies’ frequency in UK from 
2001-2008 reported that collagen VI-related myopathy has the higher frequency (19%) 
then dystroglycanopathy (12%) and merosin deficient congenital muscular dystrophy 
(10%) (Clement et al., 2012).One of the first example of collagen VI-related myopathy 
heterogenic patients was reported by Ishikawa. They discovered a UCMD patient with 
absence of collagen VI in muscle staining but no mutation was found in COL6A1-A3 genes 
(Ishikawa et al., 2004). In following years other reports of collagen VI-related myopathy 
patients with genetic heterogeneity came out (Bonnemann, 2011). However, the frequency 
of collagen VI-related myopathy phenotype with no mutations in collagen VI genes is not 
evaluated in any studies yet .In the MRC centre for neuromuscular disorders in Newcastle 
50% of collagen VI-related myopathy phenotypes do not have any collagen VI mutations 
(Debbie Hicks, personal communication). Due to mild clinical features in some BM patients 
and heterogeneity in collagen VI-related myopathy which lead to undiagnosed or 
misdiagnosed patient, the real frequency of collagen VI-related myopathy is estimated to 
be higher (Clement et al., 2012) . 
1.2.3 Differential diagnosis of collagen VI-related myopathies: 
 As described above, collagen VI-related myopathies have a broad spectrum of clinical 
phenotypes. In accordance with this, the major differential diagnosis of collagen VI-related 
myopathies varies. Discovery of patients with Limb-girdle muscular dystrophy phenotype 
and myosclerosis myopathy phenotype with mutations in COL6A1-A3 genes has led to 
classification of these two phenotypes as rare subtype of collagen VI-related myopathy 
(Jobsis et al., 1996; Scacheri et al., 2002; Merlini et al., 2008b).  
 Scacheri et al (Scacheri et al., 2002) in 2002 reported patients from three large families 
with variable limb-girdle-muscular dystrophy phenotypes. Proximal muscle weakness with 
onset from neonatal to adulthood was the prominent feature. Connective tissue 
involvement in terms of joint contractures was absent or milder than expected for collagen 
VI related myopathies. Patients have normal to slightly increased serum CK level with 
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dystrophic signs such as necrosis, fibre type variation and internal nuclei in muscle 
biopsies. Heterozygous missense mutations in COL6A1 and COL6A2 in three pedigrees 
were responsible for the disease in autosomal dominant mode of inheritance. 
 In 2008, Merlini et al (Merlini et al., 2008b) reported two siblings of consanguineous 
parents with myosclerosis features. Progressive muscle weakness from childhood, multi-
joint and Achilles tendon contractures, Slender Woody muscles –decrease in muscle bulk 
in the centre with long shaft muscles- with elevated CK levels were some of the clinical 
features in these patients. A homozygous missense mutation was identified in both 
siblings in the COL6A2 gene. This mutation lead to misfolded col6a2 protein which could 
assemble to collagen VI monomers but the subsequent trimerization was prevented. 
Absence of collagen VI in immunofluorescence staining of fibroblast and muscle biopsies 
was seen in these patients (Merlini et al., 2008b). 
 The above mentioned reports are two examples of collagen VI-related myopathy 
phenotypic variability which expand the phenotypic and differential diagnosis spectrum of 
these disorders. For patients with congenital onset of symptoms, other types of muscular 
dystrophies as well as congenital myopathies should be considered as differential 
diagnosis. Limb-girdle muscular dystrophy is a major differential diagnosis for the patients 
with adult onset symptoms and less connective tissue signs. For a classical Bethlem 
phenotype with joint contractures Emery-Dreifus muscular dystrophy is an important 
differential diagnosis (Brinas et al., 2010).   
 Patients with proximal muscle weakness, adult-onset of the disease and mild to absent 
connective tissue signs could widely overlap with limb-girdle muscular dystrophy. 
Immunohistochemical staining, muscle biopsy which could show specific pattern of LGMD 
subtypes and gene screening for Limb-girdle muscular dystrophy in particular LGMD1B 
subtypes could help better diagnosis. One other differential diagnosis for these patients is 
Central core myopathy disease. This disorder is characterized by symmetrical muscle 
weakness, delayed motor development, congenital signs of hypotonia, joint laxity or 
contractures and spinal deformity. Even muscle biopsies from collagen VI-related 
myopathy patients could resemble central core myopathy signs with minicore-like lesions 
or congenital type I fibre disproportions. MRI with central core myopathy specific sign is 
important for right diagnosis (Bushby et al., 2014). 
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 Emery-Dreifus muscular dystrophy (EDMDs) considered to be the most important 
differential diagnosis for collagen VI-related myopathy disorders. This X-linked or 
autosomal form of neuromuscular disorder is caused by mutations in Emerin or Lamin A/ C 
genes. Muscle weakness and distal joint contractures are the main feature of this disorder. 
However, interphalangeal contractures which are found in BM myopathy are absent in 
EDMDs. Furthermore, cardiac involvement is very common and severe in EDMDs while it 
has not been reported in collagen VI-related myopathies. Patients with skin involvement 
are more likely to have collagen VI-related myopathies. Also, joint hyperlaxity and skin 
involvement are the distinct features of collagen VI-related myopathies (Bonnemann, 
2011). 
 In infants or young children with muscle weakness and contractures, other forms of 
congenital muscular dystrophies which have congenital presentations should be 
considered. α-dystroglycanopathies, merosin-deficient muscular dystrophy or MDC1a, 
Fukuyama disorder or MDC1C (FKRP mutations), MDC1D(LARGE mutations),muscle-
eye-brain disorders are some examples of these CMDs. Moreover, cardiac involvement, 
brain abnormalities revealed by MRI and highly increased CK level are some features 
which help to distinguish the true pathology (Bushby et al., 2014). 
 Ehlers-Danlos syndrome for patients with joint hypermobility is also a differential 
diagnosis. However, skin hyperelasticity, as a sign of Ehlers- Danlos syndrome, is rarely 
seen in collagen VI-related myopathies. Furthermore, muscle weakness and contractures 
are either absent or very mild in Ehlers- Danlos syndrome compare to Bethlem myopathy 
(Bushby et al., 2014). 
 As genetic and paraclinic means of diagnosis improve, the differential diagnosis for 
collagen VI-related myopathies will be broader. In 2013, our team together with Cossins et 
al (Cossins et al., 2013) reported novel genesALG2 (Asparagine-linked glycosylation 2) 
and ALG14 (Asparagine-linked glycosylation 14) in three families with large pedigrees. 
Two of these families with three affected individuals had been treated for congenital 
myasthenic syndrome in Oxford. They show an autosomal dominant pattern of inheritance 
for two mutations in ALG2 and ALG14 gene, respectively. ALG2 is a member of post-
translational glycosylation family. Other members of this family such asDPAGT1 have 
been identified in myasthenic patients as disease-causing genes (Belaya et al., 2012). The 
later family was a large family with four affected siblings and unaffected parents. This 
 
 
 
 
17 
 
Saudi Arabian family shows an autosomal recessive pattern of inheritance and had been 
referred as Ullrich congenital muscular dystrophy phenotype with no mutations in COL6A 
genes in the Centre for Neuromuscular Disorders in Newcastle. All four affected 
individuals had a history of hypotonia, muscle contractures and delayed motor milestones 
during infancy or the first year of life. Ambulation was lost in four affected siblings. 
Respiratory insufficiency was seen with variable severity in all four affected individuals. No 
cardiac or skin involvements was seen. Muscle weakness had a progressive pattern in 
proximal muscle without fluctuation. No history of ptosis was recorded. Previous evaluation 
did not reveal any mutations in COL6A genes and immunofluorescence staining for 
collagen VI in fibroblast of patients was normal. Autozygosity analysis identified a region of 
27 MB in chromosome 9 (9q31.1) as the homozygous candidate interval. Whole-exome 
sequencing was used to identify mutations in this candidate interval. With filtering 
algorithm less likely pathogenic variants based on their frequency (>1%) and prediction to 
be non-pathologic were excluded. The resulting 48 candidate variants were investigated 
through Sanger sequencing. One variant c.214-
226delGGGGACTGGCTGCinsAGTCCCCCGGC p.72-75delGDWLinsSPR was identified 
in ALG2. Figure 1.4 shows this variant in the family.  
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Figure 1.4. Asparagine-link-glycosylation2 (ALG2) segregation in a large 
family of Ullrich like phenotype. An indel in the gene Asparagine Link 
Glycosylation-2 (ALG2 exon1 NM.033087.3:c.283-
296delGGGGACTGGCTGCc.283-293insAGTCCCCGGC p.73-
76delGDWLinsSPR) was found which completely segregated with UCMD in 
corresponding pedigree. Affected individuals are homozygote for this variant 
while unaffected individuals are heterozygote for the variant. The variant acting 
as recessive. 
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 Retrospective clinical evaluation which revealed signs of myasthenic syndrome as facial 
weakness and repetitive nerve stimulation (RNS) which showed an increase in two 
examined patients led to a diagnosis of congenital myasthenic syndrome in these patients 
(Cossins et al., 2013). 
 The above mentioned case, as an incidental finding during our research for novel genes 
in collagen VI-related myopathy phenotypes has broadened the spectrum of these 
disorders differential diagnosis. 
1.2.4 Pathogenesis of collagen VI-related myopathies: 
 Collagen VI is known to be responsible for around 50% of collagen VI-related myopathies 
(Debbie Hicks, personal communication). Collagen VI is a heterotrimeric monomer mainly 
consisting of three α-chains: α1, α2 and α3. These chains are encoded by COL6A1, 
COL6A2 and COL6A3 genes.The first two genes are on chromosome 21q22 and COL6A3 
is on 2q37. A short chain of 331-336 amino acid is the backbone of each of the collagen VI 
α-chains. Figure 1.5 shows collagen VI chains and their assembly (Bushby et al., 2014). 
 
 
 
 
 
 Collagen molecules undergo different steps of assembly. A cysteine residue is always 
placed in the N-terminal part of each collagen chain. This residue is necessary for 
Figure 1.5.Collagen α1 (VI), α2 (VI), α3 (VI) polypeptide chain 
structure. Three α chains encoded by COL6A1, COL6A2 and 
COL6A3 genes. Each chain comprises of von wilebrand factor A 
domains and fibronectin type III domains. Cysteine residue which is 
crucial for collagen VI dimerization and tetramerization is 
demonstrated in each chain From (Lampe and Bushby, 2005) 
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intracellular assembly and subsequent dimerization and tetramerization of collagen VI. 
Collagen (α1) VI and collagen (α2) VI have similar structures with two possible C-terminal 
and one N-terminal von wileberand globular A domain. C-terminal undergoes post-
translational assembly and splicing. For example COL6A2 has two spliced C-terminals.  
The C1is enough for monomerization but C2 is important in post-translational assembly 
Collagen (α1) VI and collagen (α2) VI chains are likely to derive from duplication of a 
common ancestral gene. Collagen (α3) VI chain has one large and spliced N-terminal 
domain with one C-terminal domain. The distinct role of these splice variants is unknown 
but the truncated splice variants (with any affected domains) seem to have lesser effects 
than non-spliced ones (Demir et al., 2004). 
 
 Three additional COL6A genes, COL6A4, COL6A5 and COL6A6 have been identified in 
mouse. Two of these genes, COL6A5 and COL6A6 are also present in humans, while 
COL6A4 is interrupted by and is not functional. COL6A5 and COL6A6 are able to 
substitute for COL6A3 during collagen VI trimerization. However, no patients with 
mutations in these genes have been reported so far (Fitzgerald et al., 2008; Bushby et al., 
2014). 
 COL6A1, COL6A2 and mainly COL6A3 combine to make a collagen VI monomer. This 
trimeric then undergoes a complicated assembly process which starts from C-terminals. 
Gly-X-Y motifs in the C-terminus play important role to establish the monomerization. In 
this motif, One glycine is repeated in every three amino acids. X and Y represent two other 
amino acids. N-terminal cysteine in α1 and α2 chain should interact with C-terminus 
globular end cysteine of another α chains in order for two collagen VI monomer twitch to 
each other in an antiparallel arrangement. Two collagen VI dimers are associated to each 
other in parallel direction to form a tetramer. Thus, dimers of collagen VI as well as 
tetramers are stabilized with disulfide bonds. Collagen VI is secreted to the extracellular 
matrix as tetramers. These tetramers then align end to end to form microfibrils. These 
microfibrils of collagen VI in extracellular matrix have the periodicity of 100-105nm and 4.5 
nm diameter (Bonnemann, 2011). Figure 1.6 shows collagen VI molecules assembly. 
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(Bonnemann, 2011) 
 
 
 Collagen VI is found in many tissues and organs such as muscle, tendon and endothelial 
part of vessels, cornea, eye, skin and cartilage. In these tissues, collagen VI is localized in 
the extracellular matrix material called basement membrane (Bonnemann et al., 2011). 
The basement membrane in muscle tissue is neighbouring muscle fibres. It was believed 
that the basement membrane had only anatomical role in muscle structure. However, 
recently it has been found that the basement membrane is an active structure with 
signalling, synaptogenesis and myogenesis roles (Bonnemann, 2011). Therefore, 
mutations in basement membrane proteins such as collagen VI are responsible for some 
of the muscular dystrophies. Other type of neuromuscular disorders are caused by 
mutations in the dystrophin-glycoprotein complex (DGC) which comprises crucial proteins 
for muscle function and integrity. DGC is a complex of glycoproteins and oligomeric 
proteins which localizes to the sarcolemmal membrane and mediates linkage of actin 
Figure 1.6.Schematic picture of collagen VI molecule assembly. Upper figure shows 
intracellular assembly from the heterotrimeric monomer composed of all three a chains 
(*), via antiparallel dimer (†) to tetramer (‡) formation. The lower picture shows the 
formation of the beaded collagen microfilaments with 100-nm periodicity of tetramers, 
These microfilaments formed by close interaction of the C- and N-terminal globular 
domains (Bonnemann, 2011). 
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filament to extracellular matrix and maintains muscle membrane stability (Bushby et al., 
2014). Figure 1.7shows a schematic picture of DGC complex.
 
 
 
 In addition, collagen VI is located around the pericellular space of tendons and nerves. 
Immunofluorescence staining shows the affinity of collagen VI for other basement 
membrane molecules such as collagen type IV, perlecan and lamininɣ1. Collagen VI in the 
extracellular matrix mostly interacts with collagen II and collagen IV fibrils and possibly 
collagen I (as the most abundant type of fibrils), fibronectin, fibulin-2, perlecan, decorin, 
byglycan, heparin and hyaluran. Collagen VI also binds to cell surface of CD44, NG2 and 
integrin. The specific receptor for collagen VI in muscle cell is unknown (Bonnemann, 
2011). 
Figure 1.7. Schematic picture of DGC complex. Different molecules in DGC 
complex and their interaction was depicted in schematic view. Collagen VI is an 
extracellular molecule in this complex 
(https://neuromuscular.wustl.edu/musdist/dag2.htm). 
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 The exact pathomechanism for collagen VI-related myopathy is unknown. It has been 
suggested that collagen VI could play roles in proliferation, adhesion and DNA synthesis 
for mesenchymal cells and neural crest. Research reveals an absence of collagen VI from 
basal lamina in UCMD patients. In these patients basal lamina has also lost attachments 
to extracellular matrix. These findings suggest a role for collagen VI in basement 
membrane attachments (Ishikawa et al., 2002). Furthermore, collagen VI plays a role in 
fibronectin organization in fibroblasts cells. Without collagen VI anchoring fibronectin in 
ECM, the extracellular matrix might be disorganized (Bushby et al., 2014). However, the 
role of collagen VI in myogenic tissue is unknown. It might be that collagen VI affects 
myogenic cells through an indirect pathway, because collagen VI is secreted from 
interstitial fibroblasts in muscle tissue (Zou et al., 2008). It is suggested that collagen VI 
induces myogenic cell DNA synthesis and proliferation. Furthermore, there is a possibility 
of direct link between collagen VI and muscle matrix via NG2 (Petrini et al., 2005). Several 
studies suggest that collagen VI could influence apoptosis in cells through relatively 
unknown pathway (Irwin et al., 2003; Petrini et al., 2005) 
 Our understanding of collagen VI-related myopathies has developed via animal modelling. 
Homologous inactivation of COL6A1 locus helped to generate a mouse model of collagen 
VI deficiency. This mouse shows very mild neuromuscular phenotype, in contrast to 
patients with complete collagen VI α1 chain deficiency who show severe UCMD signs.  
However, myopathic signs such as necrosis, phagocytosis and variation in fibre type 
diameter were reported from collagen VI deficient mouse. Furthermore, contractile 
strength is reduced in this mouse which could be associated with ultrastructural 
disorganization of sarcoplasmic reticulum or mitochondria (Bonaldo et al., 1998). 
Mitochondrial permeability transition pore (PTP) in COL6A1-/-  null mouse had dysfunction 
which led to early breakdown of mitochondrial potential in mitochondria pre-challenged 
with oligomycin (Irwin et al., 2003). This PTP dysfunction is under influence of cyclophilin 
D and with adding wild type collagen VI or cyclophilin D inhibitor cyclosporine A could be 
corrected (Palma et al., 2009). Collagen VI-cyclophilin D double-knockout mouse has 
prevented PTP dysfunction and decreased muscle apoptosis which confirms cyclophilin D 
role in PTP dysfunction (Palma et al., 2009). Increased apoptosis was reported also in 
fibroblasts cell cultures from collagen VI-related myopathy patients and muscle biopsies of 
patients (Merlini et al., 2008a). In addition, electron microscopy of COL6A2 affected 
individuals’ skin biopsy reveals abnormality in mitochondria (Zamurs et al., 2015).  
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However, PTP dysfunction is not specific of COL6A1 -/- mouse and was also seen in 
merosin-deficient myopathy (Millay et al., 2008; Hicks et al., 2009a). Thus, more studies in 
this field is needed to reveal potential relation between apoptosis pathway and collagen VI 
deficiency (Bushby et al., 2014). In COL6A1 null mouse mitochondria and sarcoplasmic 
reticulum have altered morphology as well (Bonaldo et al., 1998). Another observation 
about COL6A1 deficient mouse is its impaired autophagic function. This suggests a 
relation between mitochondrial dysfunction and muscle degeneration. Inducing autophagy 
in collagen VIα1 deficient mouse could ameliorate its symptoms which opens a way for 
therapeutic method in collagen VI-related myopathy patients (Bushby et al., 2014).  
 A zebrafish model of collagen VI-related myopathy which used morfolino approach to 
knock down COL6A1 and COL6A3 genes, has shown PTP dysregulation and increase 
apoptosis rate as well as impaired muscle development (Telfer et al., 2010). 
1.2.5 Phenotype/ Genotype correlations: 
 So far, a large number of mutations in COL6A1, COL6A2 and COL6A3 have been 
reported in collagen VI-related myopathies.  However, this should bear in mind that lack of 
mutations in COL6A1, COL6A2 and COL6A3do not exclude the possibility of Bethlem or 
Ullrich congenital muscular dystrophies (Bushby et al., 2014). 
 In 2010, Allamand et al (Allamand et al., 2010)reported more than 35 mutations inherited 
as autosomal recessive in 30 families and 38 mutations acting as dominantly negative in 
58 autosomal dominant patients. In Bethlem myopathy, 45 dominant negative mutations 
has been identified in 65 Bethlem families (Allamand et al., 2010).As the number of 
reported mutations in collagen VI-related disorders increase, genotype-phenotype 
correlation studies begin to emerge. We describe common genetic mutations and mode of 
inheritance for Bethlem and Ullrich congenital muscular dystrophys below. 
1.2.5.1 Bethlem myopathy: 
 BM is mostly reported as an autosomal dominant disorder, with mutations acting as 
dominantly negative in one allele inherited from a parent or emerged as de novo. 
Mutations in Bethlem myopathy could be classified in three types. The most common form 
is mutations in Gly-X-Y motif in N-terminal end of collagen microfibrils (Brinas et al., 2010). 
Lamande et al (Lamande et al., 2002) reported that this type of mutations may cause a 
kink in the collagen VI tetramer which is responsible for the dominant negative effect of the 
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mutations (Lamande et al., 2002). However, these mutations have different severity in 
clinical phenotypes based on the effect of mutation in protein assembly. The more severe 
ones fall into UCMD category (Bonnemann, 2011). 
 The second most common mutation in Bethlem myopathy is in frame deletion of exon 14 
in collagen α1 (VI) chain. This mutation results in a lack of one cysteine which is important 
for the dimer assembly. Because the covalent attachments which stabilizeing dimers form 
between parallel cysteins. The more severe forms of these mutations which could inhibit 
monomerization, could also cause UCMD (Pan et al., 2003). The third most common 
mutations in BM patients are those which do not affect triple helical domain of protein.   
These types of mutations are mostly seen in patients with the Limb-girdle muscular 
dystrophy pattern (Scacheri et al., 2002). In 2009, Foley et al (Foley et al., 2009) reported 
a case of autosomal recessive Bethlem myopathy. The two affected individuals were 
compound heterozygous for a single nucleotide deletion (exon 23; c.1770delG), which 
caused in-frame deletion of exon 23in one allele (maternal) and a missense mutation in the 
other allele (paternal) of COL6A2. While Homozygosity for the null allele inhibited collagen 
tetramerization, the affected mother do not show any symptoms. It seems that the 
missense mutation from paternal allele could increase pathogenicity, and the affected 
heterozygous siblings represent Bethlem phenotype (Foley et al., 2009). The similar 
mechanisms of compound heterozygosity was described by Gualandi et al with one 
truncated mutation and one missense mutation in COL6A2 (Gualandi et al., 2009). 
1.2.5.2 Ullrich congenital muscular dystrophy: 
 The first UCMD mutation described were null mutations in COL6A2 inherited in an 
autosomal recessive pattern and that to absence of collagen α2 (VI) in patients’ muscle 
biopsy (Camacho Vanegas et al., 2001). Subsequently, a large number of mutations which 
led to premature stop codon in collagen VI α1, α2 and α3 have been reported. All these 
mutations are inherited in an autosomal recessive pattern and cause an absence or 
significant decrease in the amount of protein in immunohistochemical evaluation. The ones 
that located in alternatively spliced regions always show milder symptoms(Lampe and 
Bushby, 2005). Furthermore, haploinsufficieny in one of collagen VI chains does not affect 
the protein structure and many of heterozygote individuals with these mutations are 
healthy carriers. Splice-site mutations which lead to out-of-frame exon skipping or in frame 
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exon skipping in C-terminal of the protein are another example of UCMD recessive 
inheritance (Bonnemann, 2011). 
  As mentioned above the number of mutations acting as dominant negative in UCMD is 
almost equal to recessive mutations. De novo mutations which cause in-frame exon 
deletion and often acting as dominant negative are responsible for high proportion of 
dominant UCMDs (Allamand et al., 2010). These mutations always cause exon deletion in 
N-terminal part of the collagen chain. Thus, collagen chain could assemble to dimers and 
tetramers but spare cysteins in these parts affect higher-order assembly in mutant chains. 
Generally, UCMD phenotypes associated with dominantly acting mutations are more likely 
to present milder symptoms and achieved ambulation during infancy. However, the course 
of the disease is still progressive (Foley et al., 2011). While heterozygous dominant 
negatively-acting mutations and recessively-acting loss-of-function mutations are the two 
common way of inheritance in UCMDs, in 2011, Foley et al (Foley et al., 2011) described 
large genomic deletions on chromosome 21q22.3 which is inherited as autosomal 
recessive in two families. Clinically unaffected parents had large genomic deletions of 
COL6A1 and COL6A2 which could obscure the true genetic causation of the disease in 
non-deleted allele when it inherited hemizygously. These unaffected individuals provide 
evidence that haploinsufficiency for COL6A1 and COL6A2 is not a disease mechanism for 
Bethlem myopathy. Single nucleotide polymorphisms (SNP) array was used to detect the 
deletion that included COL6A1 and COL6A2 with adjacent genes (Foley et al., 2011).In 
2010, bovolenta et al (Bovolenta et al., 2010) represented a GCH system to detect copy 
number variants in coding and non-coding regions of COL6A1-A3 genes and other related 
genes. They investigate a cohort of 12 BM patients with this system and find a deep 
intronic mutation in COL6A2 gene in BM patient. This mutation from a non-affected parent 
when accompanied with polymorphism from another unaffected individual led to BM 
symptoms (Bovolenta et al., 2010). It is important to remember single nucleotide 
sequencing could not detect such mutations in patients and more complicated modes of 
mutation segregation in collagen VI-related myopathy remain to be elucidated. 
1.2.6 Collagen VI-related myopathy diagnosis strategy: 
 After considering the clinical presentation, collagen VI-related myopathy may include in 
differential diagnosis table for a neuromuscular patient. There are laboratory, imaging and 
genetics steps which help to confirm Collagen VI-related myopathy diagnosis. 
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 Serum creatine kinase level as one cheap and available laboratory test is measured in 
neuromuscular disorders. CK in collagen VI-related myopathy can be normal, slightly 
elevated or highly elevated (up to five times). CK could go back to normal levels during 
course of the disease (Bushby et al., 2014). Magnetic resonance imaging (MRI) of limb 
muscles is another diagnostic method in BM and UCMD patients. Imaging in these 
patients reveals a picture of connective tissue and fat replacement in muscle which is 
focused around the fascias of muscle. This pattern is mostly seen in tight muscle such as 
rectus femoris and vastus lateralis (Mercuri et al., 2002). The periphery of the involved 
muscle has markedly increased signals with central sparing. Central shadow in these 
patients describes as increased signal in the anterior part of rectus femoris is mostly 
focused around central facsia. MRI of calf muscles represents diffuse and increased 
signals of fatty infiltration in soleus, gastrocnemius, tibialis anterior and popliteous muscle 
(Mercuri et al., 2003). Figure 1.8 represents muscle MRI in patients. 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
Figure 1.8. MRI features in collagen VI related myopathy. A) MRI of normal 
tight muscle. B) Diffuse pattern of involvement with relative sparing of the 
Gracilis and Sartorius muscle. A rim of abnormal signals is visible around 
muscle periphery with relative central sparing. Signal intensity is in the central 
part of muscle markedly increased (Bushby et al., 2014). 
A 
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Electromyography (EMG) is another method specified for neuromuscular disorders. 
Pathologic changes of muscle demonstrate in EMG as reduced number of high-amplitude 
polyphasic motor unit potentials and prolonged insertional activity (Allamand et al., 2010). 
 Muscle biopsy is another method for differentiating different types of muscle disorders.  
Muscle biopsy in UCMD demonstrates common dystrophic features of replacement of 
muscle fibers with fibrous connective tissue, fatty infiltration, fibre diameter variation and 
muscle degeneration signs. In Bethlem myopathies muscle biopsy could be variable and 
shows normal to mild myopathic features. These features include muscle fibre 
disproportion and fibre atrophy. These features are ameliorating with age. Muscle biopsy 
sometimes mimics core-muscle myopathy signs which could cause false diagnosis 
(Bonnemann et al., 2011). Immunohistochemical studies in muscle for collagen VI show a 
spectrum of absent to moderately or markedly reduced signals around basal lamina that 
could be normal for endomysium. In severe cases with normal immunofluorescence 
staining of collagen VI in fibroblast, a dual- labelling of collagen VI with a basement 
membrane marker as perlecan or collagen IV is helpful. In these cases proper localization 
of collagen VI was lost because the secreted protein could not assemble to extracellular 
matrix. In milder cases this detachment from basal lamina could be partial or muscle 
immunolabeling present as normal. Figure 1.9 and 1.10 demonstrates 
immunohistochemical staining of muscle in patients (Bonnemann et al., 2011; Bushby et 
al., 2014). 
 
 
 
 
Figure 1.9.Immunohistochemical staining of collagen VI in muscle biopsies 
of normal and mutant individuals. Collagen VI is absent from basement 
membrane of muscle biopsy of an individual with collagen VI related myopathy 
(B) compare to control (A). Collagen Vi signals depicted in red and demonstrated 
with black arrow pointed basement membrane in control panel (Bushby et al., 
2014). 
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 Because of limitations for accessing muscle biopsies, immunohistochemical staining in 
dermal fibroblast from collagen VI patients has been considered in several studies 
(Jimenez-Mallebrera et al., 2006; Hicks et al., 2008). Hicks et al (Hicks et al., 2008) 
reported that immunofluorescence staining for collagen VI in dermal fibroblast from 
patients is a sensitive and specific method to diagnose collagen VI subtle abnormalities. 
78% of genetically confirmed Bethlem patients reported to demonstrate abnormalities in 
immunofluorescence staining. They suggested to use immunofluorescence staining as 
predictive tool to guide genetic test for collagen VI-related myopathy phenotype (Hicks et 
al., 2008). Figure 1.11 shows possible changes in immunofluorescence staining of 
collagen VI in Bethlem patient fibroblasts. 
Figure 1.10.Dual labelling of basement membrane markers in muscle 
biopsies of normal and mutant patients. Detachment of collagen VI (red) 
from basement membrane marker (green) is demonstrated in patients compare 
to normal biopsy. In normal biopsy attachment lines (yellow) are demonstrated 
as combination of collagen VI(red) and basement membrane marker(green) 
(Bonnemann, 2011). 
100µm 50µm 
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 Genetic tests are widely believed to be the gold-standard for Bethlem myopathy 
diagnosis. Genetic analysis sequences all exons in three COL6A (A1, A2, A3) genes 
(Lampe et al., 2005). However, in order to confirm pathogenicity of a genetic variation, 
inheritance pattern of that variation in the corresponding pedigree should be investigated 
(Bonnemann, 2011). Analysing collagen VI production in dermal fibroblasts with 
immunofluorescence staining that could show signal reduction due to less protein 
Figure 1.11.Immunofluorescence staining of fibroblasts for collagen VI in 
collagen VI-related myopathy. Immunofluorescence staining of collagen VI 
(green) in fibroblasts of normal individuals which presents well0organized, linear 
and unidirectional pattern in normal individual (A). Negative control with cell 
nuclei presents in blue (B). Immunofluoresence staining of BM patient fibroblasts 
which present disruption in unidirectional collagen VI microfibrils (C). Stippling 
pattern in BM patient (D), rearification pattern (less collagen VI is observed) in 
BM patient (E), Intracellular retention pattern which collagen VI can only 
observed when cell membrane permeabilized with TritonX100 in BM patient (F) 
Scale bar=100um (Hicks et al., 2008). 
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production, to identify splice-site variation in patients with no mutations in collagen VI is a 
helpful method (Lampe et al., 2008). Exon sequencing is not suitable method for large 
exonic deletions. For example, large exonic deletions of COL6A1 and COL6A2 have been 
reported to be missed during exome sequencing (Foley et al., 2011). In order to detect 
such variation, the increased use of chromosomal micro-array platforms including those 
based on single nucleotide polymorphism (SNP) is seen in novel reports. These methods 
also leads to an increasing catalogue of genomic deletion and duplication variants of 
unknown significance (Bonnemann, 2011; Foley et al., 2011). 
1.2.7 Available treatment and management of collagen VI-related myopathy: 
 Currently available therapeutic strategies for collagen VI-related myopathy mainly focus 
on managing various clinical presentations of these disorders as well as improving quality 
of life. During neonatal period, for severe cases, therapeutic interventions should provide 
non-invasive treatments for respiratory problems due to chest muscle weakness or feeding 
reflux. Contractures are primarily addressed by stretching program in conjunction with 
dynamic splint. In severe cases, surgery to release contractures for example in Achilles 
tendon should be considered. However, there is a possibility of contractures recurrence 
after surgery as well as limited effect on flexor contractures especially in fingers. Brace as 
the first step of scoliosis management is implemented. New scoliosis surgery techniques 
also may apply in special conditions. For adult respiratory problems, upright positioning 
and bilevel positive airway pressure are beneficial. Furthermore, regular follow-ups for 
adult with respiratory involvement are necessary to prevent high speed progression of the 
disease and update clinicians about respiratory status. Ventilation support could stabilize 
patient’s condition for long time. Calcium and vitamin D are two supplementary drugs 
which prescribed to maintain bone marrow density in collagen VI-related myopathies. 
Feeding problems due to muscle weakness is another problem. Appropriate diet for 
Bethlem patients as well as supportive device and surgery ,like percutaneous gastrostomy 
tube, is helpful (Bonnemann, 2011). 
 To date, several pharmacological and molecular approaches have been investigated in 
collagen VI- related myopathies. As fiber apoptosis has previously identified in collagen VI- 
related patients, antiapoptotic drugs as possible therapeutic strategies are implemented in 
animal model and clinical trials. Cyclosporin A in one clinical trial with five patients was 
reported to be beneficial for reducing apoptosis and improving mitochondrial permeability 
 
 
 
 
33 
 
transition pore(PTP) but had no effect on muscle strength (Merlini et al., 2008a; Merlini 
and Bernardi, 2008) 
 Apart from a pharmaceutical approach, several genetic approaches were evaluated in 
collagen VI-related myopathies. Various modes of inheritance and different pathogenic 
mechanism for BM and UCMD are two important challenges for developing a genetic 
approach for collagen VI-related myopathies. Using siRNA to silencing mRNA mediated 
decay pathway in one UCMD patient with COL6A2 null mutation was reported to increase 
amount of collagen α2 (VI) chain and even reduce the symptoms (Usuki et al., 2006). In 
addition, siRNA allele specific silencing to knockdown genes with dominant negative 
mutations has been tested in COL6A3alleles. It has been shown that this approach could 
increase collagen VI deposition in fibroblasts and improve its pattern in a mouse 
model(Bolduc et al., 2014). 
1.3 Extracellular matrix structure and composition: 
 Extracellular matrix (ECM) is part of connective tissue, which is found in tendon, 
ligaments, bone and different organs. The extracellular matrix is composed of three main 
elements: proteoglycans, various glycoproteins and collagens (Halper, 2014b). Collagens, 
as the most abundant proteins of human body, will be described in detail later. 
Proteoglycans which are divided into two subtypes, large and small molecules, are an 
important component for assembly and regulation of extracellular matrix. These proteins 
play a role in cell proliferation through their interactions with different growth factors. Small 
proteoglycans or leucine-rich proteoglycans (SLRPs) are sub-classified into class I-V. 
Various members of class I and II such as decorin, biglycan, fibromodulin and lumican 
bind to collagens and share attachment sites. They could also substitute for each other in 
animal models (Iozzo, 1998). 
 Aggrecan and Versican are two examples of large proteoglycans. The two molecules 
mainly localize in the cartilage, where they act as resilience provider. They also play a role 
in tendon strength. Mutations in large proteoglycans could lead to heart deformity and 
dysfunction (Iozzo, 1998). 
 Glycoproteins are another type of structural and signalling proteins in the extracellular 
matrix. Several glycoproteins have been identified acting as structural or mediating signals 
during developmental phase of extracellular matrix. Other roles of glycoproteins include 
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their roles in normal tissue physiology, tissue homeostasis, responding and adapting to 
environmental changes such as mechanical loading/unloading and tissue damage or 
regeneration. In addition, during cancer, tissue fibrosis and anomalies, glycoproteins are 
involved in tissue response. Glycoproteins expression could be modulated by mechanical 
stress and mechanical loading on specific tissue. Collagens and glycoproteins also have 
similar expression patterns (Halper and Kjaer, 2014). The most important glycoproteins in 
extracellular matrix structure will be described below. 
1.3.1 Collagens: 
 Collagens are the most common proteins in connective tissue and the extracellular matrix. 
All 28 collagen molecules are trimers which are composed of at least one collagenous 
domain (C) as well as several non-collagenous domains (NC).The collagens are classified 
according to their domain structure and supramolecular organization. Each collagen is 
given a roman number (I to XXVIII) in chronological order of discovery. Forty-five different 
genes encode these 28 collagens. α chains are structural unit of collagens. Each α chain 
is different in its structure and is encoded by a different gene. Moreover, each α chain has 
distinct primary structure which is unique in amino acid sequence and domains. α chains 
are forming trimers which are an assembled form of collagen primary structure secreted to 
ECM. Collagen trimers are either homotrimer which means they are composed of three 
identical α chains or heterotrimer which means they are composed of three different α 
chains encoded by three different genes. Collagen I is a homotrimer while collagen VI is a 
heterotrimer (α1, α2 and α3). Some heterotrimeric collagens, such as collagen V have 
more than one chain composition. Collagens could be grouped according to their 
suprastructural organizations(Halper, 2014a). Table 1.1 shows the collagen classification. 
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Classification Collagen type Supramolecular 
organization 
Fibril-forming collagen I,II,III Striated fibrils, 
Striated fibrils retained N-
terminal domains 
V, IX  
XXIV, XXVII 
FACIT collagens   IX, XII, XIV Associated with fibrils, 
other interactions 
FACIT-like collagens XVI, XIX, XXI, XXII Interfacial regions, 
Basement membrane 
zones 
Basement membrane IV Chicken wire network with 
lateral association 
Transmembrane 
collagens 
XIII, XVII, XXIII, XXV Transmembrane and 
shed soluble ectodomains Gliomedins, ectodysplasin  
Beaded-filaments forming VI Beaded filaments, 
networks 
Anchoring fibrils VII Laterally associated anti-
parallele diameter 
Hexagonal networks VIII, X Hexagonal lattices 
Multiplexin collagens 
(Endostatin–XV and 
XVIII) 
 XV, XVIII   
 
 
Basement membranes, 
cleaved C-terminal 
domains influence 
angiogenesis  
Other molecules with 
collagenous domains 
XXVI, XXVIII Collagenous domains in 
primarily non-collagenous 
molecules 
 Acetylcholinesterase, 
adiponectin, C1q, 
collectins, surfactant 
protein 
 
 Table 1.1. General Classification of different collagen types. Modified from (Halper and 
Kjaer, 2014). 
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 Collagen VI which has been described before is classified as beaded fillament-forming 
collagen. Collagen VI suprastructure can have different forms included beaded fibrils, 
hexagonal structure or broad banded structure (Wenstrup et al., 2011). Figure 1.5 shows 
different forms of collagen VI previously. 
 Collagen VI interacts with many molecules including collagen I, IV and XIV, decorin, 
biglycan, heparin, fibril associate glycoproteins (MAGP1). Through its wide distribution and 
several binding partners, collagen VI is proven to have different roles. Like other collagens, 
collagen VI interactions` with various molecular complexes could affect its suprastructure. 
For example, biglycan interactions with collagen VI tetramers could induce hexagonal 
lattice but decorin is less likely to induce hexagonal form.  It should be remembered that 
collagen VI different functions are applied through its various forms. These different forms 
could simply add or remove small non-collagenous molecules in extracellular matrix. 
Collagen VI is essential in muscular extracellular matrix as its lack leads to collagen VI-
related myopathy disorder. Furthermore, it is important in tendons and ligaments (Izu et 
al., 2012). 
 In the COL6A1-/- null mouse model, tenocyte expression is changed, which is due to 
disruption of cell-matrix interaction and increase in metaloproteinase activity. In addition, 
absence of collagen VI in mouse model results in dysregulation of fibrillogenesis, reduced 
load and stiffness with an increase in tissue density (Izu et al., 2011a). 
 Collagen XII as novel disease-causing gene for collagen VI-related myopathy phenotype 
which is the main focus of our investigation, is a member of FACIT-collagens. Fibril 
associated collagen interrupted triple helix (FACITs) are a group of collagens which 
attached on fibril-forming collagens such as collagen I, II and III.FACIT collagens may 
associate and interact with other glycoproteins and ECM components. The nature of this 
interaction is not fully understood. FACIT collagens which will be described later are 
known to be responsible for biomechanical and tensile features of fibril-forming tissues 
(Young et al., 2002; Zhang et al., 2003).  
 FACIT-like collagens share the same structural characteristics with FACIT collagens.  
FACIT-like collagens are collagens XVI, XIX, XXI and XXII. It is believed that these 
collagens are associated with collagen fibrils mainly in musculoskeletal connective tissues. 
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However, their distinct function in musculoskeletal tissue is not fully understood yet (Koch 
et al., 2004). 
 Among other types of collagens, collagen IV is important due to its unique structure and 
contribution to basement membrane. It is part of an integrated network which interface 
between tissues. Its contribution to basement membrane includes many tissues such as 
neuromuscular tissue, especially near vasculature. 
 There are several types of basement membranes whose composition is dependent on the 
anatomical sites. Likewise, collagen IV which is encoded by six different genes has various 
heterotypes. Collagen IV is known to be an important binding partner for collagen XII in 
different tissues such as tendon, ligament and musculoskeletal tissue (Khoshnoodi et al., 
2008). 
 All collagens have their own specialized function and contribute to tissue higher order 
assembly. One major determinant of every tissue`s function and structure for example 
ligaments and tendons is its collagen composition. In tendons collagen I with 90% of 
composition is the most abundant collagen type. While the other collagens added to 
tendons` composition diversity and collaborate in fibril assembly and higher order 
structure. Furthermore, each collagen in its supramolecular structure could work 
differently, depending on its location and combination of protein complex interactions 
(Yang et al., 2014). 
1.3.2 Collagen fibril formation and assembly: 
 Collagen fibrils’ have got various assembly steps. These steps will be described for the 
fibril-forming collagen. The differences between assembly of these collagens with collagen 
VI and XII, the main focus of this research, will be described in detail in chapter 3 and 4. 
Collagens are synthesized as amino acid chains, assembled into heterotrimeric 
polypeptides in rough endoplasmic reticulum (RER), packed as trimers in Golgi apparatus 
then secreted to ECM (Halper and Kjaer, 2014). Fibril-forming collagens (I, II, III, V, IX, 
XXIV and XXVII) are secreted to ECM as procollagen. Procollagens contain a non-
collagenous N-terminal and a C-terminal part which consist of collagenous and non-
collagenous domain. In the form of procollagen, collagens cannot assemble into 
microfibrils. Various enzymes cleave procollagens from C-terminus to N-terminus and 
make propeptides from procollagens. After propeptide preparation, one large central triple 
 
 
 
 
38 
 
helical domain with a short collagenous domain will remain. The remaining molecule is 
called a telopeptide. In most fibril-forming collagens like type I and II, a telopeptide could 
process to fibril formation, while some collagens, such as collagen III and XI, cannot 
proceed to microfibrils with retention of C-terminus or partially retained N-terminal. 
Collagen molecule self-assembly is terminated in striated heterotypic microfibrils with 
periodicity of 67 nanometres (nm).These microfibrils then proceed into hierarchical 
assembly process(Halper, 2014a). Figure 1.12 shows the steps of collagens higher 
structural formation. 
 
 
 
 
 
 Collagen fibril structure is influenced by post translational modifications of collagen α 
chain and covalent modifications which occur after polypeptide chain synthesis. These 
modifications start during α chain translation(co-translational) and continue during 
Figure 1.12.Collagens` higher structural formation. Triple helical 
collagen molecules assemble into collagen fibrils. Collagen fibrils bundled 
to form fibres. Collagen fibres together with tenocyte within tendons form a 
fascicle. Each fascicle is surrounded by a loose, connective tissue named 
endotendon (Mienaltowski and Birk, 2014b). 
 
 
 
 
39 
 
secretion and assembly. Collagen post-translational modifications include hydroxylation 
and glycosylation. The number of hydroxyprolin and lysin residues in the collagen amino 
acid chain is a factor that determinethe amount of hydroxylation and glycosylation. 
Furthermore, these modifications could influence collagen fibril circumferences 
(Mienaltowski and Birk, 2014b). 
  Collagen fibril assembly can decrease by level of enzyme activity, certain mutations in 
amino acid chains and amount of interfibrilar water. In an in vitro experiment of collagen 
fibrilogenesis, number and diameter of fibrils could affected by pH and environmental 
temperature (Shoulders and Raines, 2009a). 
 Collagen fibril assembly starts in deep recesses or channels in fibroblast surface. 
Collagen fibrils evolved from protofibrils which are small and thin microfibrils. 
Compartmentalization which occurs in the extracellular matrix under firoblast`s control is 
responsible for formation of collagen fibrils from protofibrils. While fibrils are large with 
diameter range between 20-500 nm, the protofibrils are 20-40 nm in diameter. Fibrils are 
stabilized in the ECM by other matrix molecules such as FACITs and small leucin-rich 
proteoglycans (SLRPs). 
 The fibrils then proceed into fibers which could be very large in various tissues. 
Development of fibres depend on lengh and diameter increase. Fiber length will increase 
through fibril end overlaps and diameter enlargement requires attachment of fibril to 
eachother laterally. For diameter increase, all stabilizing molecules must be removed from 
fibril surface.Formation of further structures from fibers like fasicles and tendons need 
more complex tissue formation process and depend less on collagen assembly. 
As mentioned above collagen fibrillogenesis is controlled by different components such as 
FACITs and glycoproteins. Collagen fibril assembly controling elements are working 
as:nucleators, regulators and organizers (Mienaltowski and Birk, 2014b). 
 During fibre formation a significant increase will occur in fiber diameter. This diameter also 
controls mechanical properties of fibrils.Collagen V is defined as one nucleator formation 
element, especially in tendons. Collagen V nucleation provides a mechanism for fibroblast 
to identfy the fibril site formation. The more nucleation happens, the smaller the diameter 
of fibrils will be (Mienaltowski and Birk, 2014a). For example, in cornea in which 10% to 
20% of fibrils are collagen V fibrils, smaller fiber diameter is observed. Furthermore, 
cellular organellessuch as cytoskeleton, cell membrane and vesicles are important in 
nucleation. These organelles contributes in cell-direction mechanisms. This mechanism 
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helps the fibrils to secrete in cell-defined extracellular domains. This mechanism 
contributes to cell specific fibrillogenesis and evacuates nucleation site for new round of 
fibril nucleation. Organizing molecules such as fibronectins and integrins are involved in 
cell-directed fibril assembly. Integrin assembles fibronectin to collagen fibrils. Furthermore, 
fibronectin can mediate interactions between fibrils and cells. Fibronectin-collagen fibril 
network has many sites for fibril assembly. Inhibition of fibril assembly is possible through 
filling these sites. Furthermore, interventions in fibronectin-integrin interactions or 
modification of interactions between fibronectin and integrin with other molecules could 
affect fibril assembly (Kadler et al., 2008).  
 Once fibrils are preformed, it is required to increase fibrils diameter and length in order to 
contribute to tissue specific structure. This step is regulated by several macromolecules, 
among them FACIT collagens and small luecin-rich proteins (SLRPs) are the most 
important molecules. Both groups have their owntissue specific pattern of expression and 
both are fibril associated. Various expression patterns lead to different functions and fibril 
assembly among tissues for these molecules. SLRPsmainly contribute in linear and lateral 
fibril growth. Class I of SLRPs (decorin and biglycan) and class II (fibromodulin and 
lumican) are expressed in tendons(Kadler et al., 2008; Mienaltowski et al., 2008). As 
mentioned before, mouse decorin deficient model or biglycan shows the importance of 
these molecules in fibril assembly. Deficient mice demonstrate less strenght and load 
bearing capacity as well as tendon dysfunction.SLRPs function not only during 
fibrillogenesis but also during injuries, muscle and tendon regeneration and regulate and 
maintain fibril structure (Halper, 2014a). 
 FACIT collagens are another regulatory component of extracellular matrix. Like SLRPs, 
these molecules have a tissue-specific and spatially variable pattern of expression. 
Fibril growth in cartilage is regulated by collagen IX, while collagen XIV is important in 
tendon fibril growth. COL14A deficient mouse model presents large diameter fibrils in early 
stages of tendon develoment. Similarly,absence of collagen XII during in vitro 
fibrillogenesis result in large diameter fibrils. As described above, diameter growth is 
controled by separation of regulatory elements from fibrils and lateral attachment of fibrils 
into protofibrils. Regarding these findings, some authors suggested that FACITs may act 
as gate keepers which control and regulate transition of protofibrils into fibrils. Collagen 
XIV may stabilize collagen fibrils for a period to prevent excessive lateral growth and 
diameter increase in collagen fibrils (Halper, 2014a). 
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Structure of FACIT collagens which will be described later, indicates that they might have 
a role in fibril packing. Through their role in fibril packing they could regulate collagen fibrils 
diameter (Shoulders and Raines, 2009a).  
 As indicated above, collagen fibrils assembly is a complicated process which involves 
several molecules. Mutations in collagen itself and other ECM components can affect this 
process. However, finding the subsequent result of collagen mutations requires more 
research on ECM structure. Thus,novel methods for investigating ECM in an in vitro and in 
vivo system are required. One challenge to investigate collagen mutations is to distinguish 
disease-causing variants from polymorphism, as structural variability and unknown role of 
many collagens makes it difficult to predict about their variant pathogeneicity. In the next 
section roles of other micromolecules in ECM will be described (Shoulders and Raines, 
2009b). 
1.3.3 Other extracellular matrix basic components: 
 Collagens as the most abundant and important components of ECM were described in the 
previous section. Here, we review other components of ECM, mostly from glycoprotein 
group. These proteins in lower quantity are contributing to the extracellular matrix structure 
and function. Apart from their maintenance, regulatory and structural role, these proteins 
are important in ECM disorders directly or indirectly. Fibronectin, laminin and elastin are 
three examples of these proteins (Kjaer, 2004; Halper and Kjaer, 2014). 
1.3.3.1 Fibronectin: is multidomain structural protein of ECM which act as a master 
organizer in collagen fibril assembly. Fibronectin interacts with other ECM macromolecules 
and forms a bridging network which includes collagen fibrils and integrin.Fibronectin has a 
molecular weight of 230-270 kilodalton (KD) and it is widely distributed in ECM structure of 
different tissues. Fibronectin is composed of three types of fibronectin (FN) domain: FN I, 
FN II and FN III. Fibronectin type I and fibronectin type II are stabilizing the molecule 
through two sulfide bonds in each molecule.Type III fibronectin domain is composed of 
seven β-barel structure without disulfide bonds. Each FN domain is involved in assembly 
and ligand-binding of several molecules such as collagen, heparin, fibronectin and elastin. 
However, fibronectin type III domain which is widely found in collagen molecule is crucial 
for interaction with collagen fibrils and integrin (Kjaer, 2004). 
 Fibronectin has twenty isoforms in human and more than twelve isoforms in rodents. An 
inactive dimer of disulfide bonded fibronectin is secreted to ECM and is activated by 
integrin interaction. According to its general distribution in tissues, fibronectin is widely 
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expressed in human body but its expression during morphogenesis, inflamation and cell 
migration is higher. In tumor cells, the expression of fibronectin is lower but tissues 
undergoing repair express high amount of fibronectin. Fibronectin has crucial role in ECM 
assembly. It initiates ECM assembly by its binding to α5β1 integrin receptor (Halper, 
2014b). This binding induces fibronectin self-assembly through its N-terminus and lead to 
cytoskeleton formation and cell contractility. These changes open new binding sites for 
collagen fibrils on cell surface and accelerate assembly of fibrils into stable but insoluble 
form. After formation of fibronectin/collagen network, fibronectin involves other molecules 
assembly to complete ECM formation. Fibronectin has a crucial role in fibril assembly, its 
unique value for ECM assembly enabled through its capacity to bind to cell surface and 
several other molecules simultaneously. The multidomain structure of fibronectin is 
resposible for its binding capacity. By binding to several molecules, fibronectin can 
assemble collagens such type I and III, proteoglycans and other micromolecules such as 
heparin.  Fibronectin is also a marker of ECM for immunohistochemical studies because of 
its high expression and wide distribution (Halper and Kjaer, 2014). 
1.3.3.2 Laminin: is large heterotrimeric glycoprotein with 500-800 KD molecular weight. A 
large variable range of molecular weight is due to different chain size. Each Laminin 
molecule consists of three chains: α, β and ɣ. These chains also can vary in size, with 200-
400 KD for α and 120-200 for β and ɣ. Laminin is located in the basement membrane. 
Laminin has sixteen isoforms which are encoded by several distinct genes. Laminin has a 
tissue-specific pattern of expression. Different isoforms of Laminin are expressing in 
connective tissue of cornea, bone, tendon and ligaments. 
 Laminin is composed of tandem repeat domains with similarities. Structurally, laminin has 
two or three short arms with one long arm and it is a cross or T-shaped molecule. Post-
translational modification of laminin involves proteolysis of the N-terminus. Laminin binds 
to integrin, dystroglycan and sulfated proteoglycan via G receptor of its α chain. 
Furthermore,laminin can adhere to sulfatides and via this, bind to cell surface by its N-
terminal receptor (Kjaer, 2004).  
 Laminin contributes to ECM structure, it can also affect stability, proliferation and 
migration of associated cells in ECM. Laminin even influence interstitial stroma of ECM. 
This contributaion occurs through Laminin`s ability to adhere to cell receptors and other 
moleules from its both N and C terminals. Integrin is an important laminin binding partner 
in ECM which mainly adhere to Laminin through its α chains (Halper and Kjaer, 2014). 
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 Laminin`s different roles regarding its adherent cells mediated via a complex system 
which affects chromatin remodeling of promoters and transcription by binding to cell 
membrane. Like fibronectin-collagen network, laminin cites also form a laminin-collagen VI 
network in basement membrane. The distinct role of this network is unknown but it helps to 
transmit forces in musculoskeletal tissue. In addition, investigation in mouse deficient in 
collagen IV has proven the role of laminin in tendon repair and wound healing. In this 
deficient mouse collagen IV was absent from outer layer of basement membrane (Taylor 
et al., 2011). Laminin also has a signaling role to prevent cell apoptosis. However, the 
details of laminin interaction and different roles remain to be understood. 
 Laminin is one of the first ECM structures which develop during embryogenesis and it is 
found to be important for ECM formation in stem cell culture. Furthermore, laminin is a 
crucial element in different tissues such as blood vessels, nerves, skin, muscle and 
tendons. 
 Unfortunately lack of commercial isoforms of laminin makes it a challenge for decipher its 
complex role in ECM formation and stability. New applications for studying laminin in an in 
vitro system may help to open new insight in its role in different tissues such as muscle 
(Shoulders et al., 2009). 
1.3.3.3 Tenascins: are a large family of glycoproteins with molecular weight between 150-
380 KD and multimeric structure. Tenascins are given alphabetic names and classified as 
C, R, W, X and Y based on tissue expression pattern and domain organization. Tenascins 
are built of various protein domains such as fibronectin type III domains, EGF-like 
domains, heptad domains and a C-terminus globular domain. Tenascins have tissue-
specific development pattern with tenascin-C and -W mostly seen in developing tissues. 
Tenascin-X and –Y  are widley expressed in musculoskeletal connective tissue and 
Tenascin-R`s expression is predominates in nervous system during development. Among 
these proteins tenascin-C has been much investigated as it is known tobe involved in 
tumor development (Tucker et al., 2006). 
 The role of tenascin-X and Y is more related to this research. Tenascin-X is less 
glycosylated compared to other tenscins. Its highest expression level is in skeletal muscle. 
However, it has been found in other tissues such as heart, blood vessels, nervous system 
and tendons. In musculoskeletal system it has a proven role. It is known to be 
overexpressed during acute mechanical loading in muscle and muscle stress. In addition, 
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it contributes to regeneration and recovery of muscle tissue by possessing adhesive effect 
and play role in tissue coordination (Halper and Kjaer, 2014). 
 In ECM of muscle, tenascin is part of collagen proteoglycan macromolecules which 
interact with Collagen IV, FASCITs and other proteoglycans. Dysregulation of this from of 
tenascin is reported in diseases involving skeletal muscle, skin and connective tissue such 
as Ehlers-Danlos syndrome (Halper and Kjaer, 2014). 
 Furthermore, tenascin`s role in musculo-tendinus junction is crucial. In this part tenascin 
could induce regeneration and wound-healing by presenting de-adhessive effect as well as 
coordinating tissue regeneration. Some studies suggest that tenascin could orchestrate 
muscle buil up and repair. Despite its proven role in mechanical loading for tissue and 
ECM, there are still areas that need to be investigated (Halper and Kjaer, 2014). 
1.4 Collagen XII structure and function: 
 As collagen XII is the main theme of investigation in this research, Its structure and 
functional characteristics will be discussed in details. 
1.4.1 Collagen XII structure and its binding partners: 
 Type XII collagen as a member of FACIT collagen was discovered in 1989 by Gordon et 
al (Gordon et al., 1987). They isolated and sequenced a chick embryonic cDNA clone. 
This clone represented a mRNA and delineated three regions of α1polypeptide chain and 
one carboxyl domain: non-triple helical carboxyl domain (NC) and a triple helical domain or 
collagenous domain (C1) (Gordon et al., 1989). The amino acid sequencing of collagen XII 
cDNA demonstrated that the collagenous domain of collagen XII is similar to collagenous 
domain of collagen IX. This evidence has led to categorizing two molecules in one 
category. Collagen XV is another member of this group but collagen XII is the largest 
member of FACITs (Dublet et al., 1989). Further investigation revealed collagen XII 
consists of three non-collagenous domain (NC) and one collagenous tail. The non-
collagenous domains consist of several fibronectin type III (FNIII) regions and some von 
wilbrand A domains (Koch et al., 1992). The collagenous part comprise a small percent of 
molecule, while non-collagenous domains specially NC3 is extensive and help to relate 
collagen XII to other molecule such as Heparin, tenascin-X and von willbrand (Koch et al., 
1992).  
 Collagen XII exist as a homotrimer that assembles from three identical α chains encoded 
by COL12A1 genes (Bader et al., 2009).Differential splicing within these domains give rise 
to a small (220 kD) and large (320 kD) collagen XII subunits. The small subunits does not 
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have the first NC domain. Only the large subunit can carry glycoseaminoglycans (Koch et 
al., 1992). Figure 1.13 shows a schematic picture of collagen XII and its variants. 
 
Koch et al (Koch et al., 1995)generated specific antibody and cDNA probesfor  
 
 
Koch et al generated specific antibodies for alternatively spliced variants to investigate 
their characteristics (Koch et al., 1995). They reported large variant has a more restricted 
expression pattern than the small variant in embryonic tissue. The large variant only 
expressed in feather bud in chick, while the small variant expressed in all dermis part.   
They showed with their speific antibodies that collagen XII has homo and heterotrimers.  
The two subunits differs in ligand binding. The small one interacts weakly with heprin but 
the large subunit with more NC domains has extra heparin binds (Koch et al., 1995). So 
far, collagen XII structure becomes fascinating entity for this molecule. Its small 
collagenous part is resposible for collagenous chracteristics while its NC arms helps to 
FIGURE 1.13.Collagen XII large and small splicing variant with their molecular 
regions (Chiquet et al., 2014). 
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interact with various other molecules such as Decorin, Tenascin-X and collagen I 
containing fibrils. Like other collagens, understanding of collagen XII role is based on 
interpretation about its structure (Chiquet et al., 2014). Figure 1.14 demonstrates collagen 
XII interaction with other molecules in ECM. 
 
 
 
 
 
 
 
1.4.2 Collagen XII function: 
 So far the function of the two distinct form of collagen XII remains a mystery. Koch at al 
showedthat biochemically and ultrastructurallycollagen XII can be attached to collagen I 
fibrils when it is present during fibril formation but not after that. In addition, Removal of the 
collagenous domain of collagen XII reduces its coprecipitation with collagen I. Removal of 
collagen XII from In vitroenvironment for collagen fibrillogenesis could lead to increase in 
Figure 1.14.Collagen XII cross-bridging with its binding partner in extracellular 
matrix. Collagen XII cross-bridging with collagen I containing fibrils through its 
collagenous surface. This might be facilitated by Decorin AND Tenascin-X molecules. 
The pink arrow shows Fibronectin type III domains in collagen XII and Decorin which 
facilitated the interaction between two molecules. The link between collagen XII and 
collagen I containing fibrils occurs through collagenous domain in C-terminal of collagen 
XII (Chiquet et al., 2014). 
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collagen fibril diameter. They also indicated that collagen XII is specifically associated with 
fibrillar collagens like collagen I (Koch et al., 1995). Thus, collagen XII could play a role in 
in collagen I contaibibg fibril formation and diameter (Koch et al., 1995). As previuosly 
showed, collagen XII is attached to collagen I contaning fibrils through its collagenous 
domain, while its non-collagenous arms facilitating its interaction with Decorin,Tenascin-X 
and Heparin. Collagen XII and its non-collagenous binding partner could form a flexible 
bridge between ollagenous fibrils. COL12A1 knock out mice study showed phenotype of 
muscle weakness and increased elasticity of muscle-tendon units (Zou et al., 2014). These 
data suggest collagen XII network might work as absorber of sheering stress between 
collagen fibrils (Chiquet et al., 2014; Zou et al., 2014). 
 COL12A1 knockout mice also demonstrating skletal deformities as short bones and spinal 
kyphosis.Histological findings showed disorganized collagen networks in bone and 
decrease in bone specific proteins (Osteocalcin and Osteopenin). In addition Osteocytes 
of COL12A1 knockout mice shows less dendritic processes and ecreased polarity (Zou et 
al., 2014). These data suggest that collagen XII is important for bone formation and 
structure. However, it is not clear wether collagen XII role mediated through direct 
interaction with cell receptors or other molecules (Izu et al., 2011b). 
 In summary, The previous findings suggest a role for collagen XII in connective tissue 
patholog. In addition, they established a link between the structure and binding partner of 
this FACIT molecules and its function as a regulator of collagen fibrils formation and load 
bearing element (Koch et al., 1995; Chiquet et al., 2014). 
1.5 Overview: 
 In the next chapters we aim to describe novel gene from collagen family, Collagen XII, 
which we found as disease-causing in affected individuals with phenotypes overlapping 
musculoskletal as well as connective tissue disorders. These patients were classified as 
Bethlem phenotype before. In the first result chapter we aim to identify the novel disease- 
causing gene in a cohort of Bethlem-like myopathy patients with no mutations in COL6A1-
A3 genes. These novel identified gene then evaluated with immunofluorescence and 
immunoblotting techniques among normal and mutant individuals. In this step, as we 
describe later we could identify COL12A1 as a disease-causing gene in three families of 
Bethlem-like myopathy patients with no COL6A1-A3 mutations. The further evaluation 
reveals decrease in collagen XII signals in the affected individuals. 
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 In the second result chapter, we aimed to investigate collagen fibers structure from 
COL12A1 mutant individulas and compare it to healthy donors.In addition collagen fibrils 
diameter from COL12A1 mutant individual and healthy donors were measured after 
culturing fibroblasts of affected individuals and controls. In addition, collagen molecules 
were extracted from cultured fibroblasts and after inducing fibrillogenesis, the diameter of 
fibrils were measured. These experiments reveal that there are no differences in fibril 
diamters between control and affected individuals. 
 In the third result chapter we aimed to calculate C2C12 differentiation index, when 
cocultured with fibroblasts of COL12A1 affected individuals and healthy donors.in direct 
contact and inserted cell culture dish (without direct contact). 
 These experiments reveals that direct contact between fibroblasts and C2C12 could 
decrease C2C12 differentiation index in COL12A1 mutant cells compare to controls. 
Overall, our findings suggest a role for COL12A1 gene in collagen VI-related myopathy 
patient with no mutations in COL6A1-A3 genes. However, more investigation is needed to 
decipher the exact COL12A1 mutant patinets pathomechanism.  
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Chapter 2 Materials and Methods 
2.1 Primer design: 
 The program Primer3 Plus was used for designing all primers 
(http://frodo.wi.mit.edu/primer3). For each primer the standard length was set as minimum: 
19 nucleotides, maximum: 22 nucleotides and the optimal size was 21 nucleotides. The 
Eurofins MWG Operon website was used to synthesize the primers. The long mRNA 
transcript for COL12A, which is NM-004377.5, was used to design primers for the 
COL12A1gene. COL12A1 was sequenced in twelve amplicons in cDNA level. To 
sequence single polymorphisms in genomic DNA the above program were used. 
Appendixes A and B and C show the sequence, lengths, and Temperatures (TM) for each 
primer in this study. 
 
2.2 Polymerase chain reaction experiment: 
 Two different Polymerase chain reaction (PCR) programs were used to amplify DNA 
fragments. From the two programs described below for PCR, the first one was used for 
DNA amplification of less than 1000 kilo base (KB) and the second one was used for 
longer DNA amplicons. Annealing temperature in step two and three in the first program 
varied from 56 to 60 degrees Celsius (°C) according to the suggested annealing 
temperature by Eurofins for primers. In the second program the two annealing 
temperatures were constant. Table 2.1 shows materials and their concentration in each 
reaction. Table 2.2 describes the set-ups of two PCR programs.  
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Material 
Name 
Company 
Name/Catalogue 
number 
 
Amount of 
reagent used 
in 50 
microliter (µl) 
master mix 
Amount of 
reagent used in 
25 microliter 
(µl) master mix 
PCR Buffer Molzym-F18v32P013 5 µl 2.5 µl 
PCR Enhancer Molzym-119102030v353 4 µl 2 µl 
DNTPs ( dATP, dTTP, 
dGTP, dCTP) 
Fermentas/R0141, 
R0171, R0151, R0161) 
2 µl 1 µl 
Moltaq polymerase Molzym-C07V462P010 1 µl 1 µl 
Patient DNA Not applicable 1 µl 1 µl 
Forward and backward 
primers (Eurofins) 
Eurofins, MWG operon 1 µl 1 µl 
 
Table 2.1. Materials used for the PCR experiments. 
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Program one Program two 
Stages Temperature Minutes Cycle Temperature Minutes Cycle 
1 94⁰C 02:00 1 94⁰C 02:00 1 
2 94⁰C 00:15- 
01:00 
40 94⁰C 00:10 9 
3 55-60⁰C 00:15- 
02:00 
40 55⁰C 
(annealing 
temperature) 
00:30 9 
4 72⁰C 01:00-
02:00 
40 68⁰C 
(annealing 
temperature) 
02:00 9 
5 72⁰C 07:00 1 94⁰C 10:00 19 
6 - - - 55⁰C 00:30 19 
7 - - - 68⁰C 02:00 19 
 
Table 2.2.Two different PCR set-ups. 
 
 The 2% w/v agarose (Sigma-Aldrich, A9539) gel stained with 1 µl SafeView (NBS 
Biologicals ,NBS-AG 500) was used to visualize PCR products of less than 1000 KB and 
1% w/v agarose gel was used for products of more than 1000 kb. The running time for 
each gel was at least thirty minutes at 80 Volts (V) in an electrophoresis tank (Bio-Rad). 
Visualisation of gels under UV light and documentation was done using a GelDoc-IT 
system. 
 
2.3 DNA purification and sequencing: 
 Two methods were used for purifying PCR products: one for purifying from the gel after 
electrophoresis and the second to purify from the PCR reaction directly.  QIAGEN 
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protocols (28706-Gel purification and 28106-PCR purification) were used to purify the 
DNA.  
 
2.4 In silico analysis tools: 
 The Bioedit program (http://www.mbio.ncsu.edu/bioedit/bioedit.html) was used to align 
sequences with the reference sequence. The mutation surveyor program 
(http://www.softgenetics.com/mutationSurveyor.html) was used to identify point mutations 
in cDNA amplified segments. Mutation taster 
(http://www.neurocore.charite.de/MutationTaste) and polyphen 
(http://www.genetics.bwh.harvard.edu/pph2) databases were used for variant analysis and 
predicted pathogenicity. 1000 genomes databases (www.internationalgenome.org) and the 
NHLBI Exome Sequencing project (EVS) (evs.gs.washington.edu) were used to 
differentiate polymorphisms from rare pathogenic variants. 
 
2.5 Genomic DNA extraction: 
 MagAttract DNA blood Mini M48 kit (Qiagen, 951336) was used to extract genomic DNA 
from blood samples of candidates for exome sequencing by the Northern Genetics Service 
in Newcastle. The DNA easy blood and tissue kit (Qiegen, 60504) was used to extract 
genomic DNA from the fibroblasts of individuals who required confirmation of existence of 
pathogenic variant for BM2 and BM5 families. For BM1`Whole exome sequencing (WES) 
was performed at de CODE genetics (Iceland) in 30 individuals (20 affected, 10 
unaffected) from 9 families. Illumina Nextera Rapid Capture exome kit (37 Mb) was used 
and sequenced paired-end on Illumina HiSeq2000 sequencer. Burrows Wheel Aligner was 
used for variant calling, sequence aligner and variant detection 
 
2.6 Exome sequencing analysis: 
 To prepare template DNA for exome sequencing in five Bethlem-like patients, adaptive 
focused acoustics (Covaris, Illumina Paired-End Sample Preparation kit) was used to 
produce the DNA fragments of 150 base pair (BP). Agilent Sure Select Target Enrichment 
System and Sure Select Human All Exon Kit v2 were used for the Paired-End Sequencing 
Library (v2.0.1) of Illumina. Fragments were sequenced with 75-bp paired-end reads 
output by an Illumina genome analyzer. Alternatively, the TruSeq system from Eurofins 
was used for size-selection and to purify the coding region before sequencing DNA 
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fragments on the Illumina platform. Consensus genome (hg19) was used to align the raw 
sequencing read. The result consequently was sorted and converted to a BAM file by 
using Mosaik [version 1.1.21; http://bioinformatics.bc.edu/marthlab/Mosaik (9 May 2012, 
date last accessed)]. Variant calling processes were done by the SAMTOOL method. 
Dindel was used to optimize indel calling. The final list of variants was evaluated by the 
Genome UCSC browser (https||:genome.ucsu.edu). Other in silico analysis systems were 
used to evaluate variants predicted to be pathogenic. For BM1´,WES in 30 individuals (20 
affected, 10 unaffected) from 9 families was performed at de CODE genetics (Iceland) 
using Illumina Nextera Rapid Capture exome kit (37 Mb) and sequenced 90 nt paired-end 
on Illumina HiSeq2000 sequencer. Sequence alignment, variant calling and functional 
annotation were performed with Burrows Wheel Aligner, Genomes Analysis Tool Kit and 
Variant Effect Predictor (VEP). 
 
 
2.7 Cell culture and Immunofluorescence staining in fibroblasts: 
 Primary dermal fibroblasts provided by the CNMD Biobank, Institute of Genetic Medicine, 
Newcastle University, and Normal Human Dermal Fibroblasts (NHDFC) (Promocell, 106k-
05a) were used as controls and cultured under aseptic conditions. Medium change, 
splitting and cell freezing were done every two days during the experiment.  
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Material Name Company/Catalogue 
Number 
Initial 
Concentration 
Dulbecco’s 
Modified Eagle 
Media(DMEM) 
Gibco-41966-029 4.5 g/l(D-Glucose, 
Glutamate, 
Pyruvate) 
Trypsin Gibco-25300-054 0.05%-250 ml 
Phosphate Buffer 
Saline (PBS) 
Gibco-20012-019  
Recovery Freezing 
Media 
Fotal Bovine 
Serum 
Gibco-12648-010 
 
Gibco- 10064 
 
 
 
 
 Table 2.3 shows the materials and amounts used for cell culture. 
 
  According to the immunofluorescence staining protocol, cell lines were seeded into 8-well 
glass chamber-slides (Thermo Fisher Scientific, 154534) at 90% confluency. On the 
second day, filtered sterilised ascorbic acid (Sigma-Aldrich, 4544) was added to the media 
at 1:20 dilution. Staining was done on the fifth day after seeding the cells. Before staining 
cells were checked under the light microscope to make sure they had appropriate 
confluency. Cells were fixed at room temperature for 15 minutes in 500µl per chamber of 
4% paraformaldehyde (Sigma-Aldrich, 158127) in PBS. After washing with PBS, 100 µl 
blocking reagent with and without Triton (Sigma-Aldrich,T878) was added to appropriate 
fields in order to block nonspecific binding antibodies and permeabilize the membrane. 
Blocking reagents were made as follows: 5mililitre (ml) Foetal Calf Serum 
(Gibco,10437036) and 5 ml 10 X PBS in 40 ml distilled water, for blocking reagent with 
triton; 50 µl Triton X-100 (Sigma-Aldrich, T8787) was added. After incubating for one hour 
at room temperature and washing with PBS, 100 µl dilutions of corresponding primary 
antibodies were added to appropriate fields (PBS was substituted in the negative controls 
chambers) and incubated for one hour. After 3x20-minute washes with PBS, 100 µl 
secondary antibodies, goat anti-mouse Alexa fluor-488 and goat anti-rabbit Alexa fluor-594 
diluted 1:1000 µl in a blocking buffer, were added. Incubation and washing were repeated 
three times. Finally, the slides were mounted in Vectashield mounting medium containing 
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6-diamidino-2-phenylindole (DAPI; Vector Laboratories, H-1200). All slides were visualised 
on a Zeiss Axioimager microscope using 20 and 40 objectives, with Axiovision 4.5 
software. Table 2.4 shows the concentration and features of primary and secondary 
antibodies in this study. 
 
Antibody 
name 
 
Product 
Description 
 
Company/Product 
Code 
 
Initial 
concentration 
 
Used 
Concentration 
Anti-collagen 
VI antibody 
Polyclonal 
rabbit 
ABCAM/ab3062 1 mg/ml 1/100 µl 
Anti-collagen 
XII antibody 
Polyclonal 
rabbit 
Provided by prof 
Manuel Koch, 
Cologne University 
1 mg/ml 1/1000 µl 
Alexa 594 
Anti-rabbit 
Polyclonal 
donkey 
ABCAM/A11012 2 mg/ml 1/1000 µl 
Alexa 488 
Anti-goat 
Polyclonal 
donkey 
ABCAM/A11002 2 mg/ml 1/1000 µl 
 
Table 2.4.Features of primary and secondary antibody in this work. 
 
 To optimize immunofluorescence staining, some additional steps were added to the 
conventional protocol. On the staining day, before blocking non-specific antibody stage, 
cells were incubated with 0.05 NaCl/HCl for 15 minutes. This step helped to permeabilize 
cell membranes for primary antibodies. 
 
2.8 RNA Extraction and conversion to cDNA: 
 Dermal fibroblasts were cultured to 90-100% confluency in DMEM medium with 10% FBS. 
Cells were trypsinized, centrifuged and kept in PBS. RNA was extracted according to the 
RNeasy Mini-Kit (Qiagen, 74104). 18 µl of mastermix containing RNA were incubated for 2 
minutes at 42⁰C. Then 2 µl Superscript reverse transcriptase III (Invitrogen, 18080-44) 
was added and heated at 42⁰C for 50 minutes and 70⁰C for 15 minutes. 
 
 
 
 
 
56 
 
2.9 Muscle biopsy staining: 
 Collagen XII primary and secondary antibodies were used at the same concentration as 
the cell immunofluorescence staining. On the first day, after warming up the slides for 1 
hour, they were placed in a Hellendhal jar and washed with 0.1% Triton X100 in 1xPBS for 
1 hour. Then protein block (Dako, 201402) was added to cover the whole slide surface and 
after 2 minutes was replaced with primary antibodies which were diluted in protein blocks. 
Slides were stained overnight at 4°C and remained on the shaker. On the second day, the 
secondary antibodies were added and slides were incubated at room temperature for 90 
minutes. Then antibodies were washed with PBS and slides placed in a Hellendhal jar for 
a 30 minute wash with PBS on the shaker. Finally, slides were allowed to dry and DAPI 
with Vectashield was added. Images were visualized with the Axioimager microscope. 
Medium (DMEM) with 10% foetal bovine serum was used to feed cells every two days. 
The cells 
2.10 Fibroblast Transfection: 
 The Normal Human Dermal fibroblast cells, NHDFC (Promocell, 106k-05a), passage 
number<3 were grown on T75 flasks (Sigma-Aldrich, Z707511) till they reached 80% 
confluency. Dulbecco’s modified eagle were cultured in T75 flasks for 6 days before 
transfection. Amaxa Human Dermal Fibroblast Nucleofector Kit (Lonza, CC-2511) was 
used to transfect cells. At 80% confluency, media were removed and cells were washed 
with 10 ml HBSS (Lonza, 04-315Q). 5 ml trypsin was added and cells were incubated for 2 
minutes at 37⁰C. Detachment of cells was checked with the light microscope (Leica). Then 
trypsin was neutralized with TNS (Lonza, CC5002) with the equal amount of 5 ml. 100 µl of 
trypsin+ TNS media were collected and cells were counted with a hemocytometer (Sigma-
Aldrich). Relative amount of media, 6 ml, were collected in order to have 5 x106cells for 
nucleofection. The media were centrifuged (top table Eppendorf centrifuge, 5417R) at 200 
G for 10 minutes and cell pellets were resuspended in 100 µl nucleofector kit solution. 10 
µl of COL12A1 shRNA (Santa Cruz, sc72958SH) or 5 µl of Green fluorescent protein GFP 
(Thermo Fisher Scientific), provided with the kit were added to each sample. Samples 
were transferred into provided cuvettes and program 0U22 was used for transfection in the 
electroporation machine (Lonza). This program used electric shock which is adjusted with 
chemical solution to move in recombinant products. 
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Samples were then seeded on 6 well plates (Sigma-Aldrich, CLS3516) with appropriate 
labelling for collagen XII and GFP controls. 1.5 ml preincubated media were added to 
them. Eight hours later puromycine (Invivogene, 10 mg/ml, 58-58-2) were added to 
samples in order to select transfected cells. Samples stayed in puromycine for 10 days 
and media was changed every day. The surviving cells were collected into 96 well plates 
(Sigma-Aldrich, CLS3912) and left to grow in 100% confluency. Western blotting and RT-
PCR were used to detect gene knock down.  
 
2.11 Immunoblotting: 
 Fibroblasts were cultured on 6 well plates (Sigma-Aldrich, CLS3516) with DMEM medium, 
10% FBS and 50 µg/ml L-ascorbic acid (Sigma-Aldrich,A4403) until they became 100% 
confluent. Cells were washed with PBS. Then media were replaced with serum-free 
DMEM with 50 µg/ml ascorbic acid for 48 hours. For preparing medium extract for 
westernblot, the 24-48 hour media containing ascorbic acid was collected in a 15 ml falcon 
tube (Sigma-Aldrich, CLS430791) and centrifuged for 5 minutes at 1500 rpm. Then media 
supernatants were split into 100 µl aliquots. 900 µl ethanol was added to each aliquot. 
After mixing, samples were frozen at -80⁰C for 3 hours or longer before running 
westernblot. 
 For preparing cell layer extract, the cell layer was rinsed with cold 1x PBS and 6 well-
plates were kept on ice for five minutes. 200 µl complete RIPA buffer consisting of 150 mM 
sodium chloride (Sigma-Aldrich, S9888), 1 ml Triton X100, 5% sodium deoxycholate 
(Sigma-Aldrich, 302-95-4), 0.1% sodium dodecyl sulphate, (Sigma-Aldrich, 71727), 50 mM 
Tris (Sigma-Aldrich, 77-86-1) with pH 8.0 were added to each well. The cell layers were 
scraped and collected in a 1.5 ml Eppendorf tube (Sigma-Aldrich, T9661). The tubes were 
put on ice for 5 minutes, then spun down at 1400 rpm for 15 minutes at 4°C. The 
supernatant and cell lysate were kept separate. For running samples of cell lysate 2 µl of 
each supernatant were combined with 5 µl 4×LDS loading buffer (ThermoFisherScientific, 
84788) containing 10% beta-mercaptoethanol (Sigma-Aldrich, 560000), heated for 5 
minutes at95°C. 
 During the running stage, samples were loaded on to synthetic 1 mm Nupage (Life 
technologies) gels. 4-12% Bis Tris gels (Life technologies, NP0321BOX) were used for 
proteins less than 120 Kd as Emerin (Novocastra 6120-07, 1:50) and collagen VI. 3-8% 
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Tris Acetate gels (Life Technologies, EA0357BOX) were used for proteins of more than 
200 Kd such as collagen XII. 
 Bis Tris gels were run for 45 minutes and Tris Acetate gels were run for two hours at 150 
mV in the XCellSureLock system (Invitrogen). For molecules<120 Kd, 35ml Tris acetate 
running buffer (Thermo Fisher Scientific, LA0041) was washed with 700ml water. For 
120Kd<molecules 35 ml of MOPS running buffer (Thermo Fisher Scientific, NP0001) was 
used. Then mini-gels were cut and put into the transfer buffer. PVDF membranes (Thermo 
Fisher Scientific, 88518) were pre-wetted in 100% methanol for thirty seconds and the 
transfer step was done at 350 mA for 1.5 hours in a Bio-Rad mini-Protein III electroblot 
system. Membranes were blocked with 5% BSA (Sigma–Aldrich) in 1X TBST for 1 h 
before incubation with primary antibodies; anti-human collagen XII (gift of Prof. Manuel 
Koch, 1:2000) and anti-Emerin (Novocastra 6120-07, 1:50) overnight. 10x TBST is made 
up of NaCl (87.66 g/l), 2M Tris (pH 7.8) (250 ml/l), Tween-20 (5 ml/l, Sigma-Aldrich, 9005-
64-5), Ultrapure water (to 1 l) and diluted to 10x for the working solution. 
 The day after, membranes were incubated with secondary antibodies; goat anti-rabbit, 
HRP conjugated (Invitrogen G21234, 1:3000) and goat anti-mouse, HRP-conjugated 
(Invitrogen G21040, 1:3000) for one hour. High mark prestained protein ladder (Thermo 
Fisher Scientific, LC5699) for collagen XII immunoblotting and standard protein ladder 
(Thermo Fisher Scientific, 26616) for collagen VI were loaded on to gels to differentiate 
between proteins. Agfa X-ray films (VWR) were used to reprint images of protein bands. 
Imaging was performed on a Bio-spectrum imaging device (UVP, Upland, CA, USA) using 
Vision Works v7.0.2. Collagen XII bands are predicted to be found at 330 KD, collagen VI 
bands at 110 KD and Emerin bands as control at 45 KD. An Image J analyzer was used 
for statistics and band calculation. Oddyssey image software (Li-cor biosciences) was also 
used to reprint the images. In order to use the Oddyssey system, following primary 
staining, membranes were incubated with goat anti-rabbit (1:10000) and goat anti-mouse 
(1:10000) Li-cor system secondary antibodies. Special Li-cor blocking reagents were used 
to block primary and secondary antibodies. 
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2.12 Electron microscopy: 
2.12.1 Transmission electron microscopy for tissue: 
 Tissue from skin biopsies of normal and mutant individuals was rinsed in 0.1 M sodium 
cacodylate (Sigma-Aldrich, 233854) post-fixed in 1% OsO4 (Agar Scientific) for 1 h and 
dehydrated in sequential steps of ethanol (25, 50, 75 and 100% twice) prior to 
impregnation in resin (TAAB Lab Equipment) and polymerized at 4°Cfor 24 h. Semi-thin 
sections of 1 µm were cut and stained with 1% toluidine blue (Sigma-Aldrich, T3260) in 1% 
borax. Ultrathin sections of 70 nm were cut using a diamond knife on a Leica EM UC7 
ultramicrotome. Sections were mounted on Pioloform -filmed copper grids prior to staining 
with 1% aqueous uranyl acetate and lead citrate (Leica) and viewed on a Philips CM100 
Compustage Transmission Electron Microscope. Images were taken at a magnification of 
×20 000 and ×46 000.  
 
2.12.2 Immunogold microscopy on cultured cell: 
 24 well-inserted tissue-culture plates (Cornings, 3470) were used for growing NHDFCs 
and patient fibroblasts. Cells were grown to full confluence. A DMEM medium with 10% 
FBS and 100 mg ascorbic acid was used to feed the cells. After five days, the process of 
fixing for immunogold electron microscopy was started. 
In immunoelectron microscopy of adherent cultured cells, cells can be processed while 
still attached to the base of the plastic culture dishes. We describe a pre-embedding 
immunoelectron microscopy technique for chemically fixed tissue culture cells attached to 
the base of a culture dish. 
 After decanting the tissue culture medium and rinsing the cells with PBS (Gibco, 10014-
422), the PBS was aspirated. 3% PFA (Sigma-Aldrich, P6148) in 0.1 M PB (Thermo 
Fisher Scientific, P5244) was added and gently swirled. Then the cells were kept for 15 
minutes at room temperature. The fixative was removed and cells twice again were rinsed 
with PBS. The washing Buffer then removed and cells were kept on 0.1% Triton X100 
(Sigma-Aldrich, T8787) in PBS to permeabilize the cell wall. Incubation was done for 25 
minutes at room temperature. Then the blocking reagent was aspirated and cells were 
rinsed twice with PBS. Cells were washed again for 5 minutes three times with 0.02 M 
glycine (Sigma-Aldrich, 56-40-6) in PBS. The washing buffer was aspirated and 3% BSA 
(Sigma-Aldrich, 10416-59-8) in PBS was added. The cells were incubated for 30 minutes 
at room temperature to block the non-specific binding antibodies. Then the blocking buffer 
was aspirated and the cells were washed with 0.1% BSA in PBS. The primary antibody, 
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collagen XII anti-rabbit was diluted with 1% BSA in PBS. 1 µl of antibody was added to 
500 µl of 1% BSA in PBS. The cells were incubated with the primary antibody for 3 hours 
at room temperature. Then the antibody was aspirated and cells were washed with 0.1% 
BSA in PBS. The secondary nanogold antibody, anti-rabbit IgG (Nanoprobes, 12348) was 
diluted 1 µl in 50 µl of 1% BSA in PBS. The cells were incubated with the secondary 
antibody overnight in a refrigerator. On the second day, the nanogold solution was 
aspirated and cells washed six times for five minutes with 0.1% BSA in PBS. Then the 
cells were washed six more times only with PBS. Following the second wash steps cells 
were incubated in 1% Glutaraldehyde, GA (TAAB) in 0.1 M PB for 10 minutes at room 
temperature. After removing the fixative by aspiration, the cells were washed again with 
PBS for five minutes. Then the cells were incubated four times for 15 minutes with 50 mM 
HEPES-NaOH pH 5.8. After the last wash with HEPES solution (Sigma-Aldrich, 7365-45-
9), the cells were washed twice with distilled water. Then silver-enhanced Nanogold 
particles (Nanoprobes, 2012) were added. The silver-enhanced solution was prepared as 
described in the protocol (Nanoprobes, 2012). Solutions A (initiator) and C (activator) 
were added and followed by solution B (moderator). Then one drop of the enhanced 
solution was added to wells apart from keeping one row for negative enhancement. The 
cells were incubated for 6 minutes in a water bath to activate the enhancement particles. 
The enhancement solution aspirates very quickly and cells were washed five times for 1 
minute in distilled water to terminate the silver enhancement reaction. The cells again 
were washed in PBS once for five minutes. Then the cells were fixed for 1 hour at 4⁰C in 
0.5% Osmiumtetroxide, OsO4 (TAAB) in 0.1 M PB. After aspirating the post-fixatives the 
cells were rinsed twice for 5 minutes in 0.1 M PB. Then 0.1 M PB was aspirated. 
 The following procedure was used to embed attached cells after growth on inserted wells 
and staining. The cells were incubated for 10 minutes in 50% ethanol to dehydrate them. 
The dehydration process was followed by a second 10 minutes in 70% ethanol, then 10 
minutes in 90% ethanol, the fourth 10 minutes in 95% ethanol and the last part in absolute 
ethanol for 15 minutes. Ethanol was removed after the last part without allowing the cells 
to dry. Epoxy resin (Fibre Glass Direct) was filled in each well to make it half full. The 
specimens were incubated for one hour at room temperature. The epoxy resin was 
aspirated and new epoxy resin was added to the cells and left overnight. The next day the 
new epoxy resin was added and allowed to polymerize for 4 days. The fifth day first left 
the polymerized resin plate to cool in room temperature, then the plastic part of the tissue 
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culture plate was removed as much as possible with pliers. The goal is to have separated 
resin blocks each from a well. 
 Then each of these removed wells was placed with the bottom facing upward. With a 
hammer, the bottoms of the wells were stroked to detach the epoxy resin together with 
the resin-embedded cells from the plastic plate. Then the resin block was cut into small 
pieces with a serali saw, and the samples were cut into pyramid-shaped pieces. The 
ultrathin sections were then placed in var-coated TEM grids. These grids were coated 
with metal followed by carbon backing up to inhibit negative charges and thermos 
damage. The sections were then stained with 2% aqueous uranyl acetate (TAAB) solution 
for 10 minutes. The grids were washed with distilled water.   
 The sections were first checked with light microscopy to make sure that we had got good 
samples. Then electron microscopy was used to get images. Image J analysis software 
was used to analyse the images. 
 
2.13 In vitro fibrillogenesis: 
 In order to check whether there is any difference between collagen fibril sizes, a method 
was used to extract collagens from mutant and normal dermal fibroblasts, then the 
molecules were induced for in vitro fibrillogenesis. For extracting type I collagens, NHDFC 
and mutant cells were grown to full confluency in six T75 flasks (Fisher Scientific, 35135). 
The fibroblasts were fed with Dulbecco's modified Eagle medium, DMEM which has the 
pH of 7.4 and buffered with 24 mM sodium bicarbonate (Sigma-Aldrich, 144-55-8) and 25 
mM HEPES. 10% foetal bovine serum (Gibco, 10500-056) was added to the medium. The 
cells were incubated at 37°C, with 5% carbon dioxide and 95% oxygen supply. Once the 
cell cultures were confluent, the growth media were removed and cells were incubated at 
37°C in 0.5% calf serum in a DMEM medium. 100 µg/ml streptomycin sulphate (Sigma-
Aldrich, S6501-5G) and 100 µg/ml penicillin G sodium (Thermo Fisher Scientific, 
15140122) was added. The media were supplemented with daily 100 µM ascorbic acid for 
four days. Each day the media were collected. Following the fourth day, the cells were 
incubated with DMEM which has 10% foetal bovine serum and allowed for three days for 
regrowth before repeating the ascorbic acid treatment and collagen harvest. The collected 
media were precipitated each day with 2 volumes of 95% ethanol to 1 volume of media.   
An amount of 20 µl of 200 Mm Phenyl methansulfonylfluoride (PMSF) (Sigma-Aldrich, 
P7626) with a final concentration equal to 4.0 Mm was added to each solution for 
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preventing protease activity. The precipitates were collected by centrifugation at 10000x g 
for 45 minutes. The supernatant was discarded and the pellet re-suspended in 0.5 normal 
acetic acid (Sigma-Aldrich, 537020) and kept overnight. The day after, the solutions were 
recentrifuged at 10000x g for 30 minutes and digested with 1 mg/ml pepsin. The 
supernatant was kept for further use. The soluble protein was dialyzed overnight at 400-
fold volume excess of 0.5 N acetic acid and digested with 1.0 mg/ml pepsin (Sigma-
Aldrich, P4656) on ice overnight. These samples were lyophilized and then dissolved in 5 
mM acetic acid to a final concentration of 1.0 mg/ml. The concentration of samples was 
checked with a modified Bio-Rad protein assay. The samples were then kept on -80 
freezers and were used for collagen fibrillogenesis. 
 
2.14 Collagen fibrillogenesis assay: 
 The concentrated and extracted protein with 1 mg/ml concentration from previous 
experiments was used to induce fibrillogenesis. One control sample of collagen I (abcam, 
AB34710) extracted from a rat tail was used as a control for the fibrillogenesis 
experiment. 1 mg/ml of extracted collagen samples from the mutant and controls were 
dialyzed in 500 ml of 5 mM acetic acid (Sigma-Aldrich, 537020) at room temperature on 
the shaker to induce fibrillogenesis. Samples stayed on the shaker overnight. The day 
after, dialysis clips (VWR, 80-6484-32) were opened and 1 ml of solution with induced 
fibrils were taken to the electron microscopy unit for negative staining. 1 µl of each 
sample were taken to the electron microscopy unit and diluted with 10 µl of water, then 
uranyl acetate with 10% dilution was added to samples for 10 seconds and dehydrated 
under lamps. The samples were then transferred on to the bench and an electron 
microscopy grid was floated on one droplet of samples. The excess of water was 
absorbed with absorbent papers. Then collagen fibrils were viewed via electron 
microscopy. 
 
2.15 Fibroblast / C2C12 coculture assay: 
 Small plastic flasks were used for growing cells in this assay. Two control fibroblasts, two 
mutant fibroblast and one Duchenne muscular dystrophy (DMD) samples were used. 
Each cell line used in this assay had less than 5 passages to begin with. One NHDFC cell 
line was purchased from biologic company (Promocell, C-12352). The other control 
fibroblasts were provided by biobank in Newcastle Centre for Neuromuscular Disease. 
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These fibroblasts were obtained from skin biopsy of one orthopaedic anonymous patient 
in Royal Victoria Infirmary (RVI) hospital affiliated to national health system (NHS). One 
DMD fibroblast which were used as a positive control was provided by the biobank. These 
fibroblasts were obtained from a skin biopsy of a confirmed DMD patient with deletion in 
exon 49 and 50 of DMD gene. Furthermore, C2C12 myoblast cell lines were obtained 
from the biobank. The all cell lines were matched by age and gender (20-30 year old 
group, male), in order to model in vivo extracellular matrix/myocytes interaction in an in 
vitro system, Fibroblasts were grown to 50% confluency. In muscle biopsies interstitial 
fibroblasts were ranging from 20% to 70% confluency.  Two frozen vials of fibroblasts 
from the first passage were grown in T25 flasks (Fisher Scientific, 156367) and each of 
them was expanded in five T25 flasks after four days. This experiment was repeated 
twice to obtain enough fibroblasts (50 vials) of less than five passage for the whole 
experiments. One frozen vial of C2C12 cells was grown in T75 flask (Fisher Scientific, 
156370) and expanded into 10 flasks after three days. Each of these flasks later 
expanded to five flasks and frozen (50 vials) before starting differentiation by getting 
attach to each other from surface angels.  
 For fibroblast/C2C12 coculture in direct contact, Fibroblast cells were seeded in plastic 
slide flasks (Thermo Fisher Scientific,170920).The cells were fed with DMEM medium 
composed of 10% foetal bovine serum with 100 IU/ml Penicillin(Sigma-Aldrich, 
P4330)+100 µg/ml Streptomycin(Sigma-Aldrich, P4333). Cells were incubated in 37°C in 
a humidity saturated atmosphere with 5% CO2 and 95% o2.The cells were supplemented 
with 5 ml media every two days during growth time. 36 hours after seeding fibroblasts 
when the cells have around 50% confluency, they were treated to inhibit mitotic activity. 
The growth media was replaced with mitotic media composed of DMEM with 8µg/ml 
mitomycin C (Sigma-Aldrich, M0503). The cells were incubated in 37°C for two hours. 
Then media was removed, the cells were washed with PBS and growth media was 
added. 12 hours after mitomycin treatment, C2C12 cells were seeded on top of the 
fibroblast layer. C2C12 were fed with growth medium consisting of DMEM and 10% horse 
serum (Sigma-Aldrich, F0146) for 24 hours and checked for not starting attachments to 
each other or being confluent more than 50%. On the second day of growth the media 
were changed to low horse serum medium (3%) to induce differentiation in 
C2C12.Differentiation days counted on D0, D1…D5.The differentiation media was 
changed every two days during differentiation. In the day sixth of differentiation (D6), 
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media was removed and cells were washed with PBS. Then cells were fixed in 4% 
paraformaldehyde in PBS for 5 minutes at room temperature and stained with phalloidin 
(Thermo Fisher Scientific, 8878) to detect actin filaments. After fixation, cells were 
washed with PBS for three times, five minutes. One ml of 0.1% TritonX100 was added to 
each slide flasks for ten minutes. Cells were washed with PBS twice and one ml of 50 
µg/ml 488 phalloidin conjugate solution (Sigma-Aldrich, P2141) in PBS (1%) were added 
to them for 40 minutes. Cells were washed three times, five minutes with PBS. Flask 
casquettes were removed and plastic slides were air dried. One drop of DAPI was added 
to each slide and coverslips were placed and pushed. After phalloidin staining, the slides 
were brought to the immunofluorescence microscopy unit and five images from different 
locations on each slide were taken.  
 Images were visualized with image J analyzer provided by Newcastle University. The 
differentiation index was determined by the number of cell nuclei in myotubes divided by 
the total number of nuclei in image field. Nuclei number were counted manually and 
repeated twice for each image.  
 After obtaining these results, experiments were repeated three times. Each time one 
flask of two mutant fibroblast cell lines, two flasks of control human dermal fibroblast cell 
lines from commercial and in house, One DMD adult fibroblast of in house were grown 
and C2C12 cells of the same passage were seeded on top of them. The whole 
experiment was done by one person. The examiner was blinded about source of cells in 
each image. 
 
 The above experiment was designed and done to show the effect of direct contact of 
fibroblast cell lines on C2C12 differentiation. In order to understand the paracrine effect of 
fibroblast/C2C12 coculture on C2C12 differentiation, the second part of this experiment 
was done by growing fibroblasts and C2C12 on different surfaces in one dish, sharing the 
same medium. Frozen vials of fibroblasts from the first passage were seeded and grown 
on inserted 12-well cell culture plates. Figure 2.1 shows inserted cell culture plates. 
 
 
 
 
65 
 
 
 
 
 
 The fibroblasts were seeded on the top plastic insert. The cells were fed with previously 
described growth medium. 24 hours after seeding cells, top inserts were seen under light 
microscope to check cells confluency. In order to maintain same experiments conditions, 
mitotic treatment for fibroblasts was done when cells reach of 50% confluency according 
to previously described protocol. Fibroblasts were incubated in growth media for 12 hours 
after mitotic treatment. 200 µl of C2C12 cells were seeded on bottom layer equal to 
density of 50000 cell per cm2 in each well. Fibroblast growth media was replaced with 
high serum media (10% horse serum) in dish and inserts. C2C12 cells at the bottom layer 
were checked under light microscope to confirm non-attachments or overgrowth. 24 hours 
after seeding C2C12s, high serum medium was switched to low serum medium (3% 
horse serum) to induce differentiation .On the sixth day of differentiation (D6), inserts 
were removed and C2C12 cells were fixed with 4% PFA in PBS to start phalloidin 
staining. Phalloidin staining was done according to previously described protocol. Triton 
X100 and phalloidin antibody solutions were added at 200 µl volume on each well. 
Images were taken with confocal microscopy (Nikon) with a two-channel light system. 
Five independent images were taken from each field. Then the number of nuclei inside 
the myotubes was counted and the percent of whole nuclei inside the tubes in each field 
were divided by that to obtain C2C12 differentiation index. For two experiment 
differentiation index of control groups and mutant groups was compared to each other 
and to DMD cell line using appropriate statistical analysis. 
 
 
Figure 2.1.Inserted cell culture dish. Fibroblasts were 
grown on insert surface and C2C12 cells were grown on the 
bottom of the wells. Modified from (Zou et al., 2008). 
 
 
 
 
66 
 
2.16 Image J analyzer: 
 Image J analyzer was used to analyse images. The software was downloaded 
fromhttps://imagej.nih.gov.The images were taken using fixed exposure time and Z-stacks 
of staining were merged into a single image for capturing image. Image J quantified pixels 
within a defined area around a group of 4-7 cells. The cells were used in groups of 4-7 
because the area around cells fora single cell was unidentifiable. For immunofluorescence 
experiments the pixel density around each group has been compared. For electron 
microscopy experiments the horizontal distance between two opposite points was 
measured.  
 
2.17 Statistical analysis: 
 Independent t-test was used to analyse results for immunohistochemistry and electron 
microscopy experiments. Unpaired two proportional t-test was used for co-culture 
experiment analysis. All statistical analysis was done in Microsoft office excel 2016 
program. P-value for statistical analysis was set at p<0.001***, p<0.01**, p<0.05*. 
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Chapter 3 collagen XII; Novel disease-causing gene in heterogenic 
Bethlem-like myopathy phenotype 
3.1Introduction: Genetic heterogeneity in Ullrich congenital muscular dystrophy and 
Bethlem myopathy: 
 The Collagen VI-related myopathies encompass a range of neuromuscular disorders with 
progressive muscle weakness, skin and joint involvements. Phenotypic spectrum of these 
disorders as mentioned before includes severe phenotype of Ullrich congenital muscular 
dystrophy (UCMD) (OMIM 254090), a milder phenotype of Bethlem myopathy (BM) (OMIM 
158810), intermediate phenotypes and overlapping phenotypes with Limb-girdle muscular 
dystrophy and myosclerosis myopathy (Allamand et al., 2010).  
 Phenotypic diversity of collagen VI-related myopathy leads to large number of differential 
diagnoses. Ehlers-Danlos syndrome (OMIM 130020), Emery- Dreifus muscular dystrophy 
(OMIM 310300),Central core disease and fibre type I disproportion (OMIM 117000) should 
be considered among most important differential diagnosis for collagen VI-related 
myopathies (Allamand et al., 2010).  
 The clinical manifestations of collagen VI-related myopathy is the first step to distinguish 
between different forms of this disorder. In the severe Ullrich form, symptoms appear 
during the neonatal period: hypotonia, distal joint hyperlaxity and sometimes contractures 
.A walking aid maybe needed for these children in the first decade of life before further 
progression of muscle weakness leads to wheelchair dependency. Severe Ullrich patients 
never learn to walk. They develop respiratory insufficiency as well (Foley et al., 2013). A 
prominent contracture phenotype with rigid muscles, which resembles myosclerosis 
myopathy, has been reported in UCMD patients. In the milder form of collagen VI-related 
myopathy, Bethlem myopathy, a considerable diversity in the phenotype has been 
reported (Deconinck et al., 2010). In Bethlem myopathy, contractures rarely present before 
the age of two years. However, hypotonia, clubfoot and torticolis may present in newborns 
(Baker et al., 2005). Muscle weakness is less severe and could be mild. A mild 
presentation of proximal muscle weakness shows phenotypic overlap with different forms 
of Limb-girdle muscular dystrophy (Bovolenta et al., 2010). 
 Three major genes (COL6A1, COL6A2 and COL6A3) are responsible for most cases of 
collagen VI-related myopathies(Baker et al., 2005).Three other COL6A genes (COL6A4, 
COL6A5 and COL6A6) are expressed in the humans and other species (Sabatelli et al., 
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2012a). These genes are homologous to COL6A3 but their expression is more limited 
among non-human species. COL6A4 expression in humanis inhibited by a chromosome 
break due to a large-scale pericentric inversion on chromosome three (Hicks et al., 2016). 
In addition, in other species COL6A4 is unable to make triple heterotrimers for secretion 
out of the cells (Bonnemann, 2011).So far, none of the recently discovered COL6A (A4-6) 
genes were associated with collagen VI-related myopathies. A clear phenotype-genotype 
correlation has been identified in COL6A1, A2 and A3 genes which are underlying the 
majority of collagen VI-related myopathies’ spectrum (Zulian et al., 2014).  
 Both severe and mild phenotypes could be inherited through dominant and recessive 
mutations (Lampe et al., 1993; Palma et al., 2009). However, severe phenotypes mainly 
associate with recessive mutations and milder phenotypes are mainly associated with 
dominant phenotypes. It should bear in mind that some dominant negative mutations could 
lead to severe phenotype (Lampe et al., 2008). 
 The wide range of clinical manifestations of collagen VI-related myopathies makes the 
diagnostic procedure multileveled and dependent on paraclinical and genetic testing as 
well as history taking and clinical examinations (Foley et al., 2013). So far, exome 
sequencing for COL6A1, A2 and A3 genes is the gold standard for collagen VI-related 
myopathy diagnosis. It is estimated that COL6A1-3 gene mutations are responsible for 
around 75%-70% of patients with phenotypes resembling UCMD and 60-65% of Behtlem 
myopathy (“collagen VI-related myopathy” phenotype) and have been effectively ruled out 
in the remaining number of patients (“discovery cohort”) (Bovolenta et al., 2010). Collagen 
VI-related myopathy diagnosed individuals with no mutations in COL6A genes, could 
reflect the undiagnosis deep intronic or splice variant mutations which cannot be identified 
by exome sequencing (Bonnemann, 2011; Foley et al., 2011). However, other affected 
individuals who composed the heterogenic cohort suggest that one or more additional 
disease-causing genes exist that can give rise to a phenotype resembling BM or UCMD if 
mutated (Bovolenta et al., 2010).  
One of the first examples of genetic heterogeneity in collagen VI-related myopathy was 
reported in 2004 (Ishikawa et al., 2004). Ishikawa et al identified one UCMD phenotype 
from a cohort of eight affected individuals with no mutations in COL6A1-A3 genes. All of 
the eight patients had signs of UCMD in their muscle evaluation. In 2005, another report of 
heterogenic UCMD was done through evaluation of five UCMD patients. Four of these 
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patients had dominant negative mutations in collagen VI (Baker et al., 2005). Another 
report of collagen VI-related myopathy genetic heterogeneity during evaluation of MRI 
findings of affected individuals added to previous reports (Mercuri et al., 2005). Petrini et al 
reported a UCMD phenotype in whom collagen VI mutation was excluded. However, in 
electron microscopy of muscle biopsies the patient demonstrated density reduction areas 
between reticular lamina and lamina densa with focal loss of microfibrils around basement 
membrane similar to collagen VI-mutant UCMDs (Petrini et al., 2007). In Centre for 
Neuromuscular Diseases in Newcastle during developing a diagnostic 
immunofluorescence method for Bethlem myopathy several cases of BM with no 
mutations in collagen VI had been found (Hicks et al., 2008). It is estimated that around 
40%-50% of suspicious collagen VI-related myopathy phenotypes who were referred to 
the MRC Centre for Neuromuscular diseases in Newcastle are heterogenic (Debbie Hicks, 
personal communication). Regarding the importance of mutation detection for genetic 
counselling and future therapeutic approaches in these patients, finding novel disease-
causing genes in heterogenic collagen VI-related myopathy cases is an emerging issue. 
3.2 Aim: 
In this chapter, we aim to: 
 Identify novel disease causing gene by exome sequencing in a cohort of patients with 
Bethlem-like myopathy phenotypes in whom mutations of the COL6A1-3 genes have been 
ruled out previously. 
 Describe phenotypic spectrum and unifying clinical features of affected individuals with 
novel disease-causing gene. 
 Confirm pathogenicity of variants derived from our pipeline by bioinformatic in silico 
analysis, pedigree segregation studies and immunoblotting evaluation.  
 
3.3 Material and methods: 
3.3.1 Clinical and genetic characteristics of a Bethlem-like myopathy cohort with no 
mutations in COL6A1-3 genes: 
3.3.1.1 Patients: A panel of thirty-six patients with Bethlem-like myopathy symptoms has 
been evaluated in this study. Twenty-four of these patients were referred to the MRC 
Centre for Neuromuscular Diseases in Newcastle since 2001. History taking, clinical 
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examination and genetic analysis were done in the Institute of Human Genetics (IGM) in 
Newcastle by medical and laboratory staffs of this centre. . Professor Kate Bushby, 
Professor Volker Struab and Professor Hanns Lochmuller were responsible for clinical and 
genetics re-evaluation of these patients in the MRC centre for Neuromuscular disorders. 
Twelve other patients were referred to MRC Centre for Neuromuscular Disease in 
Newcastle from Universitat Catholic Lueven (UCL) Centre for Neurology in Belgium (nine 
patients) and Oxford centre for neuromuscular disorder (Three patients). Clinical 
evaluation and genetic analysis had been done by medical staff of those corresponding 
centres. Professor Francesco Mantoni in Oxford University and Professor in UCL Belgium 
were responsible for first clinical and genetics evaluation of corresponding Bethelem-like 
patients from their centres. We received the results of these evaluations in combination 
with affected individuals’ fibroblasts in MRC Centre for Neuromuscular Disease in 
Newcastle from 2013 to 2015. These patients were added to the Newcastle cohort. 
Professor Francesco Mantoni in Oxford University and Professor in UCL Belgium were 
responsible for first clinical and genetics evaluation of corresponding Bethelem-like 
patients from their centres. 
 3.3.1.2 Clinical and laboratory findings: Clinical features and individuals’ information 
which were recorded for all affected individuals included age, gender, age at onset, 
hypotonia, muscle weakness, independent walking, wheelchair dependency, pattern of 
muscle weakness, joint rigidity and contractures, joint hyperlaxity, cardiac involvement, 
skin involvement, neurologic deficit, neurologic examination results, respiratory problems, 
scoliosis and skeletal abnormalities, CK level, Immunofluorescence staining (IF) of 
collagen VI in dermal fibroblasts and muscle biopsy findings. 
 Skin and muscle biopsies for all of these affected individuals from Newcastle cohort were 
collected in Newcastle medical school affiliated hospitals. Samples were kept in biobank of 
MRC Centre for neuromuscular Diseases in Newcastle and dermal fibroblasts were 
extracted from those samples. Collagen VI IF staining in dermal fibroblasts was done in 
research laboratories affiliated to the MRC Centre for Neuromuscular Diseases in 
Newcastle. Muscle staining was done in Muscle Immunology Unit (MIU) of MRC Centre for 
Neuromuscular Diseases in Newcastle. Figures 3.1, 3.2 and table 3.1 represented clinical 
and paraclinical characteristics of these patients. 
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Neonate(13.88%)
1Month-1Year(19.44%)
1Year-10Year(47.22%)
10Year-20Year(5.55%)
20Year-40 Year(5.55%)
<40Year(8.33%)
20Year-40Year(41.66%)
40Year-60Year(44.44%)
<60Year(13.88%)
Figure 3.1: Age of onset in affected individuals. The largest 
number of patients is represented in the third age group which is 
1-10 year-old individuals.  
Figure 3.2: Affected individuals’ current age. Current age is 
shown in different age groups. The largest number of patients is 
in the “between-40-to-60-years” group. 
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 As the figures demonstrate the largest number of patients had been diagnosed in 
their first decade of life after the neonatal period.  According to the table the majority 
of patients survived till late adulthood and remain ambulant which represents a mild 
disorder and a slow progression of the disease. 
 The most common symptoms of collagen VI-related myopathy had been checked in 
these patients. Joint contractures, abnormalities in muscle biopsy and a high 
creatine kinase level are the most frequent symptoms among the patients. 
Symptoms such as spine abnormality and skin involvement which are more specific 
for collagen VI-related myopathy present in less than half of the patients. Respiratory 
symptoms such as reduced Forced Vital Capacity (FVC) and hypoventilation have 
been seen in about thirty five percent of patients, while cardiac symptoms are very 
rare and only present in one or two patients. Unreported or rare symptoms of 
neuromuscular disorders such as lipodystrophy and seizures are reported. Systemic 
diseases like hypertension and diabetes had been reported in two affected 
individuals. 
 
3.3.1.3 Genetic analysis: 
 Collagen VI-related myopathy in particular Bethlem myopathy as a differential 
diagnosis was suggested for these patients and a genetic examination was done. 
The exome sequencing for COL6A1,A2 and A3 was done once in Northern Genetics 
Service in Newcastle by NHS genetic laboratory staffs for diagnostic purposes and 
again in Centre for Genetic Analysis in Oxford University by genetic laboratory staffs 
register these patients in a research data gathering all Bethlem -like patients with no 
COL6A1-A3 mutations.COL6A1-A3 variants which derived from Sanger sequencing 
in Northern Genetics Service in Newcastle was found to be non-pathogenic by 
laboratory staffs according to In silico analysis. In silico analysis was done using 
mutation taster (http://www.neurocore.charite.de/MutationTaste) and polyphen 
(http://www.genetics.bwh.harvard.edu/pph2) for variant analysis and predicted 
pathogenicity. In addition, 1000 genomes databases (www.internationalgenome.org) 
and the NHLBI Exome Sequencing project (EVS) (evs.gs.washington.edu) were 
used to exclude polymorphisms from rare pathogenic variants. 
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 Genetic analysis for Limb-Girdle Muscular Dystrophy, Ehlers-Danlos syndrome and 
Myasthenia Gravis was done in part of the cohort by genetic laboratory staff in 
Northern Genetic Service in Newcastle (table 3.1).Based on literature reviews 
several newly discovered genes for neuromuscular disorders were also investigated. 
Ten candidate genes for heterogeneity in collagen VI, namely PLOD3, P4HA1, 
P4HA2, P4HA3, BGN, DCN, PLOD1, PLOD2,P4HB and COL5A1, were Sanger 
sequenced in Newcastle cohort patients’ by Dr Debbie Hicks prior to this study(Hicks 
et al., 2014). All the variations which were found in these genes were deemed non-
pathogenic by in silico analysis. Family pedigree evaluation suggested autosomal 
dominant mode of inheritance for most of the affected individuals. After discovering 
the novel COL12A1 mutations in two patients of these five pedigrees, by Golara 
Torabi Farsani another COL12A1 mutation was discovered in a patient from 
undiagnosed cohort of 20 individuals with neuromuscular disorders. These patients 
also had been referred to Newcastle Centre for Neuromuscular disorders in 
Newcastle from 2001 and had been evaluated by our medical staff and Doctors. The 
whole exome-sequencing (WES) was done in these patients on 2012 at Decode 
institute. The bioinformatics analysis of WES was done in MRC centre for 
neuromuscular disorder in Newcastle by Dr Debbie Hicks and Dr Steven Laval. The 
detailed information of patient analysis for this cohort was given in Material and 
Method chapter of this research (section 2.6). 
 The novel COL12A1 patient who we call it BM1` will be described later. The reason 
he was not included in the first Bethlem-like myopathy patients with no mutations in 
COL6A1-A3 genes was that clinical presentation of this patient is different from other 
collagen VI-related patients. The symptoms such as lipodystrophy in this patient was 
not reported in other Bethlem-like myopathy patients before.  
 
3.3.2 Clinical and genetic analysis of five overlapping BM phenotype myopathy 
cohort with no mutations in COL6A1-A3: 
 
3.3.2.1 Clinical features and corresponding pedigree: 
 Five patients from the previously described Bethlem-like phenotype cohort were 
selected. The selection criteria for these patients included the most overlapping 
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phenotype with BM, homogeneity with other selected members in disease symptoms 
and progression, availability of patients and their biologic samples, clear pedigree 
and family history, availability of parental DNA, negative Sanger sequencing and 
linkage analysis for COL6A1-A3 genes, with normal immunofluorescence staining for 
collagen VI. This selection was done by principal investigators of MRC centre for 
Neuromuscular disoders prior to this research. Figure 3.3 shows the pedigree of 
each individual patient.  
 
 
 
 
 
 
 Table 3.2shows the clinical features and immunofluorescence staining results for 
dermal fibroblasts for each Bethlem-like patient.  
 
 
Figure 3.3: Five pedigrees of Bethlem-like patients. Three pedigrees 
demonstrates autosomal dominant de novo pattern of inheritance while BM2 and 
BM5 are autosomal dominant inherited. The star (*) shows proband which 
genetically more evaluated in our research.  
BM2 
patient 
BM1 
patient 
BM3 
patient 
BM5 
patient 
BM4 patient 
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Patients (The 
pedigree related 
number) 
First presentation Main clinical 
findings 
Fibroblasts IF 
results 
 Bethlem-like 
1(BM1) 
Infancy. Delayed 
motor milestones, 
walking difficulties. 
Finger flexion and 
elbow contracture,  
Proximal muscle 
weakness 
Normal 
 Bethlem-like 2 
(BM2) 
Infancy. Delayed 
motor milestones. 
Hyperlaxity, 
Muscle weakness 
Normal 
 Bethlem-like 3 
(BM3) 
Infancy. Difficulty 
in walking.  
Joint hyperlaxity, 
Proximal muscle 
weakness 
Normal 
 Bethlem-like 4 
(BM4) 
Childhood. 
Delayed motor 
milestones. 
Finger flexion and 
elbow contracture. 
Muscle weakness 
Normal 
 Bethlem-like 5 
(BM5) 
Childhood. 
Difficulty in walking 
and stair climbing. 
Finger flexion and 
elbow contracture, 
Proximal muscle 
weakness 
Normal 
 
Table 3.2 Clinical features of five non-collagen VI-related Bethlem-like patients. 
3.3.2.2 Genetic analysis: 
 Genomic DNA of these patients was extracted from peripheral blood and sent for 
whole exome sequencing (WES), which was done according to the Illumina protocol 
that was described in detail in the material and methods chapter before. The first 
step for the selection of variants, all non-synonymous, non-sense and splice site and 
very rare variants in other collagen genes included COL22, COL2, COL6A6, 
COL15A1, COL12A1, COL4A3 were chosen. For each pedigree more than two 
hundreds rare, non-synonymous variants were derived from the pipeline. Computer 
based analysis revealed no common variant in at least three pedigrees. The variant 
calling section was done by DR steven Laval. We decided to focus on all collagen 
variants in each pedigree in the first step. The existence of the variants and their 
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pattern of inheritance in corresponding pedigrees were confirmed by Sanger 
sequencing by Golara Torabi Farsani. Figure 3.4 shows the Variant calling for each 
pedigree. 
 
 
 
 None of the variants appeared as de novo mutations in the pedigrees for BM1, BM3 
and BM4. In those corresponding pedigrees mutations present in affected individuals 
were inherited from a non-affected parent. However, in BM2 and BM5, two very rare 
variants in the gene COL12A1 were discovered which segregated with the disease in 
corresponding pedigrees. These two variants and their features will be described 
later. Appendix A shows the list of primers and variants which were sequenced. 
Figure 3.4.Variant calling in each pedigree. Segregation of selected variant after 
variant calling and in silico analysis in corresponding pedigrees. Variants in red has 
the frequency more than 0.005 according to 1000 genome study and all are 
polymorphism. 
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3.4 Result: 
3.4.1 Discovery of threeCOL12A1 variants in corresponding pedigrees of three 
Bethlem-like affected individuals: 
 Two affected individuals from previously described pedigrees (BM2 and BM5) and 
one affected individual from undiagnosed neuromuscular cohort (BM1’) identified 
with COL12A1 mutations derived from exome sequencing and verified by Sanger 
sequencing. These variants completely inherited with autosomal dominant pattern of 
inheritance. The details of these mutations will be described below. Appendix B 
shows primers for these mutations. 
3.4.1.1 Genetic analysis in BM2: 
 The first new mutation (NM: 004370 c.8357A>G: p.Gly2786Asp) was identified in pedigree 
of BM2. Figure 3.5 shows pedigree and sanger sequencing result for this patient. 
 
 
 
 
 This change causes a substitution of the neutral amino acid residue (Glycine) with a 
negatively charged residue (Asparatic acid) in a fibronectin type III domain of the 
Figure 3.5: mutation in BM2.Segregation of p.Gly2786Asp (BM5) with 
autosomal dominant pattern in corresponding pedigree. The black wide 
arrows represent the site of substitution. The black narrow arrow point at 
green shade of Adenine signal parallel with Guanine signals. DNA for 
unaffected members was not available. 
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protein. This substitution occurred in a conserved Gly-X-Y motif which is known to be 
very important in the post-translational assembly of collagen trimers .A failure in the 
trimer assembly prevents the secretion of collagen chains to the extracellular matrix. 
These changes are reported to be pathogenic in other collagens 
includingCOL6Agenes. This variant is not reported in the 1000 genomes database 
(www.internationalgenome.org), NHBLI exomes sequencing project (EVS) 
(https://esp.gs.washington.edu/drupal) or the ExAc database 
(http://exac.broadinstitute.org). In silico analysis with Mutation Taster 
(http://mutationtaster.org) predicted that this change could be pathogenic and 
showed that the residue at this position is highly conserved among mammalians. 
These in silico analysis and genetic sequencing was done by Golara Torabi. 
 
3.4.1.2 Genetic analysis in BM5: 
 The second variant in the COL12A1 gene (NM: 004370 c.5893T>C: p.Arg1965Cys) 
was found in a family with three affected members (BM5). This variant segregated 
with the autosomal dominant pattern of inheritance in the corresponding pedigree. 
Figure 3.6 shows pedigree and sanger sequencing result for these patients. 
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>  
 
 
 
 
 
 In silico analysis revealed that the p.Arg1965Cys variant is located in a fibronectin III 
domain of collagen XII which is predicted to be important in the attachment of 
proteins to other extracellular matrix components. The addition of a cysteine in the 
polypeptide chain of collagen XII would also lead to an unpaired cysteine which 
could form aberrant disulphide bonds.  
 Further investigation through Mutation Taster tool predicted the change to be a 
disease-causing variant.  This change is detrimental for the whole collagen structure 
because it could produce a new disulphide bond. This change is present at a low 
frequency (0.016%)I n the NHBLI Exome Sequencing project(EVS)but absent in the 
1000 genomes databases. This frequency is only reported for Afro-american population. 
Figure 3.6: COL12A1 mutation in BM5. A) Segregation of c.5893C>T: 
p.Arg1965Cys (BM5) with an autosomal dominant pattern in the 
corresponding pedigree. The substitution nucleotide site is highlighted in 
black. B) Control sequence for the healthy member of family. 
A 
B 
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The ExAc database shows a frequency of 0.000083641 for this variant. These in silico 
analysis and genetic sequencing was done by Golara Torabi. 
 
 
3.4.1.3 Genetic analysis in BM1’: 
  In addition to the previous Bethlem-like myopathy phenotype, exome analysis in a 
cohort of undiagnosed muscle disorder patients revealed a heterozygous 5’splice 
donor site mutation (COL12A1:g.C75815009T) at the start of exon 53 of COL12A1 in 
one patient. In this research we called this patient BM1’. RT-PCR and in silico 
analysis confirmed a heterozygous in-frame deletion of COL12A1 exon 54 
(c.del:8345-8431het) which translated to a conserved region in the collagenous 
domain of collagen XII. Collagenous domains are important in collagenous features 
of the protein and are unique for each collagen molecule (Halper and Kjaer, 2014). 
This change does not exist in the NHBLI exome sequencing project (EVS), 1000 
genomes database and ExAC database. Segregation analysis revealed that it is an 
autosomal dominant de novo mutation. This mutation does not appear in other 
members of the family. According to non-overlapping phenotype of this patient which 
will be described later which included lipodystrophy, mutations in group of genes 
which mostly caused lipodystrophy were evaluated. Exome sequencing results for 
mutations in LMNA, ZMP, STE24, PLIN, PPARG, CIDEC, AGPAT2, BSCL2, CAV1, 
PTRF genes were investigated which did not reveal any new pathogenic mutations. 
The investigation was done by Dr Ana Topf according to exome sequencing results 
In addition, the whole exome sequencing result was investigated in this patient 
according to pipeline which was described before. No other pathogenic mutation was 
derived from this investigation. Figure 3.7 shows the genetic analysis result in this 
patient. 
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A
Figure 3.7.  Genomic analysis in BM1’.A) Genomic DNA analysis is shown the result 
for g. 75815009C>T (BM1’). B) cDNA sequencing for this patient is shown del: c.8345-
8432del: p.2727-2755del (BM1’) in normal individual and mutant patients. The black 
arrows represent the start of missplicing section.  
B 
A 
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3.4.1.4 Collagen XII protein schematic picture: 
 The novel described mutations in COL12A1 are localizing in different domains of 
collagen XII protein. The schematic picture 3.8 demonstrates location of each of 
these mutations. 
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Non collagenous 
domain I 
26-2495 
Non collagenous 
domain II 
2496-2747 
Collagen
ous 
domain I 
2748-
2895 
Collagen
ous 
domain 
II 
2941-
2992 
Figure 3.8.Schematic picture of collagen XII. Collagen XII molecule consists of two 
non-collagenous and two collagenous domains. The non-collagenous domains consists 
of eighteen fibronectin type III domains and four vonwilbrand A domains. The first red 
arrow shows the location of missense mutation in BM5 which is in Fibronectin type III 
domains. The red horizontal line shows location of splice variant in BM1’ which leads to 
remove part of collagenous first domain. The second arrow demonstrates the location of 
missense mutation in BM2 which is located in collagenous part of the protein. 
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3.4.1.5 COL12A1 exome screening in the cohort of Bethlem-like myopathy 
patients with no mutations in COL6A1-A3 genes: 
 
 After finding three novel mutations in the gene COL12A1 from the result of WES, 
this gene was sequenced in the cDNA level in the rest of the Bethlem-like myopathy 
patients with no mutations in COL6A1-3 genes cohort. After excluding 
polymorphisms and false positive variants no additional mutations in COL12A1 were 
found in the rest of the cohort. A list of COL12A1 primers and novel variations is 
attached in the appendix C. 
 
3.4.2 Detailed clinical review of COL12A1 mutant individuals: 
3.4.2.1 Clinical review of BM2 and BM5 affected family: 
 Generalized muscle weakness in childhood was the unifying aspect of all five 
patients. In the BM2 family, the affected child had torticolis and hypotonia in her 
neonatal period. Later she presented kyphosis and distal hyperlaxity, delayed motor 
milestones and skin involvement in form of hyperkeratosis pilaris. Finger flexor 
contracture as common sign of Bethlem myopathy in conjunction with knee and 
elbow contracture are presented in child. Her mother also presented finger flexion, 
joint contractures and muscle weakness. She reported less ability for sport in 
childhood. Collagen VI immunofluorescence staining was normal in both affected 
individuals. Mild to moderate CK level and myopathic features as well as fibrosis and 
type I fibre grouping were found in mother. In the BM5 family, the father suffered 
from muscle weakness in infancy which presented in difficulties in sport during 
school time, low scores on physical activity and being unable to finish races. He 
reported a relief in muscle power during the teenage period which is consistent with 
reports from four other affected individuals. The muscle weakness deteriorated 
during his 30s. Gradually he lost the ability to climb stairs, walk independently or 
stand up from a low chair. His two sons (ages23 and 26 years old) complained about 
muscle weakness. They had finger contractures and skin scarring. Skeletal 
abnormalities such as a winged scapula and mild scoliosis were found in one patient 
(BM5 family, father). Figure 3.9 shows some of the clinical presentations in these 
patients. 
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3.4.2.2 Clinical review of BM1’: 
 The patient is a 21-year-old British male with neonatal hypotonia and bendy joints. 
The parents reported delayed gross motor development during infancy, which 
improved with age. Joint hyperlaxity was one of the first symptoms in the patient 
which led to recurrent knee dislocation and a consequent operation. The patient’s 
A (BM2) 
(()9(BM
2) 
B (BM5) 
Figure 3.9. Clinical features in BM2 and BM5.A) Clinical features of affected patient 
in pedigree BM2 which is included joint hyperlaxity and spine deformity and  B) Clinical 
features of affected patients in pedigree BM5 which is included Interphallangeal joint 
deformity and skin scars (Hicks et al., 2014). 
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first medical evaluation was in 2008 because of back pain and patellar dislocation. 
Skin involvement such as a hypopigmented patch, mild contractures on finger flexors 
and scoliosis was found during the last evaluation in the MRC Centre for 
Neuromuscular Diseases in Newcastle. Generalized lipodystrophy and quadriceps 
muscle hypertrophy were unique features which are not seen in other patients. A 
mild muscle weakness was seen during physical evaluation but the patient does not 
complain about low muscle force. The muscle biopsy from the quadriceps was 
reported normal. Before including the patient in an undiagnosed cohort of 
neuromuscular disorder in Newcastle, genes such as PHL1, Lamin A/C, PTR-
CAVIN, and Pompe disease were sequenced in the patient. Laboratory evaluation 
also showed a high CK level (1301) in the patient. Figure 3.10 shows the clinical 
features of the patient. 
 
 
 
Figure 3.10. Clinical features of BM1’.New patient with g. 75815009C>Tdel: : 
c.8345-8432del, p.2727-2755del (BM1’) mutation. Scoliosis (A), Lipodystrophy with 
less distribution of fat in calf and knee areas (B) and finger flexion contractures (C) is 
presented in this patient. 
A B 
C 
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3.4.3 Immunofluorescence staining in COL12A1 mutant individuals: 
3.4.3.1 Immunofluorescence staining for collagen XII in dermal fibroblasts of 
COL12A1 mutant individuals: 
 
 Immunofluorescence staining was done by optimization of original protocol reported 
by Hicks et al (Hicks et al., 2008). The staining was repeated three times and five 
images were captured from each slides. The images were captured by Zeiss 
immunofluorescence microscope. Figure 3.11 demonstrates the result of collagen XII 
IF staining in dermal fibroblasts. 
 
 
 
 
Figure 3.11: Immunofluorescence staining of Collagen XII in dermal 
fibroblasts of affected individuals. The IF staining demonstrated inp.Gly2786Asp 
(BM2) (A), p.Arg1965Cys (BM5) (B), g.75815009C>T:c.8345-8432del,p.2727-
2755del(BM1’)(C). Normal human dermal fibroblasts (D). Collagen fibres are shown 
in red signals and nucleus in blue. Scale bar in A = 100 µm 
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 Overall, a decrease in collagen XII signals was found in mutant fibroblasts of 
affected individuals by visualization. In addition, an absence of collagen XII signals 
was found in the patient with splice donor mutation. However, degrees of variability 
in different staining batches were seen.  
 
3.4.3.2 Immunofluorescence staining for collagen XII binding partners in 
dermal fibroblasts of BM2 and BM5: 
 
 Two potential collagen XII binding partners – collagen IV and tenascin X – were 
stained with immunofluorescence antibody in dermal fibroblasts using the previously 
described method. Fibroblasts of BM2 and BM5 were used. The experiment was 
repeated three times and five images from each slide were taken. Figure 3.12 shows 
the result of this staining. 
 
 
 
 
 
 
 
Figure 3.12: Immunofluorescence staining of Collagen XII binding 
partner in dermal fibroblasts of BM2 and BM5.A-D: Immunofluorescence 
staining of dermal fibroblasts for Tenascin X (red) in p. Arg1965Cys(BM5) (A), 
p. Gly2786Asp(BM2) (B), Normal control (C), Negative control (D). E-F: 
Immunofluorescence staining in dermal fibroblasts for collagen IVA (red) in 
p.Arg1965Cys (E), p.Gly2786Asp (F), Normal control (G), Negative control (H) 
Scale bar in A = 100 µl (Hicks et al., 2014).  
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 Tenascin X staining shows decreased signals for both mutant cells and Collagen IV 
staining shows less deposition of collagen IV in the extracellular matrix area. 
However, collagen IV signals were presented in ECM both in control and mutant 
individuals. The dot pattern of collagen IV in NHDFC was not visible in affected 
individuals. 
 
3.4.4 Immunoblotting of collagen XII in COL12A1 mutant individuals: 
 
 The proteins were extracted from fibroblasts of all mutant individuals. Figure 3.13 
demonstrates the results for the BM2 and BM5 individuals. 
 
 
 
 
 
 
 
 
Figure 3.13: Westernblot for collagen XII in BM2 and BM5.Collagen XII 
westernblotting in p .Arg1965Cys (BM5) (A), p.Gly2786Asp (BM2) (B), normal 
control (C) and commercial control (D).The left A, B and C show protein detected 
in the cell culture medium. The bottom picture shows staining with Emerin as the 
control antibody for the loading amount. Collagen XII bands are predicted at 330 
kDa and Emerin as control at 35 kDa. Images were taken by hlp immunoblotting 
system (Hicks et al., 2014). 
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 There was no difference between the mutant and normal cell lines with regards to 
the amount of protein.  Also, the amount of protein which is secreted to media is the 
same between the mutants and normal control. 
Figure 3.14 shows the result for splice donor mutation (BM1’) and measurement of 
its westernblot bands’ density. 
 
 
 
 
 
 
 
 The splice donor mutation has a significantly lower protein amount compared to 
NHDFCs, also the amount of protein which is secreted to the medium is less than 
NHDFC in the mutant sample. Collagen XII both isoforms which translated from two 
transcriptional variant of collagen XII represented in extracts.  
 
Figure 3.14.Western blot for collagen XII in BM1’. 1) Western blot for 
collagen XII in media and cell extract in mutant patient with g. 
75815009C>T. c.8345-8432del, p.2727-2755del (BM1’) and normal 
control. Collagen VI were used as control in both systems. The underline 
graph shows a significant reduction in the amount of protein in mutant 
cells in compare to normal controls both in medium and cell extracts. 
Images were taken with Odyssey system. 
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3.4.5 Collagen XII immunofluorescence staining in normal mouse muscle: 
 Normal mouse muscles (Rectus femoris biopsy) were stained for collagen XII and 
compared to the collagen VI pattern of mouse muscle staining (Figure 3.15) .It 
demonstrated that collagen XII has the same localization as collagen VI.  
 
 
 
3.5 Discussion: 
 Genetic heterogeneity was described and reported in a number of patients with 
Bethlem-like myopathy phenotypes (Hicks et al., 2008). The MRC Centre for 
Neuromuscular Diseases in Newcastle and other centres have reported and followed 
up such patients. MRC Centre for Neuromuscular Diseases estimated that about 
50% of our collagen VI-related myopathy phenotype patients referred to its affiliated 
clinic in Newcastle are not associated with COL6A mutations (Hicks et al., 2014).In 
this study, we aimed to identify novel disease-causing genes for a cohort of the 
Bethlem-like myopathy phenotype which do not have any disease causing mutations 
in their COL6A genes. 
 This cohort shows some symptoms of collagen VI-related myopathy (predominantly 
the milder form, Bethlem myopathy) and other symptoms of overlapping different 
disorders. Joint contractures, muscle biopsy abnormalities and a high creatine 
kinase level appeared to be the most frequent symptoms. Abnormality in muscle 
reflexes was not seen in any patient that ruled out the chance of being neurologically 
impaired. Less than 10% of patients in this cohort were non-ambulant or wheelchair-
Figure 3.15: Collagen XII staining in mouse muscle.The left picture represents 
collagen XII in mouse muscle and the right one represents collagen VI in mouse 
muscle. Collagen fibres which have a basement membrane appearance are in 
green. Nucleus is blue with DAPI staining. Scale bar in A = 200 µm. 
A B
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dependent. Abnormalities in immunofluorescence staining and positive family history 
are the other rare symptoms. These symptoms showed that many patients suffered 
from a mild to moderate disorder. Moreover, for heterogenic Bethlem-like myopathy 
phenotypes the symptoms which represent connective tissue involvement such as 
joint contractures and spine abnormality have a higher frequency. Different muscle 
abnormalities as an indicator of neuromuscular disorder were found in these 
patients.  
 We identified COL12A1 as a potential disease-causing gene for two patients of this 
cohort with their families. Later, one patient with joint hypermobility and slight muscle 
weakness from a cohort of undiagnosed patients was identified with a splice donor 
mutation in COL12A1. Muscle weakness appeared to be fine in all patients and none 
of them loosed their ability to walk. In one family of point mutation with two affected 
members muscle weakness improved with age in three family patients. Joint 
hyperlaxity and skeletal abnormalities were noted to be the most prominent and 
common symptoms in all patients. Very recently, mutations in COL12A1 were also 
reported in two other patients with a collagen-VI/ Ehlers-Danlos myopathy symptoms 
overlap (Zou et al., 2014). The most affected patient with nonsense mediated decay 
suffers from severe muscle weakness, joint hypermobility and surgically fixed 
scoliosis. Lipodystrophy was one new symptom that is found in one of our patients 
with the splice-donor mutation (BM1’) of COL12A1 and could widen the spectrum of 
COL12A1 myopathy phenotype. Overall, the new cohort of COL12A1 mutant 
patients demonstrated more symptoms of joint hypermobility and skeletal 
abnormality with less severity in muscle weakness. Even patient with lipodystrophy 
sharing those symptoms with other affected individuals. These unifying symptoms 
could be beneficial for clinicians to include COL12A1 in the list of differential 
diagnosis. 
 
 The collagen XII molecule is a member of FACIT collagens which consist of 
collagen IV, IX, XII, XIV, XV and XIX as other members. FACIT collagens are a 
recently identified class of collagen molecules. They are unable to form fibres by 
themselves but by means of attaching to other collagen fibres they may control the 
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architecture of interstitial fibrils. These interstitial fibrils build up the insoluble 
framework common to each matrix type (Halper and Kjaer, 2014). Collagen XII is an 
extracellular matrix protein (ECM) and like other collagens has a specific site for 
glycose aminoglycans such as heparin to bind. RNA expression analysis revealed 
that COL12A1 is expressed as two homotrimer protein variants. The larger variant 
contains 330 amino acids and has a more restricted expression pattern similar to 
tenascin X. The small variant contains 220 amino acids. Both variants are comprised 
of a different fibronectin type (FN3) and von Willebrand A domain (VWA) which is 
similar to other collagen molecules. Eight more FN3 domains and two more VWA 
domains were discovered in the larger variant. Also like the other collagen family, the 
collagen XII molecule has collagenous domains which are unique to this molecule. 
The collagenous domains are near to the COOH terminal. Collagenous domains1 
and 2 (COL1, COL2) are short but collagenous domain 3 (COL3) is large specifically 
in the larger variant, and reveals a complex structure with a high affinity for molecular 
interactions. Several studies suggest an association between the collagen XII and 
collagen I striated fibre (Koch et al., 1995; Agarwal et al., 2012). Also, biochemical 
studies revealed that the large variant of collagen XII has a higher affinity to attach to 
heparin. As the collagen XII-heparin biochemical complex with the large variant does 
not detach in a higher salt concentration, a shock absorber role for collagen XII 
among other FACIT collagens is suggested (Trachslin et al., 1999). All the variants 
we found in our study affect the larger COL12A1 variant. 
 
 The variants NM004370: c.5893T>C: p.Arg1965Cys and NM004370: c.8357A>G: 
p.Gly2786Asp both are in the FN3 domain of the protein in the non-collagenous 
region. The variants in BM1’ and BM2 do not exist in the ExAc control database. 
Also, analysis with Polyphen2program predicted these changes to be pathogenic. 
Other in silico analysis revealed that these changes are located in highly conserved 
regions among species. Fibronectin type 3 domains are the largest domains in the 
fibronectin protein and are also represented in other extracellular matrix proteins. 
They are evolutionarily conserved domains and exhibit the sites of interactions with 
other molecules. These sites are mostly mapped with short repeats of amino acids 
such as Asp-Gly-Arg (RGD). None of the mutations we found interrupted the short 
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stretch of RGDs. However, NM004370: c.5893T>C:pArg1965Cys by adding one 
cysteine amino acid interrupted disulphide bonds which are important in the 
formation of the secondary structure of the protein. An aberrant structure of the 
protein could result in trapping the protein in the endoplasmic reticulum or Golgi 
apparatus. Further experiments of protein trapping for BM2 and BM5 were done by 
endoplasmic reticulum imaging on skin biopsies of these affected individuals (Hicks 
et al., 2014). Due to unavailability of skin biopsies for BM1’ the work did not repeated 
on these patient. Afterwards, the unfolded protein response pathway will be activated 
to digest and eliminate the protein. The unfolded protein response pathway has been 
suggested to be one of the mechanisms underlying neuromuscular disorders. 
Further evidence for unfolded protein response pathway activation for BM2 and BM5 
was discussed in the article by Hicks et al (Hicks et al., 2014). 
 
 In that article it has been shown that Golgi apparatus was enlarged in skin biopsy 
samples which were taken from the patient with the NM004370: c.5893T>C: 
pArg1965Cys (BM5) mutation by electron microscopy. Also, the unfolded protein 
response pathway is upregulated in the BM5 mutation by RNA studies (Hicks et al., 
2014). 
 
 Another possible mechanism for the NM004370: c.8357A>G: p.Gly2786Asp 
mutation was suggested. In silico analysis revealed that amino acid substitution in 
this patient occurred in a highly conserved Gly-X-Y motif. These repeats are most 
important in collagen structure and mutations in them are reported to cause different 
disorders. Also, substitutions of glycine residues in the Gly–X–Y motifs of the N-
terminal collagenous triple-helical domain of collagen VI are reported to be one of 
the important causes of collagen VI-related myopathy (Lamande et al., 2002). This 
type of mutation in collagen VI patients acts in a dominant-negative fashion. We 
have seen the same fashion in a collagen XII mutant patient. In collagen VI patients 
mutated α-chain subunits can become incorporated into collagen VI monomers. 
Evidence of an extra ultrastructurally visible kink in the completed triple-helical 
domain has been reported in these patients (Hicks et al., 2009b).The molecular and 
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clinical consequences of autosomal-dominant substitutions in Gly-X-Y motifs are 
variable and depend on the exact sequence context in which they occur (Lamande et 
al., 2002).  
 
 Glycine substitutions might, therefore, be seen in dominant pedigrees affected by 
typical Bethlem myopathy, but also occur as de novo mutations in patients with 
collagen VI-related myopathy phenotypes in the Ullrich CMD or intermediate range 
(Camacho Vanegas et al., 2001). We observed a reduction in the 
immunofluorescence signals of collagen XII for patient with glycine residue 
substitution. This pattern could be due to inability of the protein to interact with other 
ECM components and the consequent instability. However, there are limitations in 
structural evaluation of protein with immunofluorescence staining. 
 
 The first attempt to IF stain patient cells for collagen XII with an in-house protocol 
(Hicks et al., 2008) did not reveal any differences between normal and mutant cells. 
The optimized protocol which has an antigen-sensitive step which is permeabilize 
cell membrane with cloridric acid solution and was used before for collagen IV 
staining was used afterwards, which reveals a reduction in collagen XII signals 
(Shen et al., 2014). Immunofluorescence staining could not show whether this 
difference is a result of a quantitative reduction in the protein or if the protein is not 
assembled correctly and could not collaborate in the extracellular matrix structure 
(Jimenez-Mallebrera et al., 2006). Westernblotting for this patient also showed the 
quantitative amount of the protein for the two-missense mutations is not reduced and 
the amount of the protein which is secreted to the extracellular matrix structure is 
similar in mutant and normal cell lines. These findings in conjunction with IF staining 
results suggest that while misfolded protein could assemble correctly it could not 
contribute to ECM structure. However, the splice donor mutation shows a reduction 
in the amount of protein secreted to the medium which reflects a defect in 
intracellular protein assembly. This defect could cause the accumulation of the 
protein in the endoplasmic reticulum. Endoplasmic reticulum degradation pathway 
(ERAD) might be activated. One possible future experiment is to inhibit ERAD 
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pathway by drugs such as eeyarestatin and check whether IF staining could show 
signal increase due to release of the misfolded protein from endoplasmic reticulum. 
Fibroblasts of control and affected individuals will be treated with 1µl of eeyarestatin 
and then IF staining for collagen XII will be done for eeyarestatin treated and 
untreated cells for mutant and control individuals. We expect that the inhibition of 
endoplasmic reticulum degradation pathway with eeyarestatin lead to presentation of 
more collagen XII signals in mutant samples but many of these collagen XII fibrils 
might not be capable of assembling into extracellular matrix. 
 So far, one other individual with COL12A1 mutation was reported by Punetha et al 
in 2017 (Punetha et al., 2017).They describe an 8-year-old Polish girl who has 
symptoms of profound hypotonia and joint hyperlaxity at birth. Her mother during this 
pregnancy suffered from oligohydramnios and intrauterine growth retardation.They 
identified a novel, potentially pathogenic heterozygous missense COL12A1 
c.8329G>C (p.Gly2777Arg) variant using a targeted sequencing panel. Patient 
fibroblast studies confirmed intracellular retention of the collagen XII protein, 
consistent with a dominant-negative mutation. They reported that the patient showed 
a more intermediate phenotype, thus could expands the phenotypic spectrum for 
COL12A1 mutant affected individual. They suggested the patient presented much of 
overlapping features of Ehlers Danlos syndrom and Bethlem myopathy (Punetha et 
al., 2017). 
 The above case is also another example of COL12A1 affected individuals who 
represent with mild to moderate muscular symptoms and connective tissue 
symptoms as hyperlaxity. The new patient together with other reports ofCOL12A1 
affected individuals proved the phenotypic diversity of these group of mutant 
individuals. However, so far symptoms such as joint hyperlaxity and mild to 
moderate muscle weakness were found to be common in all cases. One rare 
symptom of lypodystrophy was found in one individual of our cohort (BM1`) but as 
the number of COL12A1 affected individuals are still few, we need more report of 
COL12A1 mutations in order to be able to describe unique symptoms for this entity 
(Hicks et al., 2014; Zou et al., 2014; Punetha et al., 2017). 
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 As mentioned above, one possible collagen-XII role is to connect different 
extracellular matrix molecules to each other or to attach them to the main 
extracellular matrix collagen fibrils such as collagen I and II. It is observed that 
collagen XII along with other matrix molecules such as fibronectin, tenascin and 
vimentin could change the extracellular matrix deformability. Immunofluorescence 
staining for other matrix molecules which might connect to collagen XII as binding 
partners shows a different pattern compared to normal controls. A reduction in both 
collagen IV and tenascin signals was seen in mutant fibroblasts. This phenomenon 
could explain the effect of mutant collagen XII molecules in patients’ extracellular 
matrix samples. 
 
 Localization studies suggest that collagen XII protein variants could work as 
interfibrillar attachments but this function could not be described in detail (Koch et al., 
1995). It would be reasonable to predict that, as a fibril-associated molecule they 
might either cross-link or separate collagen fibrils while determining or maintaining 
interfibrillar distances. This function appears unlikely for collagen XII variants 
because they appear at all collagen distance. Such molecules might also be 
predicted to secure the collagen fibril to the elastic network or the type VI collagen 
network. While interactions of collagen XII variants with type VI collagen are not 
excluded by these studies, there is no obvious colocalization of collagen XII variants 
with type VI. Preliminary mouse muscle staining for collagen XII showed a 
localization pattern similar to collagen VI. However, none of the patient muscle 
sample were available for collagen XII staining. Lack of these samples is one of our 
study limitation which makes it difficult to comment on direct effect of collagen XII 
molecular abnormality in muscle samples. 
 While the first part of our study revealed a possible abnormal ECM structure for 
patients with COL12A1mutations, a broader research on possible effect of these 
mutations on extracellular matrix structure was done in the next chapter. Our findings 
emphasize the role of COL12A1 as a disease-causing gene in patients with Bethlem-
like myopathy symptoms. In vitro molecular studies also support the idea of an 
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abnormal structure of the mutant proteins. However, the exact role of collagen XII in 
the pathogenesis of the disease remains to be discovered. 
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Chapter 4 Extracellular matrix hierarchical structure in COL12A1 
mutant individuals 
4.1 Introduction: Collagen XII molecular structure, assembly, and role in 
extracellular matrix 
 Extracellular matrix (ECM) molecules are classified as collagens, elastin, 
proteoglycans and other non-collagenous structural/cell interaction proteins. 
Distinctive repetitive modules are common structural features among ECM 
molecules, which could resemble the functional domain in non-ECM proteins 
(Allamand et al., 2010). Collagen molecules are the most abundant form of protein in 
the extracellular matrix and were produced by ECM fibroblasts. These molecules 
consist of three polypeptide chains which are called α chains (Zulian et al., 2014). 
The unique protein domain of this molecule, a collagenous domain, is made up from 
intertwined α chains in a rod-like shape. GLY-X-Y motifs appear in all collagen 
molecules. GLY is glycine X and Y in these motifs are mainly proline and 
hydroxyproline (Halper and Kjaer, 2014). This sequence is required for the correct 
assembly of collagen molecules in which Glycyl residues form the centre of the triple 
helix, while folding and stabilization of the triple helix is dependent on amino-acid 
residues. Collagen molecules are not only important in ECM and connective tissue 
structures but they also have a signalling role. Two main groups of collagens are 
fibrillar and non-fibrillar. Fibrillar collagens are types I, II, III, V, XI. Non-fibrillar 
collagens are comprised of different types of collagens such as FACITs (Fibril 
Associated Collagens with Interrupted Triple Helices), short chain, basement 
membrane, multiplexin (Multiple Triple Helix domains with Interruptions), MACIT 
(Membrane Associated Collagens with Interrupted Triple Helices), and others. 
 
 So far, 28 different types of collagens have been discovered. A great level of 
diversity both in α chain structure and supramolecular aggregates is seen in different 
types of collagens. All fibrillar collagens are composed of ten different polypeptide α 
chains which are a1(I), a2(I), a1(II), a1(III), a1(V), a2(V), a3(V), a1(XI), a2(XI) and a3 
(XI) (Young et al., 2002). These chains are descended from a common ancestor 
coded by a 45 to 54 nucleotide gene. The product of this gene is a 15 to 18 amino 
acid long polypeptide which is comprised of repeating motifs of GLY-X-Y residues. 
During evolution, this ancient gene, through successive duplications and mutations 
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has grown into a family of large, related, and structurally interrupted genes which 
encode long products of 1200-1300 residues. However, the GLY-X-Y motifs are still 
preserved and a hallmark of the collagen family. While the nucleotide sequence of 
different collagen genes has been deciphered, the nucleotide/amino acid 
correspondence is not entirely clear for all collagen molecules (Mienaltowski and 
Birk, 2014b). This is mainly due to extensive post-translational modifications in the 
collagen molecule. Hydroxylation of lysine and proline residues is an essential step 
of post-translational modification and critical for collagen structure (Wenstrup et al., 
2011).  
 
 A great number of genetic hereditary diseases in humans are caused by collagen 
mutations, which shows the prominent role of collagen molecules in biomechanical 
and biochemical properties of different tissues. Some other variable and important 
post-translational modifications include oxidation and glycosylation. Evaluation of the 
primary structure of collagens reveals other features such as the distribution of some 
amino acids (lysine, glutamine, and arginine) which show a periodicity which reflects 
the end of an exon or clustering of polar and hydrophobic residues that repeats 
periodically in every 234 amino acids (Chen et al., 2014). 
 
 The secondary structure of fibrillar collagen is an α-helix. It is made up of the folding 
of polypeptide α-chains with an axial residue-to-residue spacing of 0.286 nm and 
angular separation of 108°. This structure is highly dependent on the steric repulsion 
between proline and hydroxyproline in the X and Y positions. This proline-based 
backbone results in a side chain of amino acids being exposed to the outside. 
Because of the geometry of α-helixes, which turn every three residues, and the third 
place position of glycine in the GLY-X-Y repeat, the surface of α-helixes contain a 
glycine row (Gordon et al., 1987). Point mutations which appear in the X and Y 
positions might be tolerated but mutations in glycine residues always lead to a range 
of congenital disorders of connective tissue, because they clearly interrupt the α-
helix structure and any further intercellular assembly (Lamande et al., 2002). 
Collagen fibrils are either homo- or heterotrimers of α-helixes. This depends on 
 
 
 
 
106 
 
collagen and tissue type. Collagen I is always a heterotrimer of a1(I)2 + a2(I).The 
triple helix is a rod-like, stiff but flexible, structure which is 1.5 nm wide and 300 nm 
long with a globular domain at each end (Izu et al., 2011b). This form is called 
procollagen which is excreted into the extracellular space for further assembly. In the 
extracellular space, the terminal globular domains are split to form collagen. This is a 
highly reactive molecule which very quickly becomes involved in the formation of 
fibrils. Fibrillogenesis is the generation of a large supramolecular structure from 
collagens. This structure first forms through polar, hydrophobic, and other non-
covalent bonds. Then they are stabilized by covalent bonds(Harris et al., 2005). 
 Many different techniques have been used to investigate collagen structure. 
Transmission Electron Microscopy (TEM) images have provided most of the 
information about the collagen supramolecular structure, while X-ray diffraction 
systems have helped to understand the lateral fibril structure. However, X-ray ability 
to demonstrate all the changes is limited. This approach is appropriate for 
simultaneously revealing fibril-bound material, surface features such as the cross-
banding, and some details of the inner structure of the collagen fibril, while avoiding 
the artefacts usually caused by fixation, dehydration or sectioning (Harris and 
Reiber, 2007). 
 
 FACITs as the main focus of this chapter include collagen types IX, XII, XIV. These 
types of collagens do not form quarter-staggered fibrils by themselves because their 
α-helix is a mixture of globular and collagenous domains, thus they cannot form 
fibrils so they are non-fibrillar collagens (Starborg et al., 2008b). The structure of 
these molecules can be divided into three functional parts. One part which consists 
of one or two functional domains serve for the attachment of the superstructure of 
the molecule to the fibrils. The second part has a triple helical domain, working as a 
rigid arm to project the third part out of the fibril. The third part and its functional 
domains may serve as a region to interact with ECM components and cells. The 
structure of the FACIT protein is comprised of triple helical domain (collagenous 
domain) and interrupted non-triple helical domains (non-collagenous domain).Type 
IX collagen is the best identified example of FACITs. This molecule is the first FACIT 
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that was discovered. This triple helical molecule is attached to ECM containing 
fibrillar type II collagen, such as the vitreous body of the eye and hyaline cartilage. 
This attachment is served by covalent cross-links. The role of collagen IX in this 
interaction remains to be elucidated completely. However, studies on chicken 
cartilage suggest collagen IX might help the attachment of large glycosaminoglycan 
side chains to collagen fibrils. In the ECM, collagen IX might be the means of 
attachment to fibrils. Absence of collagen IX in many connective tissues has 
revealed a need for an alternative molecule in other tissues with a similar functional 
role. Gordon et al (1987) successfully searched for such molecules (Gordon et al., 
1987). 
 
 Collagen XII was discovered from chick tendon fibroblasts in 1987 during research 
for novel collagenous sequences (Gordon et al., 1987). Collagen XII cDNA was 
highly similar to collagen IX, which is characterized above as a FACIT collagen. 
Dublet and vander Rest isolated collagenous pepsin-resistant fragments from chick 
tendons, whose amino acid sequences matched the published collagen XII cDNA, in 
the 1989 (Dublet et al., 1989). In 1989, the intact protein of collagen XII was 
characterized as a homotrimer of 220-kDa subunits, with disulphide-bonded 190-kDa 
non-collagenous domains linked to a short C-terminal collagen helix by Doublet and 
colleagues. The newly extracted molecules from the tendon, collagen XII, are cross-
shaped with three 60 nm long arms and a thinner tail 75 nm in length (Gordon et al., 
1989).In 1991, Yamagata et al. published the full-length chick collagen XII cDNA 
which encoded a subunit of 340kDa (Koch et al., 1992). Larger molecular species of 
collagen XII which were purified from chick fibroblasts and a human cell line 
confirmed that two isoform of collagen XII is existed (Lunstrum et al., 1991; Koch et 
al., 1992). Peptide sequencing has shown these larger molecules are also collagen 
XII. In fact, large variants of collagen XII have non-collagenous arms of more than 
300 kD and 90 nm in length (Koch et al., 1992). Alternative splicing is responsible for 
large and small variants of collagen XII (Koch et al., 1995). In 1991, a molecule with 
a distinct sequence and similar structure to the small collagen XII variant was 
discovered (Galetta et al., 1991). This newly discovered molecule was named 
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collagen XIV. These novel molecules became the main members of the fibril-
associated collagens with an interrupted triple helix (FACITs).  
 
 Later, the complete primary structure of an α1 chain of type XII collagen was 
identified. This molecule was extracted from chicken embryonic fibroblasts. This 
structure combines the findings of short separate domains into a large 3410 amino 
acid structure (340 kD). The extracted chicken collagen type XII sequence starts at 
the amino terminus with one unit of the type III motif of fibronectin, then one unit 
homologous to the von Willebrand factor A domain, which is followed by another 
fibronectin type III domain, a second von Willebrand factor A domain, six domains of 
type III and a third von Willebrand factor A domain. After this, ten consecutive units 
of fibronectin type III motif and a fourth von Willebrand factor A domain are placed. 
Before the start of the collagenous domain, one non-collagenous domain similar to 
the non-collagenous domain type four of collagen IX is placed. At the end of the 
molecule are two short collagenous domains. A motif of Arg-Gly-Asp as potential cell 
adhesive recognition sequence is present in a terminal part of one collagenous 
domain in a hydrophilic region. Different antibodies have been raised to type XII 
collagens. These antibodies can recognize both variants of collagen XII and also 
non-specific bands of different size (Koch et al., 1995; Gordon et al., 1996). Figure 
4.1 shows a schematic picture of collagen XII protein. 
 
 
 Antibody-specific studies have shown collagen XII is widely expressed in 
mesenchymal tissues containing collagen I such as in developing bone, ligaments, 
tendons, fibrocartilage, smooth muscle and skin (Anderson et al., 2000). It is also 
Figure 4.1.Schematic picture of collagen XII. Collagen XII protein short and 
long isoform are represented in this picture. 
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found in tissues with the collagen I matrix of foetal articular cartilage, mostly in its 
superficial layers (Williams et al., 1992). In adults, the expression of collagen XII is 
more restricted to dense connective tissues such as the periodontal ligament 
(Karimbux et al., 1992), dermis around hair follicles and cornea of the eye (Anderson 
et al., 2000). Fibroblasts are the primary source for the secretion of collagen XII in 
adults and in embryo mesenchymal cells are the sites for collagen XII secretion. 
Large and small variants of collagen XII are expressed differently(Anderson et al., 
2000).However, the gene expression mechanism and function of different collagen 
XII variants are not clearly understood. Gene expression might be upregulated 
during osteogenesis and some cancer progressions, according to different studies 
(Tzortzaki et al., 2006; Karagiannis et al., 2012). It has been suggested that tensile 
strain by acting on cells regulates collagen XII expression. There is a promoter 
responsible for tensile strain in COL12A1 in the chick’s first exon. Also, another 
promoter for C-Jun was identified in the APO1 promoter for COL12A1(Arai et al., 
2008). Localization of collagen XII in basement membrane has been reported, but 
it’s role is unknown (Farhat et al., 1979). Investigations showed in vivo expression of 
collagen XII induced by chronic loading (Karimbux et al., 1992). According to these 
findings, static versus strain forces regulate COL12A1 gene expression (Kania et al., 
1999; Trachslin et al., 1999). 
 
 Collagen XII is important in extracellular matrix assembly. First, immunogold 
labelling studies by Koch et al showed placement of collagen XII on large collagen I 
ECM fibrils. Second, in this study it was shown that decoration of collagen XII could 
be reconstituted in vitro by adding collagen XII on to large collagen I fibril monomers. 
In this study, it was also shown that in the absence of collagen XII, collagen I 
monomers are thicker. Collagen XII also interacts with neighbouring compartments 
in ECM (Koch et al., 1995; Veit et al., 2006). For example, the non-collagenous type 
III domain of the molecule which is protruding from the fibrillar structure is bound to 
tenascin-X, another ECM component. Immunoelectron microscopy studies showed 
collagen XII was attached to decorin, fibromodulin, and cartilage oligomeric matrix 
protein molecular components as well (Bateman et al., 2009). Collagen XII with this 
binding partner could form a bridging network to absorb sheer stress forces on 
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collagen fibrils and attach them to each other (Wessel et al., 1997; Trachslin et al., 
1999). 
 
 Apart from diverse studies that showed a possible role for collagen XII in ECM 
assembly and characteristics, collagen XII deficient animal model, repeated some 
clinical features of mutant COL12A1  individuals (BM2, BM5 and BM1’) who we 
described in previous chapter. COL12A1-knockout mice suffer from muscle 
weakness and joint contractures which could be the result of increased elasticity in 
muscle tissues and lack of strain forces. Also in these mice, the histologic pattern of 
bone meshwork is siginficantly disorganized which is represented in mouse 
kyphoscoliosis and shorter long bones (Zou et al., 2014). Formation of osteocyte 
nodules in the osteoblast culture of a COL12A1-/- mouse is delayed, and the polarity 
of cells is decreased. It seems that the collagen XII protein is important for proper 
osteoblast/ osteocyte differentiation, either through direct contact or a signalling 
pathway. Integrinα1β1 is a potential candidate signal molecule for collagen XII acting 
in the osteocyte differentiation pathway (Arai et al., 2008; Izu et al., 2011b). 
However, it might not act similarly in all creatures. The integrin α1-/- mouse 
phenotype does not resemble the collagen XII null mouse, which suggests a different 
role for these molecules (Bolduc et al., 2014).  
 
 We identified missense and splice donorCOL12A1 mutations that are responsible 
for Bethlem-like myopathy phenotypes (Hicks et al., 2014). Bethlem myopathy as a 
collagen-VI-related myopathy as previously described is a muscle/connective tissue 
disorder which could have overlap with other connective tissue disorders such as 
Ehlers-Danlos syndrome (Wessel et al., 1997). Around 50% of collagen VI-related 
myopathy patients have a normal collagen VI level and no mutation in the collagen 
VI genes (Hicks et al., 2008). Overall, the identified patients suffer from muscle 
weakness, joint hyperlaxity, skin tags and skeletal problems such as scoliosis 
(Bonnemann, 2011).  
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 One of the families we identified with a point mutation has structurally abrupt 
disulphide bands (BM5) and in the other family a Glycine residue substitutes in the 
Gly-X-Y motif (BM2). These patient symptoms improve with age. The last family with 
splice donor mutation shows more joint hyperlaxity. Also, lypodystrophy was seen in 
the patient which is a new symptom in the collagen XII myopathy cohort (BM1’). 
Reduced collagen XII signals were present in ECM immunofluorescence staining of 
patients while immunoblotting did not show any reduction in the protein secreted to 
ECM in BM2 and BM5 family. This demonstrates that misfolded protein was detected 
but could not assemble into ECM structure. Two other affected COL12A1individuals 
which reported parallel to our cases show the same symptoms with a change in the 
expression level of the collagen XII protein (Bolduc et al., 2014; Hicks et al., 2014; 
Punetha et al., 2017). These findings support the pathogenic nature of mutations and 
their consequent effect on connective tissue. However, the link between human 
connective tissue pathologies and molecular interactions of collagen XII in the ECM 
structure is unknown.  
 Based on previous findings, we aim to identify the role of collagen XII in the ECM 
ultrastructure. First the skin biopsy of one affected individuals (BM5) was taken and 
compared with healthy donors. Then fibrillar collagen structures from affected 
individuals (BM5 and BM1’) and healthy donors were evaluated both in cultured 
samples of fibroblasts and in vitro assembled samples. We hypothesized that 
misfolded collagen XII may lead to larger collagen fibrils diameter during collagen 
fibrillogenesis.  
4.2 Aim: 
 In this chapter we aim to: 
 Investigate collagen fibres structure from COL12A1 mutant individuals and compare 
it to healthy donors. 
 Measure collagen fibrils diameter in ECM structure surrounded fibroblasts of 
COL12A1 mutant individuals and compare it to healthy donors. 
 Measure collagen fibrils diameter in in vitro assembled collagen fibrils of COL12A1 
mutant individuals and compare it to healthy donors. 
 
 
 
 
112 
 
 
4.3 Evaluation of collagen fibrils diameter in extracellular matrix of COL12A1 
mutant individuals: 
4.3.1 Electron microscopy evaluation of skin biopsies from BM5: 
4.3.1.1 Individuals: 
 Skin biopsies were taken from patients with the p.Arg1965Cys mutation (BM5) from 
keloid scars in Newcastle University affiliated hospitals. The preparation for electron 
microscopy was performed by the staff of electron microscopy unit in Newcastle 
University. Then the samples were compared with a skin biopsy of healthy donors. 
Healthy donor was matched in age and ethnicity with mutant individuals. Healthy 
donor was one of control samples which is kept in electron microscopy units. The 
examiners were blind about the nature of the samples. 
4.3.1.2 Electron microscopy findings: 
 The findings were based on evaluation at the ultrastructural level by TEM. Cross-
sectional images show a dense packaging of collagen fibrils in the nodules in control 
samples. In patient samples regions with relatively loose packing were found as well. 
Also, a variable size and shape in the collagen fibres was seen (Figure 4.1).This 
variation could be a result of difference in collagen I fibrils diameter (collagen fibres 
in ECM of skin are mainly composed of collagen I fibrils). Previous findings as 
described in this chapter introduction, suggested collagen XII as a binding partner of 
collagen I could affect collagen I fibrils diameter and length during collagen I fibrils 
assembly (Agarwal et al., 2012).  However should bear in mind that biopsies were 
taken from kloid scar in BM5 patient and the abnormal findings could be just 
common characteristics of collagen fibres in kloid scars (Moinzadeh et al., 2013). 
This issue will be discussed in discussion later .This variation in longitudinal sections 
show a disruption in collagen fibres longitudinally and laterally in patient samples. 
However, in the control subjects the longitudinal collagen fibres were continued 
(Figure 4.2). Evaluation of areas with fibroblasts in the extracellular matrix showed a 
dilated rough endoplasmic reticulum in the affected individuals. Also, vascular 
membrane thickening was found in the mutant samples by visualization (Figure 4.3). 
Figure 4.2, 4.3 and 4.4 demonstrate these findings. 
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Figure 4.2. Cross-sectional images of collagen fibres. Cross-sectional 
images of collagen fibres in the extracellular matrix from healthy donors (A) and 
p.Arg1965Cys (B) skin biopsies. Black arrows indicate abnormal collagen fibre 
with a prominent layer in periphery of the fibre. 
 
A 
B 
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Figure 4.3.Images of longitudinal fibres. Longitudinal sections of collagen 
fibres in the extracellular matrix in healthy donor (A) and p.Arg1965Cys mutant 
cell lines (B) from skin biopsies. White arrows demonstrates sites of breaks in 
mutant collagen fibres. 
 
A 
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Figure 4.4.Images of vessel wall. Vessel wall of healthy donor (A) and 
p.Arg1965Cys skin biopsy (B). Black arrow shows red blood cells and white 
vertical arrow points to vessel wall thickening. White horizontal arrow points to 
the location of a discontinuity of vessel wall in mutant samples. 
 
B 
A 
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4.3.2 Electron microscopy evaluation of collagen fibrils in ECM from BM1’: 
 Fibroblasts of cells with mutations from splice donor mutant individual (BM1') were 
cultured, and as previously described in material and methods section prepared for 
electron microscopy. Fibroblasts were left attached to the plastic of the culture dish 
and their surrounding ECM, fixed into resin and sectioned with a diamond knife. 
Under electron microscopy collagen fibrils were identified. These tubular structures 
normally appeared near fibroblasts cells. Then collagen XII molecules, which had 
been stained with collagen XII antibody (provided by Prof Manuel Koch) and 
secondary immunogold anti-rabbit antibody, appeared as single black dots on 
collagen fibrils. Using the silver enhancement kit for immunogold staining led to 
some islets of collagen XII antibody and protein conglomeration on collagen I fibrils.  
These artefacts were not taken into account during evaluation. Collagen XII 
molecules were presented in both affected individuals and healthy donors. According 
to previous studies, the absence of collagen XII in the in vitro environment for 
making collagen fibrils leads to an increase in collagen fibril diameter. The aim of this 
experiment was to assess the effect of mutant collagen XII samples on the collagen 
fibril diameter. After identifying locations with collagen fibrils three images were taken 
from each location from mutant and normal samples. In each experiment at least two 
locations were identified and experiments were repeated three times. In each 
independent image collagen monofibril diameters were measured from ten different 
locations horizontally. The distance between these locations was kept as 500nm. 
Analysis was performed using ImageJ analyser. Then unpaired t-test as used to 
compare measurements with the normal control, with significance set at 5%. Excel 
was used for analysis. This experiment showed there was no significant difference 
between collagen monofibril diameters between mutant and normal cell lines. Figure 
4.5 demonstrates the transmission electron microscopy images used for analysis. 
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Figure 4.5.Immunogold collagen fibril images. In vivo cultured collagen 
fibrils from normal human dermal fibroblast cells (NHDFCs) is shown as 
long cylindrical structure. Collagen XII molecule represent on them as 
black dots (A, B and C). In vivo cultured collagen I fibrils from splice donor 
mutation is shown as long cylindrical structure (BM1`). Collagen XII 
molecule represent on them as black dots. Black islets are integration of 
immunogold particles (D, E and F). 
A D 
B E 
C F 
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 Table 4.1 and graph 4.1 shows the statistical value and comparison in diameter 
between mutant (BM1`) and control cell lines. 
Total Experiment 3 Experiment 2 Experiment 1  
Mutant NHDFC Mutant NHDFC Mutant(BM1`) NHDFC Mutant NHDFC  
337nm 364nm 328nm 362nm 300nm 288nm 373nm 438nm MEAN 
71.3 84.5 47.5 73.5 32.3 56.2 123 105 SD 
211nm 188nm 293nm 278nm 246nm 188nm 211nm 246nm Min 
434nm 562nm 361nm 414nm 340nm 387nm 434nm 562nm Max 
 
Table 4.1 demonstrates the result of fibril diameter measurement of cultured 
fibroblasts from three different experiments. 
 
 
 
 The mean diameter of samples for controls was 364 nm while the average diameter 
for mutant samples was 337 nm. The experiment of in vitro fibrillogenesis was 
repeated three times. Unpaired t-test reveals there is no siginificant difference 
364
337
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280
300
320
340
360
380
400
NHDFC Mutant
Fibril diameter
nonmeter
Collagen fibrils  from cultured fibriblasts cells 
Graph 4.1.Statistical analysis of collagen fibrils diameter 
from cultured fibroblasts. The graphs demonstrated that there 
is no difference between mutant cells (BM1`) and NHDFCs.  
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between mutant and normal samples’ fibril diameter (P> 0.05). Collagen XII 
molecules were seen on collagen I fibrils in both mutant and healthy donors. The 
presence of collagen XII molecules on missplicing donor samples (BM1`) indicates 
that collagen XII molecule is secreted to ECM in both mutant and healthy donors. 
However, as electron microscopy is not a quantitative method we could not detect 
and compare the difference in the amount of collagen XII protein which is secreted 
into ECM in normal and mutant cell lines in this experiment. Immunoblotting studies 
for collagen XII protein in BM1`(results showed on chapter 3) represented a 
reduction on collagen XII protein secreted to ECM. The difference between these 
two results just echoed the different variations that they measured. 
 Figure 4.6 shows an image of two fibroblast cells attached to the plastic culture dish. 
Collagen XII molecules which are under assembly are represented inside cells as 
black dots. This figure represent the presence and localisation of collagen I fibrils 
which are neighbouring fibroblast cells and is a confirmation of true detection of 
collagen I fibrils. 
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Figure 4.6.Fibroblast cell from the in vivo 
experiment. Vertical arrow represents 
collagen I fibrils. Horizontal arrows represent 
cytoplasm of a fibroblast (A), cell nucleus (B), 
cell wall (C), intercellular space (D), Plastic 
part of the cell culture well (E). Intracellular 
collagen XII molecules represent in black 
dots. 
A 
B 
C 
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4.3.3 Electron microscopy evaluation of collagen fibrils in ECM from BM1’: 
 Following the result of ECM collagen fibril measurements, we embarked on in vitro 
collagen fibrillogenesis investigations. Fibroblasts from patients with a splice donor 
mutation (BM1’) and controls were taken and grown in order to extract collagen from 
those according to the previously described method (Vomund et al., 2004). This 
method also described in details in material and method section. 
 Fibrillogenesis was induced in these collagen solutions by adding 0.5 normal acetic 
acid under dialysis. Then solutions with collagen fibrils were taken to the Electron 
Microscopy Unit for negative staining which was described in material and methods 
section. In this method micro particles were covered with uranyl acetate and one 
drop of samples were put on grid. These grids then set on electron microscope 
imaging. 
 Fibrils were identified as long tubular lines in the images. Figure 4.7, table 4.2 and 
graph 4.2 shows the resulted fibrils and fibril diameters measurements from in vitro 
fibrillogenesis experiment for mutant and normal cell lines. 
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Figure 4.7.Images of induced fibrils. In vitro induced fibrils from splice 
donor mutant sample is shown (A, B). In vitro fibrils induced from NHDFCs 
is shown (C, D).Collagen fibrils are presented as long tubular structure. 
D B 
A C 
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total Experiment 3 Experiment 2 Experiment 1  
MUTANT NHDFC MUTANT NHDFC MUTANT NHDFC MUTANT NHDFC  
311nm 285nm 379nm 288nm 296nm 338nm 258nm 229nm MEAN 
87.9 97.4 130.042 54 33.5 115.7 48.93 31.5 SD 
188 172 211nm 186nm 242nm 179nm 188nm 172nm Min 
562 586 502nm 387nm 342nm 586nm 404nm 352nm Max 
 
 Table 4.2 demonstrates the result of collagen fibril measurements. 
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Collagen fibrils from in vitro fibrillogenesis 
Graph 4.2.Comparison of mean fibril diameter between 
mutant and normal fibrils. The average diameter of mutant and 
normal control is shown in induced fibrillogenesis experiment. 
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  Also, extracted collagen I (Thermo Fisher Scientific) from a rat tail was used at 1 
mg/ml concentration and fibrillogenesis was induced in this sample along with 
collagen extracted from fibroblasts. The average diameter of 325 was recorded for 
collagen fibril from rat tail. This commercial sample was used as a positive control for 
the three independent experiment. Figure 4.8 shows the induced fibrils from 
extracted collagen I rat tails. 
 
 
 
 The mean diameter of samples for controls was 285 nm while the average diameter for 
mutant samples was 311 nm. The experiment of in vitro fibrillogenesis was repeated 
three times and each time at least five images from each sample were taken. In each 
sample two fibrils, which are continued in the whole field, were measured. The 
horizontal diameter of each fibril was measured with using Image J. The horizontal 
diameter counted as the shortest distance between two opposite points on the fibril 
Figure 4.8. An induced collagen fibril 
from commercial rat tail extracted 
sample.  
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diameter. The diameters was measured for at least ten opposite points on each fibril 
started from the part on the highest point of the image to the lowest point. The 
highest and lowest point have 500 nm distance from image frame line. The distance 
between highest and lowest point was devided into at least ten part to set opposite 
points. The examiner tried to keep equal distances. However the distances were not 
measured with Image J. The diameter between two points were calculated by Image 
J analyzer. Unpaired t-tests were used to compare diameter in mutant cell lines and 
normal controls. There was no significant difference between mutant and normal 
fibril diameters (P> 0.05). 
 
4.4 Discussion: 
 
 There is evidence that an absence of collagen XII from the environment could lead 
to thicker collagen I fibrils (Koch et al., 1995). Koch et al, extracted collagen I 
molecules from chick tails. Then induced fibrilogenesis in collagen I molecules in an 
in vitro system. By adding high salt concentration (NaCl) they eliminate collagen XII 
molecules from the fibrilogenesis environment while a low salt concentration induced 
collagen I fibrilogenesis in presence of collagen XII. Immunogold antibodies against 
collagen XII were used to detect presence or absence of collagen XII on In vitro 
synthetic collagen I fibrils. The image of collagen fibrils were taken with Transmission 
electron microscopy. The images represented thicker collagen I diameter in the 
absence of collagen XII molecules. We tested this hypothesis in our work, whether 
structural abnormalities in the collagen XII molecule could lead to thicker collagen 
fibrils as it is the case for absence of collagen XII. We used samples of splice-donor 
collagen XII mutation (BM1’) along with a control samples (NHDFCs) to do the in 
vivo and in vitro experiments. We could not find any differences in collagen fibril 
diameters between normal and mutant samples. 
 
 In order to determine the effect of a COL12A1 mutation on the ECM we used skin 
biopsy samples because this is one of the organs which presents with collagen 
abnormalities. The effect of collagen abnormalities in skin has been described 
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before. TEM staining for nodules of extracellular matrix showed an altered collagen 
fibres ultrastructure. Moinzade et al reported that immunohistochemistry staining of 
the dermis in a scleroderma patient showed collagen XII was deposited in nodules 
and in the papillary dermis with aberrant forms. Fibrils of thinner and irregular 
collagen I has a deposition of collagen XII on them (Moinzadeh et al., 2013). In our 
experiment, we identify that the skin biopsy of COL12A1 mutant individuals has 
irregular collagen fibres with breaking in length and irregular cross sectional pattern 
(Figure 4.1 and 4.2). A basement membrane thickening of the endothelial wall of 
capillary was also seen. These findings may support the ultrastructural abnormality 
in keloid scars of patients. However, because we compare scars from COL12A1 
affected individuals with normal part of healthy donors, it might be that the similar 
changes that we found are variations of every pathologic nodule compared to 
controls. It would be valuable if we could compare one sample of the skin biopsy of a 
mutant patient’s normal skin region with the same skin location in normal controls. 
The unavailability of skin biopsy from a normal part of skin in any of our mutant 
individuals is on limitation in this study. However, this experiment for proving the 
abnormal collagen fibres characteristics in patients with collagen XII mutation was 
important. The same features were seen in skin tags of a Bethlem-like myopathy 
patient with the collagen VI mutation (Kirschner et al., 2005; Starborg et al., 2008a). 
In consequence, our study of skin biopsy scars` imaging in collagen XII mutant 
patients represent the same scar abnormalities (variation in collagen fibres diameter, 
breaks in collagen fibres length and thickening of capillary cell walls membrane) 
which had been reported in collagen VI patients before.  
 One other limitation was there was not enough tissue in our samples to do 
immunohistochemistry staining for collagen XII in skin biopsies. However, 
Moinzadeh et al (Moinzadeh et al., 2013) compared a nodular part of a systemic 
sclerosis patient with a normal part of a control individual and found different pattern 
for collagen XII distribution.  
 After proving the abnormality in the nodular part of the skin in patients with collagen 
XII mutations, we aimed to identify whether collagen XII plays any role in fibrillary 
collagen assembly and structural formation. As mentioned earlier, ECM is composed 
of collagenous and non-collagenous parts. Fibrillar collagens are collagen I, II, III.   
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These are the most abundant forms of collagen in the ECM. Their assembly in 
collagen fibrils start from inside the cell and continue in the ECM environment. 
Collagen fibrils in skin and musculoskeletal connective tissues are mostly composed 
of collagen I (Halper and Kjaer, 2014). 
 
 As mentioned earlier, during fibrillogenesis, long fibrils first bind to each other by 
non-covalent attachments and then are fixed by covalent attachments. The 
fibrillogenesis process is a sensitive one and variables such as temperature, other 
molecules, and ionic exchange could alter that in in vivo and in vitro 
conditions(Harris and Reiber, 2007). Formation of alternative association products 
such as segment long spacing (SLS), fibrous long spacing (FLS), and symmetrical 
and spiral-banded fibrils in addition to the usual cylindrical fibrils has been reported 
in experiments that induce in vitro fibrillogenesis (Harris et al., 2005). We considered 
the influence of the environment in fibrillogenesis and to avoid this problem we 
checked the fibril diameter both in vitro and in condition more similar to in vivo. 
 
 Several studies have reported before that changing the pH or temperature during in 
vitro fibrillogenesis could affect the fibril diameter (Harris et al., 2005; Starborg et al., 
2008b). Harris et al checked the effect of pH in extracted collagen from chicken 
fibrillogenesis. It was found that a pH range of 3.5-8 was capable of fibril formation. 
However, a lower pH could produce thin and intermediate fibrils while a higher pH 
produces thicker fibrils (Harris and Reiber, 2007). Collagen fibrils normally have 
around 250-500 nm diameter (Harris et al., 2005). Different studies suggest that in 
the physiological pH (7.3) collagen fibrils are around 300-350nm (Harris and Reiber, 
2007; Starborg et al., 2008b). In our study, a physiological pH (7.5) was used to 
produce fibrils at room temperature. The fibrils average of 285 nm (control) and 311 
nm (mutant) diameter was found. These findings echoed the average range of fibril 
diameter in natural conditions. It should be noted that other fibrillogenesis studies did 
not extract collagen from cultured fibroblasts and mostly used animal sources (Harris 
and Reiber, 2007). We have a commercial positive control from rat tail extraction 
which gave a 325 nm diameter under the same experimental conditions as our cell 
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culture samples. There was no variation in fibril diameter between different repeats 
of one experiment which shows validity of our experiment. Fibrils have similar 
structure in all images and no other structures rather than cylindrical fibrils was 
observed. Also, by inducing fibrillogenesis both in vitro and from cultured fibroblasts 
we tried to avoid temperature and pH side effects. In addition, the fibril diameters for 
cultured fibroblast experiment were 374 nm (control) and 337 nm (mutant). These 
values are in normal range and closer to natural condition. This could echo the more 
similar condition to in vivo experiment from cultured fibroblasts. 
 
 We used TEM for fibrillogenesis studies. TEM is more suitable for fibrillar 
supramolecular studies compared to other models such as the X-ray diffraction 
technique. In the X-ray diffraction technique usually dismiss some features of the 
ultrastructural model because they are not compatible with the X-ray diffraction 
technique. These features are normally missed in the X-ray as noise (Starborg et al., 
2008b). However, TEM techniques have problems such as artefacts which are 
caused by dehydration, fixation and sectioning. One substitute technique to avoid 
this problem is atomic force microscopy in fluid which is not available in our centre 
(Birk et al., 1997). 
 We observed one fibril has got variation in its diameter in different points. This is 
consistent with observations of other experiments which show a discrete rather than 
continuous distribution for the collagen fibril diameter. This pattern echoed the radial 
structure of fibrillogenesis where helical layers are laid down concentrically like the 
growth rings of a tree. These structures are called C-type fibrils and are common in 
long and heterogeneous collagen I fibrils (Harris and Reiber, 2007). Another factor 
which might affect collagen I fibril diameter is gold labelling. These2 to 5nm particles 
could disturb the helical structure due to their anisotropic ability. Moreover, there are 
amino acid specific binding sites for this particle but there is no evidence that gold 
particles which label collagen XII could interact with collagen I fibrils in vivo. There 
was no, uranyl acetate which is used to stain collagen I fibrils in vitro could permeate 
into the fibril or on the surface of fibrils it may interact with periodically arranged 
amino acid chains. In this aspect, our cultured fibroblasts experiment has the value 
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to reduce these side effects. Koch et al reported that in the absence of collagen XII, 
collagen I fibrils have larger diameters (Koch et al., 1995). In that experiment TEM 
with post-embedding immunogold staining was used to image collagen I fibrils in the 
absence and presence of collagen XII. The reason for this observation remains to be 
discovered. In our experiment, we test whether collagen fibrils in the extracellular 
matrix of the patient with a splice donor mutation (BM1’) are thicker compared to 
collagen fibrils in the in vitro experiment. Immunoblotting of this sample also showed 
a reduction in the amount of collagen XII protein secreted to the media (medium 
protein extraction) while the total amount of protein (cell culture extraction) is 
significantly increased. This pattern as previously discussed suggests that despite 
the mutation does not affect the production of collagen XII; the product which is 
secreted to ECM is unstable and could not assemble into ECM structure completely. 
We also described collagen XII immunofluorescence staining pattern for BM1` as 
highly reduced collagen XII signals both intra and extracellular, because not only 
fibrillar diffuse pattern of collagen XII is missed but also the available signals is 
limited only around the nucleus which is incompetent and insufficient for intracellular 
retention. Our immunogold experiment showed collagen XII has localized on 
collagen I fibrils in both mutant samples and control. This pattern is not compatible 
with immunofluorescence staining. The reason for that is immunogold antibody for 
electron microscopy has higher affinity that even tiny amount of proteins would be 
picked but in order to have signals of that protein in immunofluorescence staining 
very larger amount of protein with correct structure is required. However, it is 
impossible to quantify the amount of collagen XII between the two samples in this 
electron microscopy study. Generally, electron microscopy is suitable for 
investigating the pattern and morphology of different structures –not for 
quantification. The lack of ability to quantify the total amount of protein is a limitation 
in our in vivo imaging of collagen fibrils by electron microscopy. Our fibrillogenesis 
investigation does not show any difference in the presence of the collagen XII 
molecule on collagen I fibrils in in vivo ECM samples. Koch et al had used an in vitro 
method to extract collagen and in order to prevent potential changes due to its 
preparation for electron microscopy they used the post-embedding method. The 
situation is of the absence of collagen XII compared to its presence in that work 
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(Koch et al., 1995). We want to check whether mutant samples could affect fibril 
diameter by not attaching to them. 
 
 Our results suggests that even if our mutant collagen XII molecule could affect 
collagen fibril characteristics, this effect does not change the diameter. There is no 
discrepancy between cultured fibroblast and in vitro fibrillogenesis experiments. 
 
 One limitation in our study is that due to a lack of facilities and time we could not 
evaluate other aspects of collagen fibrils such as collagen fibrils length in vivo and in 
vitro. It has been reported by Zuo et al that collagen XII-deficient mouse muscle had 
reduced strength force measurements (Bolduc et al., 2014; Zou et al., 2014). Tissue 
stiffness is controlled by lateral fibril connections. As previously described 
3Dimension (3D) electron microscopy reconstructions were able to demonstrate 
lateral connections of fibrils which are called banded fibrils. Even a small change in 
this lateral connection could make samples stiffer. Collagen XII as a FACIT collagen, 
which facilitates the interaction between collagen fibrils and other ECM components, 
may play a role in lateral banding (Starborg et al., 2008b). 3D construction with 
electron microscopy in our fibroblast cultured experiment may show some 
differences in lateral banding pattern However, the complicated procedure of 
preparation and analysis of images with the 3D method was beyond our laboratory’s 
potential. 
 
 The other aspect which could be evaluated is the longitudinal length of fibrils. The 
total length of fibrils varied among different tissues and it shows that in more elastic 
tissues such as the tendon a total length of a fibre could be as long as the tendon 
itself. There are limited studies about the effect of fibril length in tissue 
characteristics. However, there is a possibility that a reduction in tissue elasticity may 
occur by a change in total fibril length. Recently discovered methods such as 
continuous trans-sectional electron microscopy were used to identify collagen fibril 
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length. However, these methods need specific instrumentation and techniques. 
Besides that, they are time-consuming and expensive. 
 One other limitation is that skin biopsies from all COL12A1 affected individuals were 
not available for imaging. It worth to check variations and similarities of ultrastructural 
skin involvements in these patients. In addition due to financial and time limitation we 
could not include all mutant samples in our fibril dimeter measurements. Splice 
donor mutation was a random selection.  
 
 We evaluated the effect of collagen XII mutation in the collagen I fibril diameter in 
vitro and in cultured fibroblasts by electron microscopy. This study did not identify 
any differences between the two samples but other aspects of collagen fibrils in 
tissues with the collagen XII mutation remain to be evaluated. 
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Chapter 5 COL12A1 mutant fibroblasts effect on myofibres 
differentiation 
 
5.1 Introduction: Muscle growth and repair mechanisms 
 Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are two 
types of collagen VI-related myopathies that demonstrate the role of collagen VI as 
an important extracellular matrix (ECM) component in muscle disorders (Bonnemann 
et al., 2011). However, the exact pathomechanisms of these muscle diseases 
remains unknown (Bonnemann, 2011). Given the fact that Collagen VI as a disease-
causing gene for neuromuscular disorder is probably secreted from interstitial 
fibroblasts of ECM, the issue of myocyte/ECM interaction in muscle disorders 
becomes more important. However, both biomechanical and chemical properties of 
this interaction between myocytes and extracellular matrix remain yet to be 
discovered(Lampe et al., 1993). Myocyte/ECM interaction in tissues which are 
tolerating extensive mechanical stress, such as skeletal muscle is more important 
(Sabatelli et al., 2012b). In order to understand the mechanism of this interaction, we 
need to introduce the process of muscle development and regeneration. 
 Myocytes are the primary cell source for developing muscle tissue. When myocytes 
devide and align to each other in a fashioned way, they make myotubes. Myotube 
development leads to muscle fibre creation (Urciuolo et al., 2013). Differentiation of 
myotubes in an in vitro model starts when myocytes become angular and attach to 
their neighbouring cells. Myotubes are considered as the functional unit of muscle 
tissue and are derived from fusion and differentiation of myocytes(Piccolo et al., 
1995). Figure 5.1 represents a picture of myocyte differentiation. 
 
 
 
Figure 5.1. C2C12 differentiation stages according to number of days 
cells stayed in culture. 
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 Quiescent satellite cells are the precursor of myocytes and play an additional role in 
ECM. During muscle injuries, these quiescent cells induce proliferation and migration 
of myocytes to the site of muscle injury. Regarding this, myocytes are considered as 
the main source of muscle regeneration and repair during injury (Rao et al., 2013a; 
Rao et al., 2013b). Quiescent satellite cells have a large capacity to induce myocyte 
migration to the site of injury. Occasionally myocytes are unable to fully repair the 
damage and partial repair happens in some areas. In these regions the fibrotic scars, 
which derive from connective tissue, substitute for muscle fibres. Thus, fibrosis is not 
only a sign of incomplete muscle repair but also a sign of a muscle disorder(Rao et 
al., 2013a). Fibrosis could happen both in ECM related muscle disorders as well as 
non-ECM related muscle weaknesses (Sabatelli et al., 2012b). 
 Recent studies suggest that muscle repair is a complicated process which involves 
different components apart from myocytes and satellite cells. Fibroblasts also play 
an important role in muscle regeneration and repair (Urciuolo et al., 2013). Role of 
fibroblast which localized in ECM in regeneration and repair could be due to their 
signalling role and secretion of different molecules (Sabatelli et al., 2012b). One 
hypothesis is that these molecules could help to provide quiescent satellite cells with 
a stable environment during regeneration or induce myocytes activities (Urciuolo et 
al., 2013). Another potential way for fibroblasts to interact in muscle regeneration is 
through direct contact. Interstitial fibroblasts are neighbouring satellite cells and from 
their apical surface are in contact with the basement membrane (Urciuolo et al., 
2013). These studies shed light on the important role of fibroblast ECM in muscle 
regeneration, repair, and muscle disorder pathogenesis. 
 The potential relationship between fibroblasts and muscle tissue has been 
investigated in different studies (Rao et al., 2013a; Rao et al., 2013b; Urciuolo et al., 
2013) .In the presence of fibroblasts in vitro, cardiomyocytes changed 
morphologically and in contractile ability (Mann et al., 2011). Another study showed 
that coculturing cardiac fibroblasts with cardiomyocytes reduces misalignment and 
apoptosis rate in cardiomyocytes (LaFramboise et al., 2007). Furthermore, 
implantation of fibroblasts with cardiomyocytes during heart injury repair increases 
the scar repair rate (Nichol et al., 2008). 
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 While these studies provide evidence of positive role of fibroblast on myocyte 
growth and regeneration during coculture experiments, on the contrary, for disease 
models such as arrhythmia, coculturing fibroblasts with myoblasts can have a 
negative effect on repair. Fibroblasts tend to secrete some extracellular matrix 
proteins and these proteins first inhibit normal apoptosis in different cells which lead 
to an induction of scar. The second effect of these fibroblasts is to increase the 
distance between cardiomyocytes which interferes with their normal growth rate 
(Mann et al., 2011). There is a possibility that fibroblasts in muscular tissue might 
affect muscle growth similarly. Use of fibroblasts in muscle progenitor cell growth 
opens new areas in the muscle repair and reproduction field. Myoblasts and satellite 
cell have been used in skeletal muscle repair research. These researches showed 
some positive effects of muscle progenitor cells in repair. However, the lack of 
enough delivery, high apoptosis rate and low quality is visible (Nichol et al., 2008). 
 In addition to coculture models for investigating myocyte/ ECM interaction during 
muscle growth and regeneration, the independent effect of fibroblasts on myoblast 
growth and differentiation has been studied. Independent studies of myoblasts 
growth and differentiation widely use C2C12 cells (Ricotti et al., 2013; Muthuraman, 
2014b). As a cell line, C2C12 was introduced in 1985 by Blau et al from the murine 
fibroblast cell line. This cell line is a subclone of satellite cells which are considered 
as precursors of myogenic growth and repair. Because of rapid growth and 
differentiation ability of C2C12, these cells are commonly used in muscle growth and 
repair studies (Velica and Bunce, 2011). One study showed that C2C12 cells which 
grow on top of primary fibroblasts have a lower apoptosis rate. The alignment in 
C2C12 myotubes also increased (Muthuraman, 2014a).A recent new study checked 
the fibroblast/myoblast coculture with a reconfigurable system device which could 
help to check whether the effect of one cell line in another is due to paracrine 
secretion or direct contact, also it helps to isolate the cell line of interest and check 
the growth or differentiation of one cell line in the presence of the other (Ricotti et al., 
2013). 
  Another study has demonstrated that fibroblasts could inhibit primary myoblasts 
growth independent of contact. However, the presence of fibroblasts in close 
proximity to myoblasts could regulate differentiation and alignment in myoblasts.    
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These effects depend on the presence of both cell lines in the culture dish. The use 
of conditioned media from one into another culture could not show the same effect. 
Also, they demonstrate that transforming growth factor β (TGTβ) which is secreted 
from fibroblasts plays an important role in primary myoblasts growth. The effect is 
not independent of contact between fibroblasts and myoblasts (Melone et al., 2000). 
 The effect of fibroblasts on myoblast growth and regeneration has been studied in 
Duchene Muscular Dystrophy (DMD) patients. Dystrophin which was identified in 
1986 provided an insight into the pathomechanism of DMD in human and animals 
(Melone et al., 2000). Dystrophin, an important component of plasma membrane, is 
crucial for preventing muscle necrosis. Recently published studied demonstrated that 
primary DMD fibroblasts/ myoblast coculture had a higher growth rate in vitro 
compared to primary DMD myoblasts alone (Melone et al., 2000). Moreover, TGF-β1 
in excessive amounts induced defective DMD myoblasts production. Moreover, IGF-
binding proteins (IGFBP) are of considerable interest because they could bind with 
high affinity to IGF growth factors such as IGF-I and IGF-II. These complexes thus 
could change the capacity of cell membrane to bind to other proteins and change its 
growth action. Some studies suggest that IGFBP-3 could inhibit or induce IGF-I DNA 
synthesis depending on experimental conditions (Melone et al., 2000; Muthuraman 
et al., 2014).Several studies model in vivo ECM/ myocytes interaction through 
primary fibroblast/ primary myoblast coculture or adult fibroblasts/primary myoblast 
coculture .However, the effect of adult fibroblasts in C2C12 growth and differentiation 
has not been investigated yet (Zou et al., 2008; Rao et al., 2013a).  
 In these interactive coculture systems collagen molecules are important key factors. 
Regarding the role of collagen VI, a wealth of observation from different studies 
suggests that this molecule is an important member of the satellite cell niche for 
producing ECM components (Zou et al., 2008; Bonnemann, 2011). Like other 
collagen molecules, collagen VI is secreted by interstitial fibroblasts in satellite cell 
niche and its expression might be regulated by myogenic cells. These cells are also 
crucial for deposition of collagen VI on cell membrane (Urciuolo et al., 2013). The 
anatomical region of the satellite cell niche is between the plasma membrane and 
endomysial tissue of the muscle fibre. Asymmetrical distribution of muscle cells and 
their contact with apical part of satellite cells is the anatomical characterization of 
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satellite cell niche (Melone et al., 2000). Also, in the satellite cell niche muscle 
elements are in contact with ECM from their basal part. Transcription factors like 
Paired box protein 7(PAX7), MyoG and MyoD control growth and differentiation of 
satellite cells. The role of these factors in collagen VI related disease has been 
investigated, recently (Urciuolo et al., 2013). In the muscle regeneration process, 
satellite cells play a key role by producing two different cell lines. Highly 
differentiated primary cell type which derives to myoblasts and a population of stem 
cells. The myoblast later under goes differentiation and fusion process, while the 
stem cell population under goes self-renewal. Satellite cells growth, differentiation 
and activities are controlled by the ECM components. One of the key factors in this 
regulatory process are the mechanical properties of ECM.  Regarding this factor, the 
role of collagen VI in changing ECM mechanical stiffness could also influence 
satellite cell activities (Sabatelli et al., 2012b; Urciuolo et al., 2013). 
 Recent studies suggest that collagen VI is an essential part of the satellite niche in 
ECM which helps to preserve satellite cell activities such as muscle regeneration and 
self-renewal (Urciuolo et al., 2013). Urciuolo et al showed in COL6A -/- mice grafting 
with wild type fibroblasts which result in collagen VI deposition could rescue satellite 
cell self-renewal and muscle stiffness (Urciuolo et al., 2013). 
 These findings confirm previous findings of Zou et al (Zou et al., 2008) which 
indicate interstitial fibroblast as the primary source for secretion of collagen VI in 
ECM. In their study, they cultured human derived fibroblasts with primary mouse 
myogenic cells. The two cells were cultured in inserted cell culture wells, under two 
different conditions that two cell culture mediums were mixed or kept independently. 
They found in both conditions secreted collagen VI was able to deposit on myocytes. 
A very little amount of collagen VI synthesis was also reported in C2C12 which 
reflected the dedifferentiation state in these cells (Zou et al., 2008). 
 We recently demonstrated collagen XII as disease-causing gene in six patients with 
Bethlem-like myopathy symptoms (muscle weakness, skin and skeletal abnormality, 
joint hyperlaxity) from three different pedigrees (Hicks et al., 2014). Collagen XII as 
part of extracellular matrix component shows cell membrane localization in zebrafish 
model and our mouse muscle staining which resembles collagen VI localization 
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(Bader et al., 2009; Telfer et al., 2010). Telfer et al, showed COL6A1 expressed in 
skin basement membrane near the dermal-epidermal junction and colocalized with 
Laminin (Telfer et al., 2010). Bader et al, reported the presence of COL12A1short 
isoform in zebrafish model which started expression from emberynic time. Collagen 
XII was expressed in skin in basement membrane of dermal-epidermal junction, in 
other connective tissues such as skeletal muscle it express in connective tissue 
surrounding muscle fibers. In addition collagen XII was localized on collagen fibrils. It 
is colocalized with Laminin which is a basement membrane marker but its 
expression is more than Laminin (Bader et al., 2009)Given the fact that all these 
patients have symptoms of ECM defect and collagen XII is also an ECM component, 
the question of whether collagen XII induces a muscle disorder with the same 
pathogenesis becomes an important issue (Chiquet et al., 2014). 
 Many in vitro studies of ECM/ myocyte interaction have used C2C12 myoblast cell 
lines. In these cells myogenic differentiation and fusion between myoblasts to form 
multinucleated myotube is induced after changing high-serum culture medium (10% 
foetal bovine serum) to low-serum culture medium (2-5% horse serum). During the 
differentiation process, myotubes elongate and express several proteins such as 
myosin, α-actin, troponin and other contractile components (Urciuolo et al., 2013). In 
order to quantify myotube differentiation in in vitro studies, the total level of these 
myotube specific proteins is measured. One other widely used method to quantify 
myotubes differentiation is a fusion index calculation. In this method, after staining 
myotubes with antibodies against myotubes specific proteins, the number of nuclei 
inside myotubes is counted (Velica and Bunce, 2011).  
 In this study, we investigate the effect of fibroblasts of mutant COL12A1 individuals 
on C2C12 cell growth and differentiation and compare it to controls. Fibroblasts were 
cocultured with C2C12 cells. Two methods of coculture were used. One of them, 
allows direct contact between two cell lines, whereby, a mixture of two cell types 
(fibroblasts, myoblasts) in direct contact is used to investigate myocytes/ fibroblast 
interactions. For example, Melone et al, in an in vitro model of Duchenne Muscular 
Dystrophy (DMD) fibroblasts cocultured with primary myoblasts, represent an 
increased expression of Insulin Growth Factor-Binding protein 5 (IGFBP5) and 
downregulation of DMD myoblasts growth were observed.   
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 The second method, used by Zuo et al, used cell culture inserted plates to coculture 
Normal Human Dermal Fibroblasts cells with mouse primary cell lines. NHDFCs 
were cultured in inserts while mouse primary cells were cultured in cell culture 
plates. In this system the two cell culture mediums were mixed. They found collagen 
VI deposition on myoblasts and identified fibroblasts as the primary source for 
collagen VI secretion (Zou et al., 2008). 
 These studies helped us to design our coculture methods. We aim to determine the 
influence of NHDFCs and mutant COL12A1 fibroblasts on C2C12 differentiation. 
This influence has been investigated through two coculture systems. One of the 
systems investigated myotube differentiation through direct contact and another one 
help to investigate the effect of two culture mediums on C2C12 growth and 
differentiation. For determining myotubes differentiation, we stained cells with an 
anti-actin antibody and calculated the myotubes differentiation index. The two 
methods and achieved results will be described later in this chapter. 
5.2 Aim 
 In this chapter we aim to: 
 Calculate C2C12 differentiation index when cocultured with COL12A1 affected 
individuals and healthy donors in a mixture (direct contact) 
 Calculate C2C12 differentiation index when cocultured with COL12A1 affected 
individuals and healthy donors in inserted cell culture dish (without direct contact) 
 
5.3 Results: 
5.3.1 Fibroblast/ C2C12 coculture in a mixture with COL12A1 mutant 
individuals’ fibroblast: 
 C2C12, one control fibroblast and DMD fibroblasts cell lines were obtained from 
biobank in the MRC Centre for Neuromuscular Diseases Newcastle. One 
commercial fibroblast control (NHDFC) was purchased from Promocell. Fibroblast 
cells of different origin (Biobank control, Commercial control), DMD with deletion in 
exon 49 and 50, mutant fibroblast of BM5 and mutant fibroblast of BM1`were seeded 
in slide flasks. Dulbeco`s modified eagle medium (DMEM) composed of 10% foetal 
bovine serum (FBS) and penicillin/streptomycin was used to grow cells. In muscle 
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biopsies the interstitial fibroblasts range from 20% to 70% (Melone et al., 2000). In 
order to model in vivo extracellular matrix system in an in vitro model, fibroblasts 
were grown to 50% confluency. At this point cells were treated with mitomycin 
(Sigma-Aldrich) to prevent mitotic activity. Then C2C12 cells were added to slide 
flasks on top of the fibroblast layer. Growth media was switched to DMEM with 10% 
horse serum. 24 hours later high serum medium was replaced with low serum (3% 
horse serum). Substitution of cell culture medium induces C2C12 differentiation to 
myotubes. 
 On the day six of differentiation, cells were fixed with Paraformaldehyde (PFA) and 
stained with phalloidin and DAPI to determine myotubes actin and cell nuclei. 
Images were taken with Zeiss immunofluorescence microscope. Five independent 
images were taken from each slide. The experiments were repeated three times. 
Figure 5.2showes the results for six cell lines from three different experiments. In all 
experiments the fibroblast and C2C12 were grown under the condition of direct 
contact between cell layers.   
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 The differentiation index in each image was calculated to determine the effect of 
fibroblasts on C2C12 myoblast cell culture. Number of nuclei inside myotubes were 
counted manually and divided by the total number of nuclei in each image. Table 5.1 
showed C2C12 differentiation indexes for three independent experiments, mean and 
standard deviation for each cell lines. 
Figure 5.2.Phalloidin staining for Fibroblast/ C2C12 coculture mixture. Actin fibres 
were imaged in green with phalloidin and cell nuclei were imaged in blue with DAPI. (A, 
B, C) mutant BM5 fibroblast/ C2C12 coculture. (D, E, F) mutant BM1` fibroblast/ C2C12 
coculture. (G, H, I) positive control: DMD fibroblast/ C2C12 coculture. J, K, L) Control 
fibroblast (commercial)/ C2C12 coculture. (M, N, O) Control fibroblast (Biobank)/ C2C12 
coculture. (P, Q, R) Negative control: only C2C12 culture. Images showed three 
independent experiments (n”3).Scale bar in A = 100 µm. 
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BM1` BM5 DMD NHDFC2 NHDFC1 C2C12  
0.271 0.228 0.441 0.474 0.546 0.23 Experiment 1 
0.252 0.211 0.453 0.491 0.518 0.215 Experiment 2 
0.266 0.218 0.450 0.480 0.527 0.185 Experiment 3 
0.263 0.219 0.448 0.482 0.522 0.21 Mean 
0.023 0.014 0.017 0.016 0.014 0.022 SD 
 
 Table 5.1. Nucleus differentiation index for six different cell lines in mixture 
coculture. Graph 5.1 showed total percent of nuclei inside myotubes for six groups of 
fibroblast/C2C12 coculture: Mutant BM5, mutant BM1`, positive control of DMD 
fibroblasts, Normal Human Dermal Fibroblast Cell (NHDFC), Biobank control, 
negative control of C2C12. 
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Graph 5.1.Myotubes differentiation index in mixture coculture with 
fibroblasts. Myotubes differentiation index as Percentage of nuclei 
inside myotubes is shown in vertical graph.  Six different cell types: BM5, 
BM1`, DMD, NHDFC1, NHDFC2, C2C12 alone were compared to each 
other. 
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 Two proportional t- test was used to calculate P-value of COL12A1 mutant 
fibroblasts compare to control cells (NHDFC1+NHDFC2), C2C12 and DMD 
fibroblasts. In addition, differentiation index of DMD fibroblasts were compared to 
normal controls (NHDFC1+NHDFC2) and C2C12 cells. P-value forCOL12A1mutant 
cells compare to normal control and C2C12 was P< 0.01. While P-value for 
COL12A1 mutant fibroblasts compare to DMD fibroblasts was P>0.05. P-value of 
DMD fibroblasts compare to normal control and C2C12 was P>0.05. 
 Statistical analysis was done with SPSS software. Statistical analysis shows 
NHDFC/ C2C12 coculture increase C2C12 differentiation compare to COL12A1 
mutant/ C2C12 coculture or other type of the cells coculture. COL12A1 mutant/ 
C2C12 coculture did not influence C2C12 differentiation compare to C2C12 culturing 
alone. DMD fibroblasts/ C2C12 coculture also did not affect C2C12 differentiation 
compare to C2C12. 
 
5.3.2 Fibroblast/ C2C12 coculture without direct contact inCOL12A1 mutant 
individuals’ fibroblasts: 
 In the previous experiment, the effect of fibroblast /C2C12 coculture through direct 
contact between two cell types was investigated. The present experiment evaluated 
whether coculturing C2C12 with medium sharing fibroblasts influence C2C12 
differentiation index. Five previously described control and mutant fibroblasts: BM5, 
BM1`, DMD, Commercial control, Biobank control, C2C12 were grown on an inserted 
12 cell culture dish.  
 Fibroblasts (passage<5) were grown on top of wells with DMEM growth media 
composed of 10% foetal bovine serum and penicillin/streptomycin solution. 
Fibroblasts were grown to 50% confluency and were treated to inhibit mitotic activity 
with mitomycin (Sigma-Aldrich).12 hours later, C2C12 cells were seeded on the 
bottom of each well and muscle growth media was added.24 hours after seeding 
C2C12, myoblast growth media was switched to myoblast differentiation media (3% 
horse serum) to induce differentiation. 
 On the sixth day of differentiation, C2C12 cells were fixed using PFA and stained 
with DAPI and phalloidin in the cell culture dish. Images were taken with Nikon 
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confocal microscope.  Five independent images were taken from each well. The 
experiments were repeated three times. Images for six cell lines from three 
independent experiments were shown in figure 5.3. 
 
 
 
 
 
 
 
 The differentiation index in each image was calculated manually by counting the 
number of nuclei inside myotubes and divided by the total number of nuclei in each 
image. Table 5.2 showed nucleous differentiation index, mean and standard 
deviation for three independent experiments in six cell lines.  
Figure 5.3.Phalloidin staining for Fibroblast/C2C12 coculture in inserted cell 
culture dishes. Actin fibres were imaged in green with phalloidin and cell nuclei were 
imaged in blue with DAPI. (A, B, C) mutant BM5 fibroblast/C2C12 coculture. (D, E, F) 
mutant BM1` fibroblast/ C2C12 coculture. G, H, I) positive control: DMD 
fibroblast/C2C12 coculture. (J, K, L) Control fibroblast (commercial)/C2C12 coculture. 
(M, N, O) Control fibroblast (Biobank)/C2C12 coculture. (P, Q, R) Negative control: only 
C2C12 culture. Images showed from three independent experiments. Scale bar in A = 
100 µm. 
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BM1` BM5 DMD NHDFC2 NHDFC1 C2C12  
0.271 0.256 0.295 0.288 0.289 0.245 Experiment 1 
0.266 0.234 0.284 0.293 0.281 0.224 Experiment 2 
0246 0.251 0.297 0.262 0.264 0.233 Experiment 3 
0.261 0.247 0.292 0.281 0.278 0.232 Mean 
0.013 0.011 0.007 0.016 0.012 0.010 SD 
 
 Table 5.2 Nucleus differentiation index for six different cell lines` coculture without 
direct contact. 
 Graph 5.2 shows total percent of nuclei inside myotubes for six groups of 
cocultures: Mutant BM5, mutant BM1`, positive control of DMD fibroblasts, Normal 
Human Dermal Fibroblast Cell (NHDFC), Biobank control, negative control of 
C2C12. 
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Graph 5.2.Myotubes differentiation index in coculture with 
fibroblasts but no direct contact. Myotubes differentiation index as 
Percentage of nuclei inside myotubes is shown in vertical graphs.  Six 
different cell types: BM5, BM1`, DMD, NHDFC1, NHDFC2, only C2C12 
were compared to each other. 
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 Differentiation index ofCOL12A1 mutant fibroblasts was compared to normal 
controls (NHDFC1+NHDFC2), C2C12 and DMD fibroblasts. In addition, 
differentiation index of DMD fibroblasts were compared to normal controls 
(NHDFC1+NHDFC2) and C2C12 cells. Two proportional t-test was used to calculate 
P-value. P-value for COL12A1 mutant cells compare to normal controls, DMD 
fibroblasts and C2C12 was P> 0.05. Also, P-value of DMD fibroblasts compare to 
normal control and C2C12 was P>0.05. 
 Statistical analysis shows fibroblast/ C2C12 coculture in an inserted well does not 
influence C2C12 differentiation index inCOL12A1 mutant fibroblast/ C2C12 coculture 
or other type of the cells coculture.  
5.4 Discussion: 
 Different studies suggest that in collagen VI-related myopathies, the cells that cause 
disease (fibroblasts) are different from the cells that express the disease (muscle) 
(Lampe et al., 1993; Zou et al., 2008). Given this fact, collagen VI-related 
myopathies and in a broader spectrum ECM disorders are considered to be non-cell 
autonomous disorder and investigating pathogenesis mechanisms of these disorders 
via coculture systems has become increasingly important.  
 In this chapter, we investigated the influence of fibroblasts on C2C12 differentiation. 
In order to model in vivo conditions in an in vitro experiment, we cocultured 
fibroblasts and C2C12 in a mixture of different cell layers with direct contact. This 
experiment shows coculturing C2C12 with affected individuals’ fibroblasts decreases 
C2C12 differentiation index. The second step, was designed to understand whether 
physical contact between two cell types induces reduction in C2C12 differentiation or 
an indirect system through chemical substances or a signalling pathway affected 
C2C12 differentiation. Second experiments showed coculturing C2C12 and 
fibroblasts in separated wells while they share same media does not affect C2C12 
differentiation index for affected individuals compare to control subjects. 
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 Previous studies in collagen VI-related myopathies suggested that coculturing 
fibroblasts and mouse primary myogenic cells in inserted wells in different levels and 
mixture of two cell types in the same dish, similar to our coculture system, could 
result in interaction between collagen VI secreted from normal human fibroblasts and 
primary myogenic cells (Zou et al., 2008; Urciuolo et al., 2013). Furthermore, Zou et 
al (Zou et al., 2008) identified deposition of collagen VI in interstitial fibroblasts and 
C2C12 independent cell cultures but not in primary myogenic cell cultures. In 
addition, they recognized retention of collagen VI in interstitial fibroblasts of three 
mutant collagen VI (COL6A1, COL6A2, COL6A3) patients but not in their myofibers. 
This study implies interstitial fibroblasts as the main source of collagen VI secretion 
in an in vitro model of muscle extra cellular matrix (ECM). These results could show 
interactions between adult human fibroblasts and primary mouse myogenic cells in 
the context of collagen VI related myopathies in an in vitro model and open a new 
window for investigating collagen VI- related myopathies and other ECM disorders 
through coculture systems. 
 In this experiment, we used adult human fibroblasts and C2C12 for coculture. Use 
of adult human fibroblast and primary myogenic cells or primary fibroblast and 
primary myogenic cells in muscle disorder research or other research has been 
reported (Ciofani et al., 2010; Urciuolo et al., 2013). One concern in using cells from 
different developmental origin is whether cells could interact with each other. One 
study showed that in a coculture of primary mouse myogenic cells and primary 
fibroblasts, there is a possibility of pluripotent fibroblast reprograming to myoblast 
(Melone et al., 2000). While, coculturing adult fibroblasts with primary myogenic cells 
does not affect cellular origin and cells could affect growth of each other. Our 
coculture model is similar to models that have been used before. Ricotti et al 
reported on an NHDFC/C2C12 coculture model with engineered free-standing 
polyacrilamide gel, C2C12 differentiation, alignment towards one direction and 
expression of differentiation gene(actin and myosin) were improved (Ricotti et al., 
2013).  
 One other concern about coculturing adult fibroblast with C2C12 in a mixture is 
density-dependent contact inhibition of fibroblast on myoblast (Melone et al., 2000). 
To avoid this, fibroblast were treated with mitomycin at 50% confluency to prevent 
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mitotic activity. Mitomycin treatment help us to save fibroblast-dependent ECM 
structure around C2C12 layer without fibroblast become overconfluent in the cell 
culture dish. 
 We used C2C12 cells as the muscle cell source. Few studies suggest that these 
cells could behave differently from primary muscle cells (Zou et al., 2008). While 
collagen VI deposition was not detected in primary mouse muscle cells, C2C12 cells 
show evidence of collagen VI production in in vitro cultures (Zou et al., 2008). 
Furthermore, collagen VI expression increased during C2C12 differentiation. Given 
the fact that we identify almost the same pattern of immunofluorescence staining for 
collagen XII in fibroblasts and the same localization in previous chapter, we 
hypothesize collagen XII might be secreted from C2C12 and affect their 
differentiation in the same way. However, we suggest expression and localization of 
collagen XII by C2C12 cells to be investigated through immunofluorescence staining.  
 We recognized coculturing C2C12 with human fibroblast in a mixture with direct 
contact between fibroblast and C2C12 increased C2C12 differentiation culturing on 
top of control fibroblast compares to C2C12 alone. While fibroblasts of affected 
individuals (BM5, BM1`) and DMD fibroblast did not increase C2C12 differentiation 
compare to C2C12 alone. Result of C2C12/NHDFC coculturing emphasize on 
previous findings (Ricotti et al., 2013). These findings as indicated in the introduction 
show primary cardiomyocytes, when cocultured with fibroblasts, present better 
differentiation rate, improved alignment and higher expression of myoblast 
differentiation indicators(Pax7, Myo D) (Mann et al., 2011), while mutant collagen XII 
fibroblast and DMD fibroblast do not influence C2C12 differentiation. An inhibitory 
paracrine effect on primary myoblast when cocultured with DMD fibroblast in a 
mixture was reported before. Overall, these findings show unlike NHDFCs mutant 
collagen XII fibroblast and DMD fibroblast did not give any physical or mechanical 
stimuli to C2C12 to increase differentiation. These findings suggest a possible role 
for collagen XII mutant fibroblast to prevent myoblast growth and differentiation in the 
affected individuals. However, the result of this in vitro experiment should be 
interpreted with caution for in vivo conditions. 
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 We observed coculturing C2C12 with human fibroblasts without contact (inserted 
wells) does not decrease or increase C2C12s` differentiation in all fibroblast groups 
(mutant and control) compare to C2C12 alone. This result might echo the fact that 
C2C12 cells could secrete the required collagen molecules for differentiation process 
independently. However, production of collagen XII in C2C12 cells with appropriate 
antibody needs to be detected in future. Furthermore, this result could suggest the 
effect of NHDFC on C2C12 differentiation is not applicable through chemical stimuli 
alone. A physical or mechanical stimuli with or without chemical stimuli is required to 
induce higher differentiation rate in C2C12 cells. 
 We obtained an average differentiation rate 0.25% for C2C12s alone with a 
standard cell growth and differentiation culture. This finding is in accordance with 
other studies which culture C2C12 alone and use manual method of counting for 
identifying C2C12 differentiation.  
 The present study evaluates 2 major cell types of fibroblast and C2C12. However, in 
a more prospective approach the role of other ECM cells like endothelia cell in 
mutant and normal individuals should be evaluated. Another caveat is that we are 
focusing on isolated cell types in an in vitro situation. One of these cell types might 
behave differently from one in muscle tissue. Moreover, there is an open possibility 
that in an in vivo situation and different histologic context other stimuli and factors 
cover the role of mutant collagen XII molecules. 
 Findings of this research highlight possible interaction between fibroblast and 
myoblast during myoblast differentiation. In addition, it emphasizes the role of intact 
extracellular matrix and fibroblast component in myoblast differentiation. Mutant 
collagen XII secreted from affected individuals` fibroblast could destroy the 
appropriate histological context of muscle differentiation. It seems the possibility of 
this influence applied through direct contact is higher than being a paracrine effect. 
However, more studies on interaction between collagen XII and myoblast are 
required. One possible future work would be to investigate the localization of 
collagen XII in C2C12 cells to identify whether C2C12 interact with collagen XII 
directly. 
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Chapter 6 General discussion and future directions 
 Collagen VI-related myopathies are a group of heterogenic and clinically diverse 
neuromuscular disorders. The clinical presentations of collagen VI-related myopathy 
come as a spectrum with Ullrich congenital muscular dystrophy (UCMD) (MIM: 
254090) at the severe end and Bethlem myopathy (BM) (MIM: 158810) at the milder 
end of this spectrum. In addition, an intermediate phenotype and limb-girdle 
muscular dystrophy (LGMD) phenotypes have been included into the collagen VI-
related myopathy phenotypic spectrum (Bonnemann, 2011). Progressive muscle 
weakness with connective tissue involvement is a unifying feature of collagen VI-
related myopathies. Connective tissue involvement includes distal joint contractures, 
joint hyperlaxity, skeletal deformities such as kyphoscolios is and skin involvements 
like keloid formation and hyperkeratosis pilaris (Bushby et al., 2014). With a 
prevalence of 0.13 in 100,000 for UCMD and 0.77 in 100,000 for BM, these 
disorders are considered as rare neuromuscular disorders. However, the number of 
reported cases is increasing (Clement et al., 2012). 
 Collagen VI-related myopathies in their severe forms are often inherited in 
autosomal recessive traits, while autosomal a dominant mode of inheritance is 
frequently found in milder phenotypes (Bonnemann et al., 2011). In addition, severe 
forms of collagen VI-related myopathies can be caused by dominant de novo 
mutations (Mercuri et al., 2002), and there are also more recent reports of recessive 
BM (Gualandi et al., 2009).In 1996 (Jobsis et al., 1996) in a large pedigree of 
Bethlem myopathy and in 2000 (Camacho Vanegas et al., 2001) in Ullrich congenital 
muscular dystrophy individuals, mutations in COL6A1 and COL6A2 genes were 
reported to be disease-causing. Since then, several mutations in three distinct 
COL6A genes (COL6A1, COL6A2 and COL6A3) have been identified in collagen VI-
related myopathy patients. However, the underlying cause for several affected 
individuals with phenotypes highly reminiscent of collagen VI-related myopathy not 
bearing mutations in COL6A genes remains to be elucidated (Bonnemann, 2011). 
 Collagen VI is a beaded-filament forming member of collagen family. This 
heterotrimeric molecule is widely expressed in connective tissue in different organs 
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and plays a role as adhering, signalling and apoptotic element. Collagen VI’ distinct 
role in neuromuscular connective tissue is not fully deciphered yet, however it is 
suggested it might affect regeneration, repair and autophagic pathways in muscular 
tissues (Bonnemann, 2011; Halper and Kjaer, 2014). Immunohistochemical studies 
demonstrate in muscle biopsy of collagen VI affected individuals, that collagen VI is 
not attached to basement membrane markers like perlecan or laminin ɣ 
(Bonnemann, 2011). Thus, dual labelling of collagen VI with basement membrane 
proteins such as perlecan and laminin is a robust but not gold standard method to 
predict collagen VI-related disorders. In addition to clinical presentation and 
examinations, other laboratory and paraclinical tools like Creatine kinase 
measurement, magnetic resonance imaging (MRI), immunofluorescence staining of 
dermal fibroblast in affected individuals for collagen VI and muscle biopsy findings 
are beneficial in distinguishing collagen VI-related myopathies from other hereditary 
neuromuscular disorders. However, full sequencing analysis of all three COL6A 
genes is currently the gold standard for diagnosis (Bonnemann et al., 2011). 
 Diverse clinical features of collagen VI-related myopathy phenotypes are a reason 
for the large overlap with other neuromuscular disorders. Congenital muscular 
dystrophy, limb-girdle muscular dystrophy, merosin-deficient myopathy, Emery-
Dreifuss muscular dystrophy, dystroglycanopathies and non-muscular disorders of 
connective tissue such as Ehlers-Danlos syndrome are among the differential 
diagnosis for collagen VI-related myopathies. This issue in combination with the 
genetic heterogeneity makes the diagnosis of collagen VI-related myopathy 
diagnosis challenging (Bushby et al., 2014). 
 Several cases of “collagen VI-related myopathy -like” phenotype with no mutation in 
the collagen VI genes have been reported (Merlini et al., 2008b; Bovolenta et al., 
2010). It has been reported that in approximately 75%-79% of UCMDs and 60-65% 
of BMs the genetic cause is identified by full sequencing of three COL6A genes 
(Bovolenta et al., 2010). It is estimated that around 40%-50% of patients with 
phenotypes reminiscent or overlapping to collagen VI-related myopathy at the 
Newcastle centre for neuromuscular disorders are not caused by COL6A gene 
mutations (Debbie Hicks, personal communication). 
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 In this study I investigated a group of 24 affected individuals of collagen VI-related 
myopathy phenotype (predominantly Bethlem-like) without COL6A1-3 mutations. 
Whole-exome sequencing from five affected individuals of this group who are 
homogenous in clinical presentations generated a list of genetic variants. After 
excluding non-sense and polymorphic variants (MAF, >1%) based on in silico 
analysis, three to five variants of interest in each pedigree remained for further 
investigation. These variants were confirmed in the corresponding pedigrees by 
Sanger sequencing and pattern of inheritance for each of the variants was 
investigated. Two missense mutations in two pedigrees of affected individuals in the 
gene COL12A1 were identified to segregate with expected mode of inheritance. 
Col12A1: c.C5893T:p.Arg1965Cys is a missense mutation which segregated in a 
pedigree of three affected individuals with autosomal dominant pattern of 
inheritance. This mutation lead to substitution of one arginine with a cysteine residue 
in the fibronectin type III (FN III) domain of the protein. The cysteine residue may be 
involved with disulfide bond formation in collagen XII structure (Halper and Kjaer, 
2014). These bonds are necessary for stabilizing the collagen XII monomer. The 
c.G8357A: p.Gly2786Asp is other missense mutation which segregated in a trio with 
autosomal dominant pattern. This mutation leads to remove a glycine residue from 
GLY-X-Y motif in collagen XII α chain. GLY-X-Y motifs form a highly conserved 
region which is important in collagen α chains assembly to dimers and tetramers. In 
collagen VI, these mutations have proven to insert a kink in collagen VI fibrils. This 
kinked fibril could bond to other fibrils to make collagen VI tetramers and secreted to 
ECM. Thus, they are acting as dominant negative mutations (Lamande et al., 2002). 
Previous findings showed patients with GLY-X-Y motifs substitution could represent 
typical Bethlem symptoms, while some reports finds sporadic mild Bethlem-like 
phenotype in patients with GLY-X-Y motifs substitution (Bonnemann, 2011). 
Autosomal-dominant substitutions in Gly-X-Y motifs lead to variable molecular and 
clinical consequences and depend on the exact sequence context in which they 
occur (Bonnemann et al., 2011). When the mutated collagen alpha chains will 
participate in trimer assembly but subsequent folding of the triple-helical domain will 
be impaired, a dominant negative effect is exerted. Most deleterious are those 
missense changes that introduce residues with bulkier side chains. This was the 
case for BM2 with the replacement of glycine with aspartic acid (Long et al., 1993; 
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Lamande et al., 2002). The effect of the triple-helical domain misfolding is further 
augmented by excessive posttranslational modification, since the posttranslational 
reactions are normally terminated by folding of the protein into the triple helical 
conformation (Long et al., 1993). Discovery of a splice variant COL12A1 mutation 
potentially acting in dominant de novo fashion. The g:75814922-75815008del: 
c.8345-8432del:p.2727-2755del from whole exome sequencing of an affected 
individual with undiagnosed neuromuscular phenotypes, expand the clinical 
spectrum of collagen XII mutant patients. The mutation leads to in-frame deletion of 
exon 53 which leads to removing 27 amino acids from primary structure. 
 Immunofluorescence staining of dermal fibroblast in all affected individuals revealed 
decrease in collagen XII signals. In contrast, immunoblotting for cells from the 
patients with two missense mutation did not demonstrate any changes. Thus, in 
these patients collagen fibrils are secreted to the extracellular matrix but are unable 
to interact with other binding partners and to assemble in the ECM. In these patients 
immunofluorescence staining for two main collagen XII binding partner, collagen IV 
and tenascin reveals variations (Hicks et al., 2014). Immunofluorescence staining for 
splice variant mutation demonstrated an absence of collagen XII in extracellular 
matrix structure and collagen XII decreased in immunoblotting of cell extract and 
media. Thus, mutant collagen XII in this patient may affect collagen fibril assembly 
and secretion to extracellular matrix leading to unstable protein. Laboratory findings 
and in silico analysis for COL12A1 mutant patient suggested a misfolded protein and 
the clinical presentation of these patients shows some diversity. Lipodystrophy is a 
novel sign identified in one affected individual with the splice variant mutation, and 
might be unrelated to the myopathy. However, there are other myopathies that 
inherited with lipodystrophy (Bushby et al., 2014). A panel of twelve known genes in 
lipodystrophy has been checked in exome data to identify any pathogenic mutation 
for lipodystrophy but no variants were discovered. 
 Lipodystrophy may result from activation of endoplasmic reticulum stress pathway. 
Misfolded protein which is trapped in endoplasmic reticulum is a source for cell 
stress. However, further investigations to confirm endoplasmic reticulum stress by 
inhibiting endoplasmic reticulum associated protein degradation (ERAD) pathway 
and apoptotic assay should be carried out to confirm this mechanism (Hughes et al., 
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2017). Given the fact that affected individuals with COL12A1 mutations who we 
discovered in our cohort represent diverse phenotypes and the number of collagen 
XII-related myopathy is yet limited, it is difficult to comment whether lipodystrophy 
could be mentioned in the phenotypic spectrum of collagen XII0related myopathy. 
 We identified overlapping symptoms of joint hyperlaxity and mild muscle weakness 
in all patients. However, muscle weakness was variable from mild to moderate in 
different patients. In addition, while for missplicing and glycine substitution mutations 
family, delayed motor milestones and skeletal deformity was discovered at birth, in 
the family with asparagine substitution the symptoms started in adulthood. This 
phenotypic diversity was reported in other investigation. Zou et al, found COL12A1 
mutations in one patient with severe muscle weakness and wheelchair dependency 
but for the other affected individual moderate muscle weakness was reported (Zou et 
al., 2014). 
 Collagen XII is a member of fibril associated interrupted triple helix collagen 
(FACITs). This protein interacts with other extracellular matrix collagenous and non-
collagenous components to stabilize collagen fibrils and control fibril growth during 
fibrillogenesis (Chiquet et al., 2014). Given the fact that fibril growth is the result of 
increasing diameter and length of fibrils, we measured the diameter of collagen fibrils 
in extracellular matrix surrounding cultured fibroblast and after in vitro fibrillogenesis 
of extracted collagen from cultured fibroblasts. Statistical analysis reveals 
COL12A1mutations do not influence fibril diameter. However, in comparison to our in 
vitro assay in vivo fibrillogenesis may be a more complicated and multi-step process. 
Apart from fibroblast, other connective tissue cells like myofibres and environmental 
factors such as soluble water in ECM could affect this process (Koch et al., 1995). 
Since we are unable to fully reflect in vivo conditions during our experiment this 
result may not reflect the composition and morphology of collagen fibers condition in 
human muscle. Therefore, a better understanding of collagen XII role in ECM may 
require additional experimental strategies to address challenges in studying collagen 
fibrillogenesis including genetically modified mouse models (Mienaltowski and Birk, 
2014a).  
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 While collagen XII is expressed in muscle tissue, its distinct role in muscle is 
unknown. The third part of our research focussed on the relationship between 
collagen XII and myofibre regeneration. Collagen VI studies revealed that collagen 
VI could affect myofibre differentiation and its expression increased during the 
myogenic cell differentiation (Zou et al., 2008). Our adult fibroblast\C2C12 coculture 
system assesses the influence of mutant and normal fibroblast on C2C12 
differentiation. Fibroblast / C2C12 cocultures were carried out by mixing cells with 
direct contact and growing cells in separated wells while they were fed with the same 
media but without direct contact. Mitomycin was used to inhibit mitotic activity of 
fibroblasts which could result in activation of apoptotic pathway. Statistical analysis 
demonstrated that direct contact with normal fibroblasts increases the differentiation 
rate in muscle cells (C2C12) significantly, but direct contact with mutant fibroblast did 
not increase the differentiation rate. In addition, coculture without direct contact did 
not further enhance C2C12 differentiation (Cooper et al., 2004).  
 These findings confirm the importance of mechanical properties of ECM surrounding 
myocytes. The reduced differentiation rate in collagen XII mutant cells as well as 
Duchenne muscular dystrophy cells underlines the importance of intact ECM in 
myoblast differentiation. 
 One limitation for this study lies in the use of C2C12 cells which are of mouse origin 
and immortalised. It has been shown C2C12 cells act differently from primary 
myogenic cells in several assays (Zou et al., 2008). The result of coculturing primary 
cell line for in vivo system must be interpreted with caution (Zou et al., 2008). 
 Overall, we identified three mutations in the gene COL12A1 in three pedigrees with 
six affected individuals. Immunofluorescence studies demonstrate reduction or 
absence of collagen XII in cultured cells. Thus, secreted collagen XII homotrimers 
are unable assemble into the extracellular matrix. However, these mutations did not 
affect collagen XII fibrils diameter according to our in vitro fibrillogenesis and cultured 
fibroblast collagen fibrils visualization assay by electron microscopy. Fibroblast\ 
C2C12 coculture studies implicate biomechanical effects of the extracellular matrix 
on myogenic cell differentiation. 
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Future directions 
 Our research deciphers pathogenic variants for three of our Bethlem-like myopathy 
phenotypes without COL6A mutations, but did not uncover the underlying genetic 
cause in 20 similar patients. Identifying the genetic-cause is important to determine 
possible therapeutic approaches and genetic counselling. Our exome sequencing 
approach is a valid and robust method to discover small, exonic variants in COL6A1, 
COL6A2 and COL6A3 genes but is unable to detect deep intronic mutations which 
may affect splicing or larger or more complex rearrangements (Bonnemann et al., 
2011). Thus, analysing RNA from appropriate cells or tissues using reverse 
transcriptase PCR (RT-PCR) or RNA sequencing may be required to detect identify 
aberrant splicing. Dose sensitive methods like multiplex ligation-dependent probe 
amplification (MLPA), genomic single nucleotide polymorphism array, or whole 
genome sequencing are likely to uncover larger and more complex rearrangements, 
but the interpretation may be time-consuming and challenging (Bonnemann, 2011). 
 Investigating collagen fibrils` diameter via preparation of intact extracellular matrix 
neighbouring cultured fibroblast and in vitro fibrillogenesis experiment with 
concentrated collagen extracted from cultured fibroblast are two methods to identify 
extracellular matrix ultrastructure and collagen XII mutation`s effect on this structure. 
These efforts do not show any variation between control samples and affected 
individuals. However, FACITs are regulators of collagen fibrillogenesis by mediating 
fibrils diameter and length increase (Mienaltowski and Birk, 2014b). Investigating 
length of collagen fibrils from skin biopsies by advanced electron microscopy 
techniques may be the next step for this line of investigation. 
 Altered biomechanical features in ECM of cultured fibroblast from affected 
individuals was observed in our coculture experiment, which was also found for 
Duchenne muscular dystrophy`s cultured fibroblasts.. In order to evaluate the distinct 
role of collagen XII in myogenic cells differentiation I would suggest to examine the 
interaction through immunofluorescence staining for collagen XII in C2C12 cultures. 
Further, quantitative PCR methods could be applied to check the level of collagen XII 
expression during myogenic cells differentiation. 
 Inhibiting endoplasmic reticulum degradation (ERAD) pathway in collagen XII 
mutant fibroblast is helpful to determine the effect of misfolded proteins on cells. This 
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experiment could determine whether the endoplasmic reticulum stress is involved in 
pathogenesis of these mutations. ERAD pathway activation could happen in all 
mutant individuals. For examples, in BM2 an Arginine substitution could lead to an 
unpaired cysteine which is in the middle of the unassembled branches and may 
change the homotrimer conformation. The unpaired cysteine residues are a 
substructure that triggers the recognition of misfolded or mutated proteins, along with 
exposed hydrophobic regions and immature glycans. When folding or assembly 
intermediates expose, unpaired cysteines, ER resident chaperones or 
oxidoreductases interact with them, and as a consequence, they are retained in the 
ER or retrieved from the Golgi. This process could activate the unfolded protein 
response (UPR) pathway. The underlying mechanism for this retention is unknown 
but residues could trap in endoplasmic reticulum and immature particles could form 
aggregates which could not exit from the ER in vesicle form. This aggregates then 
lead to dilated, swollen ER (Sitia and Braakman, 2003). In addition, constant supply 
of misfolded proteins due to genetic mutation which leads to activation of protein 
response pathway could initiate chronic ER stress, which in turn induces the cell to 
activate apoptosis (Shen et al., 2004; Lai et al., 2007). BM2, BM5and BM1`have 
mutations, which result in an absence or non-assembly of collagen XII in the ECM. 
UPR array which was done by Debbie Hicks showed an upregulation of UPR 
pathway in BM2 patients. Also, evidence of dilated ER by electron microscopy was 
seen in BM5 skin biopsies (Hicks et al., 2014). These results provided proofs for 
activation of ERAD pathway in collagen XII mutant patients. Further investigation of 
ERAD pathway activation in BM1` individual who showed high reduction of collagen 
XII in ECM will be of benefit to provide more evidence for precise pathomechanisms 
acting in this family. Endoplasmic reticulum activation pathway is a proapoptotic 
mechanism. It is interesting to investigate whether apoptosis pathway is activated or 
not.  
 As precise pathomechanisms behind collagen XII mutant individuals is not 
deciphered, it is difficult to mention a distinct therapeutic drug in these individuals. 
However, according to our experience to follow collagen XII mutant individuals in 
MRC centre for neuromuscular diseases, palliative care could be of beneficial in 
these patients. BM5 individual is benefiting from walking aid. He also used a special 
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chair with higher sitting surface to reduce difficulties when tries to stand up. Another 
individual BM1` benefitting from surgery to treat recurrent jaw dislocation. The non-
pharmacological interventions could have an important place in collagen XII 
individuals. Like other collagen muscular dystrophies disease-specific therapeutic 
modalities should be considered in these patients. 
 As we have not deciphered collagen XII pathomechanisms, potential and under 
evaluation therapies which has been considered in collagen VI-related myopathy 
such as anti-fibrotic therapy would not recommended in this stage for collagen XII 
patients. 
 Overall, we identified COL12A1 as a novel disease-causing gene for Bethlem-like 
overlapping phenotype. Our immunohistochemical investigations revealed misfolding 
in collagen XII mutant protein. However, structural defect did not affect hierarchical 
structure of ECM in COL12A1 mutant individuals. In Vitro analysis demonstrated that 
mutant collagen XII fibroblasts could not contribute in C2C12 differentiation as 
healthy donors. 
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Appendix A: collagen variants primers: 
Col13A1,exon13,fwd Gacttttggcatcgatctgaat 22 60.46 232 
Col13A1,exon13,rev Agagaggttctggctttgtctg 22 60.05 232 
Col2A1,exon51,fwd Cttttgtgtctgtgcctgtctg 22 60.92 294 
Col2A1,exon51,rev Agagtttgaggagccatctctg 22 60.02 294 
Col6A1,exon14,fwd Agttgattggcctcagtttacc 22 59.53 195 
Col6A1,exon14,rev gacagaagtcaaaacggtccac 22 60.95 195 
Col12A1,exon41,fwd gactaaatgtcagcactgaaaagg 24 59.37 242 
Col12A1,exon41,rev ttggcaaaatgtagaaaagattca 24 60.01 242 
Col6A1,exon9,fwd Gtcttttctcagtggtggcttt 22 59.79 354 
Col6A1,exon9,rev Atgcctctgtgagaccagtcc 21 61.66 354 
Col6A2,exon 26,fwd CTTCAAGGAGGCTGTCAAGAAC 22 60.42 468 
Col6A2,exon 26,rev Ctgcacattcatccctcaggt 21 60.03 468 
Col19A1,exon28,fwd Tcacttggataatttatggacattc 25 58.40 297 
Col19A1,exon28,fwd aatgggggagggtagataaaga 22 60.04 297 
Col12A1,exon20,fwd tggaaaagtgatacaaaagcttga 24 60.16 288 
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Col12A1,exon20,rev aggctatcaaacgtgacacaaa 22 59.68 288 
col6a,bm1,fwd GAAGACACGCCAACACTAAGG 21 59.8 308 
col6a3,bm1,rev GGACGCTATCTTTCCAACCTC 21 59.8 308 
col6a3,bm2,fwd CAGGCTAGCGTGTTCTCATTC 21 59.8 268 
col6a3,bm2,rev Tcccacacagatggtgagaag 21 57.3 268 
col22a1,bm3,fwd Tgtcctatgtccgtttctgc 20 61.8 272 
col22a1,bm3,rev CTATGGGTCCAGAGGGTCCTT 21 55.9 272 
col12a1bm3,fwd GCCTTTGTTGGAGAAATGACA 21 55.9 284 
col12a1,bm3,rev Agcctgcctacataatgctga 21 57.9 284 
col21a1,bm3,fwd TCAAGAAAATTTGGGATTTATGG 23 53.5 302 
col21a1,bm3,rev Tatagccctcttttccccaac 21 57.9 302 
col4a1,bm3,fwd Tgtctttgtccagcttttgct 21 55.9 362 
col4a1,bm3,rev CATGTTCATTGGCATCAGAGC 21 57.9 362 
gCOL6A6e7_f AGCCTCAACAGAGTGCGAAT 20 57.3 314 
gCOL6A6e7_R TCAACATCATCATCCAATCCA 21 54.2 325 
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Col12A1,exon20,fwd tggaaaagtgatacaaaagcttga 24 60.16 288 
Col12A1,exon20,rev Aggctatcaaacgtgacacaaa 22 59.68 288 
Col12A1,exon41,fwd gactaaatgtcagcactgaaaagg 24 59.37 242 
Col12A1,exon41,rev Ttggcaaaatgtagaaaagattca 24 60.01 242 
 
Appendix B- Collgen XII affected individual’s variant: 
Ccol1212,fwd CTGAGCTCTCCGCAGAAGG 19 61.0 882 
Ccol1212,rev ACGGTGATGGAGAAGTGGAC 21 59.4 882 
Col12A1,exon41,fwd gactaaatgtcagcactgaaaagg 24 59.37 242 
Col12A1,exon41,rev ttggcaaaatgtagaaaagattca 24 60.01 242 
Col12A1,exon20,fwd tggaaaagtgatacaaaagcttga 24 60.16 288 
Col12A1,exon20,rev aggctatcaaacgtgacacaaa 22 59.68 288 
 
 
Appendix C- cDNA Collagen XII primer pairs: 
Ccol12-1fwd CCTCTCCGACCCTTTGAGC 19 61.0 924 
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Ccol12-1,rev CTTCTGCTCTTCGCCTTCTCT 21 60.0 924 
Ccol12-2fwd AGACGTTCGTAGCCCACTGAG 21 61.8 814 
Ccol12-2,rev CATCATCTTCAGCACCTGGA 20 57.3 814 
Ccol12-3fwd AGACGTTCGTAGCCCACTGAG 21 60.5 764 
Ccol12-3,rev CCCAAAATTTCTTTCTGTTTATTCA 25 54.8 764 
Ccol12-4,fwd 
CTTCTGCTCTTCGCCTTC 
TCT 
21 59.8 832 
Ccol12-4,rev CCCAAAATTTCTTTCTGTTTATTCA 25 54.8 832 
Ccol12-5,fwd CTTTTCCCTCCATGGTTTCTC 21 57.9 818 
Ccol12-5,rev TTTCCAGGATTGGAGGAAAA 20 53.2 818 
Ccol12-6,fwd GAAGGCCCAGTACTCAAGGTC 21 61.8 908 
Ccol12-6,rev CACTACTGGGAGGTTGACGTG 21 61.8 908 
Ccol12-7,fwd GCCCTAAGAAGCAGGCAGTAA 21 59.8 845 
Ccol12-7,rev GAACTGCAGTGCGGTGTTG 19 58.8 845 
Ccol12-8,fwd TTGAGGGGACTTGTGGTTTG 20 57.3 854 
Ccol12-8,rev TGGACGTCTTGAGCAAATCTT 20 55.9 854 
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Ccol12-9,fwd CATCCGAGTGGTCCTGAGAG 20 61.4 835 
Ccol12-9,rev ACGGTGATGGAGAAGTGGAC 21 59.4 835 
Ccol1210,fwd CCCAAAATTTCTTTCTGTTTATTCA 25 54.8 746 
Ccol1210,rev CCTCTCCGACCCTTTGAGC 19 61.0 746 
Ccol1211fwd GGAACCCTAGCCCGAGAC 18 60.5 846 
Ccol1211,rev TGGACGTCTTGAGCAAATCTT 20 55.9 846 
Ccol1212,fwd CTGAGCTCTCCGCAGAAGG 19 61.0 882 
Ccol1212,rev ACGGTGATGGAGAAGTG 21 59.4 882 
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